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ABSTRACT 
 
P68 RNA helicase is a RNA helicase and an ATPase belonging to the DEAD-box 
family. It is important for the growth of normal cells, and is implicated in diverse 
functions ranging from pre-mRNA splicing, transcriptional activation to cell proliferation, 
and early organ development. The protein is documented to be phosphorylated at 
several amino-acid residues. It was previously demonstrated in several cancer cell-lines 
that p68 gets phosphorylated at threonine residues during treatments with TNF-α and 
TRAIL.  In this study, the role of threonine phosphorylation of p68 under the treatment of 
anti-cancer drug, oxaliplatin in the colon cancer cells is characterized. Oxaliplatin 
treatment activates p38 MAP-kinase, which subsequently phosphorylates p68 at T564 
and/or T446. P68 phosphorylation, at least partially, influences the role of the drug on 
apoptosis induction. This study shows an important mechanism of action of the anti-
cancer drug which could be used for improving cancer treatment.  
This study also shows that p68 is an important transcriptional regulator regulating 
transcription of the cytoskeletal gene TPPP/p25. Previous analyses revealed that p68 
RNA helicase could regulate expression of genes responsible for controlling stability 
and dynamics of different cytoskeletons. P68 is found to regulate TPPP/p25 gene 
transcription by associating with the TPPP/p25 gene promoter. Expression of TPPP/p25 
plays an important role in cellular differentiation while the involvement of p68 in the 
regulation of TPPP/p25 expression is an important event for neurite outgrowth. Loss of 
TPPP expression contributes to the development and progression of gliomas. Thus, our 
studies further enhance our understanding of the multiple cellular functions of p68 and 
its regulation of the cellular processes. 
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CHAPTER 1 
GENERAL INTRODUCTION 
 
1.1 RNA HELICASES 
 RNA is a biologically important molecule that is required in almost all aspects of 
genetic expression and biological processes. Biological reactions are highly dynamic, 
requiring modulation of RNA, DNA and protein interactions in a specific order and 
efficient manner. The abilities to modify these interactions and unwind RNAs have been 
the essential functions of RNA helicases. RNA helicases modulate the structure of 
RNAs through ATP hydrolysis. Biochemical analysis has revealed that RNA helicases 
are ATPases and helicases (Staley and Guthrie 1998; Tanner, Cordin et al. 2003). They 
are expressed in almost all biological organisms ranging from bacteria and viruses to 
humans where the functions of RNA are involved. They are implicated in diverse 
biological processes involving RNA such as transcription, mRNA splicing, nuclear 
mRNA export, RNA editing, rRNA biosynthesis/assemby and translation (Luking, Stahl 
et al. 1998; Fuller-Pace 1994; Chuang, Weaver et al. 1997; de la Cruz, Kressler et al. 
1999; Tanner and Linder 2001). 
RNA helicases have a core helicase domain consisting of eight conserved motifs 
essential for helicase activity (Linder, Lasko et al. 1989) . They are classified into 
different families and superfamilies based on these conserved motifs (Linder, Tanner et 
al. 2001). DEAD-box RNA helicases derive their name from the conserved motif: Asp-
Glu-Ala-Asp (DEAD) motif (Wassarman and Steitz 1991). Members of this superfamily 
are ubiquitously expressed and are involved in all biological processes requiring RNA 
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metabolism. The family includes several members such as eIF-4A and Dbp10 (involved 
in ribosome biogenesis), Prp28, Prp5 and Sub2 (pre-mRNA splicing), Dbp5 (mRNA 
export), Ded1, eIF4A and Vasa (translation initiation), and Dbp2 and Dhh1 (RNA decay) 
(Fuller-Pace 1994; Rocak and Linder 2004) (Figure 1.1). Eukaryotic translation initiation 
factor 4A (eIF-4A) is a helicase whose crystal structure has been solved. It has a 
dumbbell-like structure made up of two globular domains linked by a flexible linker 
(Caruthers, Johnson et al. 2000). It has a function in ribosome biogenesis, and has both 
ATPase and RNA-unwinding activities (Rozen, Edery et al. 1990). P68 RNA helicase is 
another DEAD-box protein having striking homology to eIF-4A protein (Figure 1.2) 
(Ford, Anton et al. 1988; Linder, Lasko et al. 1989).  
 
1.2 P68 RNA HELICASE  
1.2.1 P68: a DEAD-box RNA Helicase  
P68 is a DEAD-box RNA helicase identified as a result of cross-reaction with 
DNA tumor virus nuclear oncogene SV-40 (Simian virus-40) antibody (DL3C4) 
(Crawford, Leppard et al. 1982). P68 is the product of the gene DDX5 (DEAD-box 
polypeptide 5) that is located on the chromosome 17q21 and consists of 13 exons and 
10 introns (Figure 1.3a). The cDNA is 3769bp long while the expressed  protein product 
consists of 614 amino-acids (Hloch, Schiedner et al. 1990). P68 functions as a RNA-
dependent ATPase, and also unwinds RNA duplexes in a bi-directional manner. It binds 
to dsRNA with stronger affinity than ssRNA (Iggo and Lane 1989; Huang and Liu 2002). 
P68 protein has been found to be quite conserved throughout evolution (Lane and 
Hoeffler 1980). Human and mouse p68 are 98% conserved (Lemaire and Heinlein 
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1993), while the chick homologue shares about 90% homology, being shorter by 19 
amino-acids (Jost, Schwarz et al. 1999). S.cerevisiae p68, DBP2, is 55% homologous 
to the human protein (Iggo, Jamieson et al. 1991). There are reports of p68 homologues 
also in bacteria (E.coli dbpA), Drosophila (DPSE/RM62), and Arabidopsis thaliana 
(AtDRH1) (Iggo, Picksley et al. 1990). 
P68, like other DEAD-box proteins, has a conserved core region of 296 amino-
acids flanked by variable N-terminal (from amino-acids 1-134) and C-terminal (from 
amino-acids 430-614) regions that share little sequence homology (Figure 1.3b) (Yang, 
Yang et al. 2004). The core region has eight conserved motifs (Figure 1.3b). Both motif I 
(GxGKT, Walker A motif) and motif III (DEAD, Walker B motif ), function as an ATPase 
responsible for ATP-binding and hydrolysis (Schneider and Hunke 1998). Motif VI 
(HRIGRXXR), always found to be together with the DEAD-motif, also binds ATP and is 
required for its hydrolysis. Mutations in motif VI affect ATP-hydrolysis (Pause and 
Sonenberg 1992). Motif IV (SAT) causes conformational changes linked to ATP-binding 
and hydrolysis and harbors helicase activity. Mutations in this motif affect helicase 
activity without affecting RNA- and ATP-binding and hydrolysis (Pause and Sonenberg 
1992). Functions of the remaining motifs, i.e. motif Ia (PTREL), motif Ib (GG), motif II 
(TPGR) and motif V (RGXD), are not very well characterized but may be involved in 
RNA-binding (Rocak and Linder 2004). P68 also has a regulatory motif, the IQ motif, in 
its C-terminal that is subjected to post-translational modification (Buelt, Glidden et al. 
1994). This motif is made up of nine amino-acid residues with a conserved glutamine 
important for ATP hydrolysis (Tanner, Cordin et al. 2003). 
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1.2.2 Expression of P68 
P68 is a predominantly nuclear protein, but shows dramatic variations in nuclear 
localization during cell cycle stages. Immunocytochemical studies have demonstrated a 
weak granular distribution of p68 exclusively in the nucleus of an interphase cell, 
especially in the nucleoplasm, but not in the nucleolus (Lane and Hoeffler 1980; Iggo 
and Lane 1989). However, during the end of telophase, p68 transiently associates with 
the prenucleolar bodies in the nucleolus (Iggo, Jamieson et al. 1991).  
P68 expression is regulated by cell growth and development, and is essential for 
normal cell growth (Stevenson, Hamilton et al. 1998). It is ubiquitously expressed in the 
developing mouse embryos and embryonic lethality is observed in p68 (DDX5) 
knockout mice at day 11.5 (Fukuda, Yamagata et al. 2007). P68 expression co-relates 
with its functions in organ maturation and in differentiation during development 
(Stevenson, Hamilton et al. 1998). P68 is important for neural and mesodermal 
development in the brains of chick, frog, and ascidian chordate embryos (Seufert, Kos 
et al. 2000).  Differentiation of adipocytes is blocked when p68 is knocked-down in 
mouse 3T3-L1 preadipocytes cells, implicating the role of p68 in potentiating the 
differentiation of adipocytes.(Kitamura, Nishizuka et al. 2001). Consequently, the 
function of p68 in cell growth and development strongly suggests that expression of p68 
has a function in cellular proliferation. P68 expression is not seen in quiescent Swiss 
3T3 cells, but is observed when induced by serum indicating a functional link to cellular 
proliferation. However, the expression levels of p68 do not necessarily match with the 
cellular proliferation status in the adult tissues, as p68 mRNA and protein have been 
found to be differentially expressed in these tissues regardless of their proliferation 
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capability, implying that p68 is regulated in a more complex fashion (Stevenson, 
Hamilton et al. 1998). Moreover, p68 expression is induced in developing epithelium in 
wound tissues by growth factors and cytokines after transient down-regulation due to 
skin injury. Increased p68 expression in keratinocytes leads to an increase in 
expression of VEGF (vascular endothelial growth factor) and proliferation in response to 
serum driving wounded area re-epithelization, an essential step in wound repair 
(Kahlina, Goren et al. 2004).  
Higher levels of p68 protein have been found in colorectal adenocarcinomas as 
compared to their normal counterparts. The overexpressed p68 is poly-ubiquitylated, a 
form of post-translational modification, raising the possibility of defects in proteosomal 
degradation and consequent development of tumors (Causevic, Hislop et al. 2001). 
Phosphorylation of p68 at Y593 is found to promote PDGF-mediated Epithelial-to-
Mesenchymal Transition (EMT) and to contribute to cell proliferation and tumorigenesis 
(Yang, Lin et al. 2006).  
 
1.3 FUNCTIONS OF P68 RNA HELICASE  
1.3.1 Function of P68 in mRNA Splicing 
Splicing is a mechanism where pre-mRNAs are modified by removal of introns 
and joining of protein coding exons to form mature mRNAs. Introns are removed by a 
macromolecular structure called a spliceosome made up of U1, U2, U4, U5 and U6 
snRNPs (small nuclear ribonucleoprotein particles) and other non-snRNP splicing 
factors (Will and Luhrmann 2001). Splicing or spliceosome assembly follows a 
sequential stepwise pathway consisting of recognition and binding of 5’-splice site on 
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pre-mRNA by U1 snRNP and U2AF recognizing 3’-splice site and the E (early complex) 
is formed. U2 snRNP then interacts with the branch-point adenosine (BP) that leads to 
pre-spliceosome A complex formation. Next, U4-U6-U5 tri-snRNP enters the pre-
spliceosome to form B complex first and then catalytic C complex. Various RNA and 
protein rearrangements take place in the spliceosome resulting in U1 and U4 release 
and ultimate intron cleavage and ligation of exon in an ATP-dependent manner (Will 
and Luhrmann 2001) (Sanford and Caceres 2004) (Wahl, Will et al. 2009).  
Recent studies have identified over 300 putative spliceosomal proteins in the 
spliceosome (Jurica and Moore 2003). DExH/D RNA helicases are one such family of 
proteins responsible for modulating such interactions using energy derived from ATP-
hydrolysis (Staley and Guthrie 1998) (Schwer 2001). P68 being a DEAD-box RNA 
helicase functions as a crucial splicing factor. It modulates U1 snRNP and 5’-splice site 
interaction at the intron-exon junctions and unwinds the transient U1-5’-splice site 
complex (Liu, Sargueil et al. 1998; Liu 2002). This step is essential for the conversion of 
pre-spliceosome to spliceosome (Staley and Guthrie 1998). Depletion of p68 from the 
system does not affect the association of U1 snRNP-5’-splice site, however, the 
spliceosome formation is impeded as U1 snRNP cannot dissociate from the 5’-splice 
site (Liu, Sargueil et al. 1998; Liu 2002). RNA helicase and ATPase functions of p68 are 
found to be crucial for this process. P68 mutants without RNA helicase and ATPase 
functions associate with the U1-5’-splice site, but inhibit U1 dissociation from 5’-splice 
site thereby preventing spliceosome assembly. P68 also functions in U4.U6/U5 
assembly independent of its ATPase and helicase activities. P68 function has also been 
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extended in alternative splicing of the oncogene c-H-ras, besides its role in splicing 
(Guil, Gattoni et al. 2003). 
 
1.3.2 Function of P68 in Transcriptional Regulation 
Gene expression is the fundamental process in which genetic information, the 
genotype, is converted to a functional gene product giving rise to the phenotype. Vast 
multitude of phenotypic differences that are observed in different cells and tissues of 
eukaryotes are largely due to differential gene expression. Gene expression is regulated 
in eukaryotic cells at many key points including activation of gene structure, 
transcription initiation, termination of elongation, nuclear RNA processing, mRNA 
transport, mRNA translation, and mRNA stability. Thus, in response to genetic controls, 
environmental factors and tissue specific controls, eukaryotic organisms employ highly 
orchestrated and elaborate transcription machinery to turn on and off genes encoding 
different proteins (Ogbourne and Antalis 1998). 
 Before transcription initiation can occur, highly organized and densely packed 
chromatin must be activated or opened by chromatin remodeling complexes that are 
themselves tightly regulated to inhibit responses to initiation factors and DNA 
transcription and allow for transcription. The opening or priming of chromatin may be 
regulated by N-terminal phosphorylation, acetylation, or methylation of free amino-
groups of lysine residues of histones. Transcription is the process by which mRNA 
synthesis occurs from DNA in distinct phases, starting with the binding of DNA-
dependent RNA polymerase to the gene promoter and ending with the formation of 
mRNA. The majority of gene expression regulation occurs at transcriptional initiation, 
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that is, regulating the assembly of transcription apparatus and positioning of RNA 
Polymerase II at the promoter (Ogbourne and Antalis 1998). 
 RNA polymerase II (RNA Pol Il) is a 8-14 subunit RNA polymerase involved in 
the transcription of protein expressing genes. It is solely dependent on auxiliary 
transcription factors (TFs) to help it to initiate transcription. RNA Pol II and auxiliary TFs, 
together called basal transcription apparatus or general transcription factors (GTFs), 
assemble on the core promoter at a precise site known as the transcription initiation site 
to form pre-initiation complex (PIC) in a highly regulated and defined order (Figure 1.4). 
In most eukaryotic core promoters, a cis-acting element, called TATA box (5’ TATAAAA 
3’), located upstream of the transcription start site (roughly 30 bp), is necessary for 
directing the transcription initiation, but not sufficient for promoter activity. Precisely, 
RNA Pol II transcription begins with the TATA-binding protein (TBP) association with the 
TATA box. Subsequently, TBP-associated factors (TAFs) bind to TBP and form a 
complex called transcription factor II D (TFIID) sufficient to complete chromatin priming 
in the vicinity of the promoter. TFIIA is then recruited to the TFIID-TATA box complex to 
undergo conformational change to allow TFIIB and the remaining GTFs to bind. Binding 
of TFIIB causes TFIIF-Pol II complex to associate with the complex. TFIIE and TFIIF 
interact with Pol II to complete PIC assembly. Although this complex is the complete 
basal transcription machinery to initiate transcription, transcription initiation is further 
compounded by different cofactors, gene specific activators or repressors, and 
chromatin remodeling (Ghosh and Van Duyne 1996; Orphanides, Lagrange et al. 1996; 
Nikolov and Burley 1997; Ogbourne and Antalis 1998). 
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 Core promoter sequences and basal transcription apparatus are required for 
transcriptional initiation of any gene but gene selective transcriptional activities require 
activators or repressors that bind to either enhancers or silencers. These transcriptional 
regulators further modulate transcriptional regulation of tissue or development specific 
genes. Most transcriptional activators function by interacting with GTFs and stabilizing 
the association of GTF with core promoter. They have two separable functional 
domains: a DNA-binding domain that binds to specific DNA sequences or enhancer 
elements and an activation domain that interacts with other proteins to stimulate 
transcription (Mitchell and Tjian 1989; Martinez 2002). TFIID is the main target for most 
transcriptional activators as it is important for the formation of the transcriptional 
initiation complex on all promoters (Buratowski, Hahn et al. 1989).  
 Transcriptional repressors perform opposite functions of activators. They repress 
transcription in two ways: general repression or gene-specific repression. During 
general repression, repressors either inhibit basal transcription machinery or block the 
activity of transcription factors. Repressors can also modulate chromatin structure or 
interact with proteins that remodel chromatin so that it is not available for transcription. 
In contrast, a gene-specific repressor controls transcription of genes by affecting the 
numbers of functional activators or by decreasing the positive effect of activators on 
transcription (Gaston and Jayaraman 2002). 
 Besides the basal transcriptional machinery and transcriptional activators and 
repressors, there is another group of factors that participate in transcriptional regulation. 
They are called coactivators or corepressors which are dispensable for basal 
transcription and may not directly bind DNA (Figure 1.5). They facilitate transcription by 
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either mediating the interaction between activators and GTFs or facilitating chromatin 
remodeling. Prototypical classes of co-activators are TAF component of TFIID, SRB 
complex, SAGA or other proteins that are involved in histone acetylation and chromatin 
remodeling complexes (Hampsey 1998; Martinez 2002). 
 Numerous studies have shown that p68 functions as a transcriptional co-activator 
for numerous transcriptional factors (Figure 1.6) (Endoh, Maruyama et al. 1999). 
Coactivator role of p68 was first elucidated in the transcriptional coactivation study of 
estrogen receptor alpha (ERα). P68 potentiates the activity of ERα AF-1 (activation 
function-1). AF1 activation domain of ERα does not require ligand while AF-2 requires 
estrogen to facilitate coregulator recruitment. This co-activator function of p68 for ERα 
AF-1 does not require RNA unwinding activity of p68 indicating that the involvement of 
p68 in the regulation of transcription is not the same as its function in RNA-splicing 
where RNA helicase activity of p68 is indispensable (Endoh, Maruyama et al. 1999). 
The ERα transcription machinery contains nuclear receptor AF-2 coactivator complex, 
such as CBP/p300, SRC-1/TIF2  steroid receptor coactivator, and SRA (steroid receptor 
RNA activator) RNA coactivator, besides p68 (Onate, Tsai et al. 1995; Voegel, Heine et 
al. 1996; Torchia, Rose et al. 1997; Lanz, McKenna et al. 1999; Watanabe, Yanagisawa 
et al. 2001). P68 binds to the activation domain (AD2) of this AF-2 coactivator complex. 
It selectively coactivates ERα-AF-1 by binding to the AD-2 domain of AF-2 complex 
allowing SRA and the SRC-1/TIF2 to directly bind to AF-2 of ERα, serving as a bridge 
between ERα and SRC/SRA (Watanabe, Yanagisawa et al. 2001). A “transcriptional 
clock” concept was defined in another study that showed the sequential assembly of 
transcriptional cofactors on the promoter of pS2, an ERα downstream gene, in 
 11 
estrogen-dependent manner. P68 interacts with the pS2 promoter along with ERα and 
the transcription factors, TBP and TFIIA, demonstrating the role of p68 in transcription 
coactivation (Metivier, Penot et al. 2003). 
Another independent study confirmed the transcriptional regulation function of 
p68 by demonstrating the presence of p68 in a multi-protein transcription complex 
containing RNA Pol II, CREB-binding protein (CBP) and p300 and showed how p68 
impacts transcription of genes that are regulated by RNA Pol II and CBP/p300 (Rossow 
and Janknecht 2003). CBP/p300 is a transcriptional coactivator that modulates 
expression of genes essential for cell growth and proliferation (Goodman and Smolik 
2000; Janknecht 2002). Within the transcriptional multi-protein complex, p68 interacts 
with CBP and RNA Pol II and stimulates CBP/p300 transcriptional activity synergistically 
requiring its ATPase-dependent function (Rossow and Janknecht 2003). In another 
study demonstrating the role of p68 as a transcriptional coactivator, p68 is identified as 
the first RNA helicase to be implicated as an important element in the DNA damage 
pathway. P68 functions as a transcriptional coactivator or a possible tumor 
cosuppressor by interacting with p53 to stimulate transcription mediated by p53. P68 is 
involved in the expression of p53-responsive genes including, p21, mdm2, and PIG3. 
Chromatin immunoprecipitation experiments demonstrated the p68 interaction with the 
p21 promoter stimulated by the drug, etoposide, further supporting the function of p68 in 
transcriptional initiation (Bates, Nicol et al. 2005). Furthermore, p68 also forms a 
complex containing Smad 3, p68, and CBP under the stimulation of TGF-β. In this 
complex, helicase activity of p68 and histone acetylase activity of CBP enhance TGF-β- 
dependent transcriptional activation (Warner, Bhattacherjee et al. 2004). 
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Functional role of p68 in the transcription systems mentioned above can be 
extrapolated to transcription activation in muscle cells. P68 associates with SRA to 
stimulate MyoD transcriptional activity required for differentiation of skeletal muscle 
cells. It serves as a bridge between MyoD and SRA within this complex and its helicase 
activity is dispensable for this process. Reduction of p68 levels in this system impairs 
the recruitment of TBP, RNA Pol II, Brg-1, and SWI/SNF complex catalytic subunit, and 
affects chromatin remodeling. Thus, this study shows that p68 is essential for the 
recruitment of the transcription machinery and chromatin remodeling (Caretti, Schiltz et 
al. 2006). The link between p68 function and proliferation is demonstrated in 
keratinocytes where overexpression of p68 increases keratinocyte proliferation and 
VEGF expression, while knockdown of p68 reduces serum-induced proliferation and 
VEGF expression (Kahlina, Goren et al. 2004). Interestingly, the phosphorylated form of 
p68 also has a role in transcriptional regulation. Activation of the gene expression of 
cyclin D1 and c-myc occurs by p68 phosphorylation at Y593, thereby promoting cell 
proliferation induced by PDGF. Phospho-p68 is recruited to cyclin D1 and c-myc 
promoters by its interaction with β-catenin. The TCF/LEF complex and ATPase/helicase 
activities of p68 have been found to be required for this cyclin D1 transcription (Yang, 
Lin et al. 2007). Thus, transcriptional regulation by phospho-p68 adds another 
dimension to the function of p68 in the transcriptional regulation. 
Another report demonstrated a function of p68 besides that of transcriptional 
initiation. P68 can also function as a transcriptional corepressor depending on the 
transcriptional complex and promoter onto which it is recruited. It associates with 
HDAC1 and represses transcriptional regulation mediated by it (Wilson, Bates et al. 
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2004). Another study showed that phospho-p68 interacts with HDAC1 and MBD3:Mi-
2/NuRD in the nuclear remodeling and deacetylation complex and activates the 
transcription of Snail1 gene from the Snail promoter. It does so by removing HDAC1 
from the MBD3:Mi-2/NuRD complex. The Snail1 transcriptional regulation by p68, in 
turn, represses E-cadherin expression indirectly (Carter, Lin et al. 2010). In another 
study of the Drosophila homologue, Dmp68, p68 is found to be required for the removal 
of mRNA transcripts from transcription sites to shut off active genes and letting 
chromatin reset to an inactive state, leading to gene deactivation (Buszczak and 
Spradling 2006). 
 Thus, several lines of evidence have established the roles of p68 as 
transcriptional coactivator/ corepressor and in most cases, RNA helicase and ATPase 
functions are not required for these functions implying that the function of p68 in 
transcription is different from its role in RNA-related processes. It is not a general 
transcriptional regulator and functions as a coactivator or corepressor based on the 
promoter or transcription complex. It has a function in transcriptional regulation by either 
acting as a link between transcription factors/ coactivators, or facilitating the 
rearrangement or recruitment of protein complexes at the gene promoter, or by 
stabilizing the transcription initiation complex, or by associating with the chromatin 
remodeling complexes to repress gene activation. Thus, it is a truly multifunctional 
protein with functions in several processes each with specific requirements. 
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1.3.3 Role of P68 in Post-transcriptional Processes. 
P68 is a pleiotrophic protein with different roles in different cellular processes. A 
study demonstrated an important function of p68 in pre-rRNA maturation. P68 and U8 
small nucleolar RNA (snoRNA) cleave pre-28S rRNA structure of pre-60S ribosomal 
subunit (Jalal, Uhlmann-Schiffler et al. 2007). Mouse Drosha complex contains p68, 
where p68 is found to be required for primary miRNA and rRNA processing and is 
indispensable for survival in mice (Fukuda, Yamagata et al. 2007). P68 is also found to 
be involved in the release of mRNA transcripts after transcription to enable 
condensation of chromatin causing gene inactivation (Buszczak and Spradling 2006). 
Apart from gene inactivation, p68 involvement in transcript release from the transcription 
site is also important in cyclical transcriptional activation processes where there is 
combinatorial recruitment of coactivators and corepressors for gene regulation (Metivier, 
Penot et al. 2003). Thus, p68 functions as an adaptor molecule that is not only involved 
in the transcription initiation but also in post-transcriptional processes of gene 
expression, such as elongation and RNA processing. 
 
1.3.4 Role of P68 in Differentiation 
Several studies have suggested the role of RNA helicases in cellular 
differentiation process. RNA helicases serve as potential regulators of differentiation by 
virtue of their ability to modulate RNA structure and interactions and their roles in RNA 
processing where a large number of proteins can be expressed from a smaller subset of 
genes (Abdelhaleem 2005). The mouse p68 is found to be expressed during organ 
differentiation in developing murine embryo (Stevenson, Hamilton et al. 1998). In situ 
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hybridization of 5 day old chicken embryos demonstrated a very high number of chick 
homologs of p68 transcripts in different embryonic tissues (Jost, Schwarz et al. 1999). 
P68 is also involved in embryonic differentiation of vertebrates. Very high embryonic 
expression of p68 is observed in neural and mesodermal tissues in the brain and spinal 
cord of chordates such as chick and frog. Mesodermal p68 expression is also seen in 
ascidian and frog embryos during gastrulation and neurulation (Seufert, Kos et al. 
2000). The p68 expression has also been observed in other organs and tissues during 
differentiation. Invariably, p68 expression is also seen in murine male germ cells, 
particularly pachytene spermatocytes and haploid spermatids (Lemaire and Heinlein 
1993). The expression of p68 is regulated in these cells by germ cell-specific proteins 
that associate with the highly conserved 3’ UTR of the gene (Sandhu, Lemaire et al. 
1995). Interestingly, rck/p54 DEAD–box RNA helicase has a role in gametogenesis 
(both oogenesis and spermatogenesis) and embryogenesis (Matsumoto, Kwon et al. 
2005). Moreover, p68 expression is important during early adipocyte differentiation. The 
in vitro model of adipocyte differentiation demonstrates the role of p68 in partially driving 
the differentiation into adipocytes where inhibition of p68 expression partially blocks 
adipocyte differentiation and simultaneously decreases expression levels of some 
marker genes (Kitamura, Nishizuka et al. 2001). Nonetheless, the exact mechanism by 
which p68 plays a role in cellular differentiation is not known. This poses several 
questions where future research could be targeted: What is the role of p68 in 
differentiation? Could p68 engage in transcriptional programs that control 
differentiation? What are the downstream targets of p68 in its function as differentiation 
regulator? 
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1.3.5 Role of P68 in Cell Proliferation and Cancer 
 P68 is essential for growth and proliferation of normal cells (Lane and Hoeffler 
1980; Stevenson, Hamilton et al. 1998; Tanner and Linder 2001). P68 shows different 
localization patterns in the nucleus during different stages of the cell-cycle. It shows 
weak granular distribution in the nucleoplasm but not in the nucleolus during interphase 
(Lane and Hoeffler 1980; Iggo and Lane 1989), However, its association with the 
prenucleolar bodies in the nucleolus is observed during telophase (Iggo, Jamieson et al. 
1991). Strikingly, serum-stimulation of quiescent cell lines increases p68 expression 
suggesting that p68 expression is functionally linked to cellular proliferation (Stevenson, 
Hamilton et al. 1998). In fact, overexpression of p68 in keratinocytes shows a marked 
increase in serum-induced proliferation of cells, whereas downregulation of p68 
decreases serum-induced proliferation (Kahlina, Goren et al. 2004). 
 Many studies have shown that p68 is essential for cellular proliferation, and 
abnormal p68 may lead to uncontrolled cell proliferation leading to cancer development. 
Two p68 abnormalities have been attributed to cancer. Dubey et al. identified a tumor-
specific somatic mutation (C→T) that causes serine to phenylalanine transition in the 
coding region of p68 with phosphorylation and calmodulin-binding sites leading to a 
unique tumor antigen being expressed on murine UV-induced sarcoma. However, it is 
still not clear whether this mutation has any effect on the function of p68 or on the 
tumorigenesis process (Dubey, Hendrickson et al. 1997). The second type of p68 
abnormality is the overexpression and post-translational modifications of p68 (Causevic, 
Hislop et al. 2001; Yang, Lin et al. 2005; Shin, Rossow et al. 2007). Overexpression of 
p68 is observed in colorectal tumors at the protein level, as compared with normal 
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tissues with the expression of p68 increasing with the progression of the disease from 
hyperplastic polyps to adenomas and adenocarcinoma (Causevic, Hislop et al. 2001; 
Shin, Rossow et al. 2007). Moreover, p68 in tumor tissues is different from the p68 
found in normal tissues. It is poly-ubiquitylated suggesting tumor-associated post-
translational modification affected proteasome-mediated degradation in tumor tissues 
implying that deregulation of p68 expression/ ubiquitylation leads to tumor development 
(Causevic, Hislop et al. 2001). Phosphorylation of p68 is yet another post-translational 
modification implicated in tumor development and cellular transformation. P68 is found 
to be phosphorylated in six different cancer cells in comparison to normal cell 
counterparts and this tyrosine phosphorylation of p68 is associated with abnormal cell 
proliferation and cancer development (Yang, Lin et al. 2005). So the overarching 
question is how does overexpression and phosphorylation of p68 contribute to tumor 
formation? An important phenomenon during colon tumor formation is the abnormal 
activation and β-catenin accumulation. Almost 80% of human colorectal carcinomas 
show abnormal β-catenin accumulation (Mirabelli-Primdahl, Gryfe et al. 1999; Brabletz, 
Jung et al. 2001; Segditsas and Tomlinson 2006; de Lau, Barker et al. 2007). The 
phospho-p68 binds to and promotes nuclear translocation of β-catenin. This stimulates 
transcription of cyclin D1 and c-myc genes leading to cellular proliferation. This 
interaction of p68 and β-catenin also stimulates EMT (Epithelial- Mesenchymal 
transition), an event that is essential not only during embryogenesis but also for 
invasion and metastasis (Yang, Lin et al. 2006; Yang, Lin et al. 2007; Thiery, Acloque et 
al. 2009). Reduction of p68 in colon cancer cells also inhibits their proliferation and 
diminishes their tumor-forming ability in nude mice (Yang, Lin et al. 2006; Shin, Rossow 
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et al. 2007; Yang, Lin et al. 2007). All these results collectively indicate that p68 
overexpression and post-translational modifications may lead to colon carcinogenesis 
through β-catenin. 
 The emerging role of p68 in tumorigenesis other than in colorectal carcinoma can 
be further substantiated by the report of p68 being overexpressed in 30-58% of breast 
tumors (Wortham, Ahamed et al. 2009; Mooney, Grande et al. 2010). Approximately 
70% of human breast tumors are ER-α-positive and current breast cancer therapy 
targets ER-α inhibition (Normanno, Di Maio et al. 2005; Yager and Davidson 2006). 
Since p68 functions as a coactivator of ER-α transcription, it is possible that increased 
overexpression and probable modifications of p68 enhances the transcriptional 
activation of ER-α and consequently the oncogenic activities of ER-α in breast 
tumorigenesis. Similarly, p68 expression is elevated in prostate cancer cells in 
comparison with the normal prostate tissues and it enhances coactivation of androgen 
receptor-regulated gene expression. These results show the p68 function in the 
progression of prostate cancer to hormone-refractory disease (Clark, Coulson et al. 
2008). 
 In contradiction, p68 has also been found to function as a tumor suppressor 
under certain situations (Bates, Nicol et al. 2005). P68 stimulates transcription from p53- 
responsive promoters by interacting with p53. P53 is a tumor suppressor protein 
encoded by the TP53 gene. It is latent transcription factor activated by genotoxic 
stresses like DNA damage to mediate transcriptional regulation of cell cycle and 
apoptosis related genes. P68 RNA helicase acts as a coactivator of p53-responsive 
genes. Interestingly, p68 knockdown inhibits p53-dependent transcription and apoptosis 
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triggered by the drug, etoposide, suggesting the importance of p68 in such processes. 
This role is further substantiated by chromatin immunoprecipitation assay that 
demonstrates the association of p68 with the p21 promoter, further extending the role of 
p68 in transcription initiation. P21 is an inhibitor of cell-cycle progression. This shows 
that the transcriptional ability of p68 plays an important role in cancer. P68 may not be 
completely essential in this process, but possibly employed only under specific 
circumstances. The ability of p68 to enhance the tumorigenesis process or act as a 
tumor-suppressor may be dependent on the form of p68 i.e. modifications, cellular 
context, or upstream signaling events. 
 
1.4 MODIFICATIONS OF P68 
 Mammalian cells constantly receive various signals from their environment to 
respond to cell growth, proliferation or differentiation. The cellular responses to these 
signals are mediated mainly by post-translational protein modifications and gene 
regulation. Post-translational modification is the process by which a protein is 
chemically modified, with ubiquitylation and phosphorylation being the most common 
ones. These modifications can modulate enzymatic activities, protein conformations, 
protein-protein interactions, protein-DNA interactions, and cellular localization of various 
proteins (Olsen, Blagoev et al. 2006). 
 
1.4.1 Ubiquitylation and Sumoylation of P68 
 Ubiquitylation is an enzymatic, post-translational modification process where 
ubiquitin, a small regulatory protein is attached to proteins to direct them to the 
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proteasome for degradation. Ubiquitylation processes employ activating (E1), 
conjugating (E2), and ligase (E3) enzymes (Hershko, Heller et al. 1983). E1 enzyme 
activates and transfers ubiquitin to the E2 enzyme. The E3 ligase forms bond between 
the glycine residue of ubiquitin and lysine of substrate (Alberts et al. 2002). The 
presence of protein tagged with ubiquitin recruits the 26S proteasome that unfolds and 
hydrolyzes the polypeptide chain of the protein to small peptides using the energy 
derived from ATP. The ubiquitin molecule(s) is prevented from degradation by de-
ubiquitinating enzymes (Hershko, Ciechanover et al. 1980; Baumeister, Walz et al. 
1998; Pickart 2004). 
 Sumoylation is another form of post-translational modification where SUMOs 
(small ubiquitin-related modifiers), which are small ubiquitin-like proteins, are 
conjugated to proteins in different cellular activities like transcription activation and 
repression, apoptosis, cell-cycle and mitosis, chromatin remodeling and 
nucleocytoplasmic shuttling (Rodriguez, Dargemont et al. 2001; Gill 2004; Hay 2005).  
However, unlike ubiquitylation, SUMO modification does not cause protein degradation, 
but modulates subcellular localization of target proteins, protein-protein interactions or 
protein-DNA interactions (Matunis, Coutavas et al. 1996; Mahajan, Delphin et al. 1997; 
Melchior 2000). 
 P68 undergoes post-translational modifications. It is overexpressed and poly-
ubiquitylated in colorectal adenocarcinoma in comparison to normal colon tissues. This 
indicates a defect in proteasomal-degradation in colorectal tumors and ubiquitylation of 
p68 occurs in the initial stages of tumor development. However, the exact sites where 
p68 is ubiquitylated remain to be identified (Causevic, Hislop et al. 2001). P68 is found 
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to be preferentially sumoylated by SUMO-2 at Lys53 amino-acid, while SUMO E3-ligase 
PIAS1 as one of its functions enhances its SUMO modification. This SUMO modification 
of p68 inhibits its ability to transcriptionally coactivate p53 by increasing its 
transcriptional repression function and enhancing its interaction with HDAC1 (Fuller-
Pace, Jacobs et al. 2007; Jacobs, Nicol et al. 2007). 
 
1.4.2 Phosphorylation of P68 
 Phosphorylation, a form of post-translational modification, is used in signal 
transduction for regulating protein activity. It is involved in almost every cellular 
processes, such as cell growth, division, differentiation, migration, metabolism, 
membrane transport, organelle trafficking, muscle contraction, immunity, learning and 
memory (Manning, Plowman et al. 2002; Manning, Whyte et al. 2002). Protein kinases 
are enzymes that phosphorylate proteins by transferring γ-phosphate from ATP, the 
phosphoryl donor, to the specific residues in proteins, usually serine, threonine and 
tyrosine (Hunter 2000). Protein kinases represent one of the largest families of genes in 
eukaryotes. They are encoded by over 500 genes and make up ~ 2% of the genome 
(Zhu, Klemic et al. 2000; Manning, Whyte et al. 2002; Caenepeel, Charydczak et al. 
2004). Roughly 30% of cellular proteins are modified by phosphorylation on atleast one 
residue, emphasizing the importance of phosphorylation (Pinna and Ruzzene 1996; 
Cohen 2000). Thus, in cells, phosphorylation (adding phosphoryl group) and 
dephosphorylation (removing phosphoryl group) by protein kinases and phosphatases, 
respectively, at specific sites are among the most general regulatory steps in the 
eukaryotic cells. Kinases and phosphatases modify the functions of proteins by 
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increasing or decreasing their biological activities, by stabilizing or tagging them for 
destruction, by enhancing or inhibiting subcellular compartment movements or 
modulating protein-protein interactions (Cohen 2002). In fact, abnormal phosphorylation 
is now identified as a cause or consequence of many pathologies such as cancer 
(Hanahan and Weinberg 2000), auto-immune diseases (Gatzka and Walsh 2007), 
metabolic disorders (Taniguchi, Emanuelli et al. 2006) and pathogenic infections 
(Sirard, Vignal et al. 2007).  
 Studies carried out by Yang et al showed for the first time that p68 gets 
phosphorylated at several residues (Yang and Liu 2004). Interestingly, p68 is found to 
be phosphorylated at tyrosine in six cancer cell-lines and not in the respective normal 
cell lines (Yang, Lin et al. 2005). This observation correlates with p68 phosphorylation 
status in tumor tissue samples where p68 is tyrosine phosphorylated in tumor tissues 
and not in the respective normal tissues. Thus, tyrosine phosphorylation in p68 is 
associated with abnormal cell growth leading to tumor development (Yang, Lin et al. 
2005). Strikingly, p68 tyrosine phosphorylation is higher in metastatic cells in 
comparison to primary cells further suggesting roles of p68 tyrosine phosphorylation 
with respect to tumor development and progression (Carter, Lin et al. 2010). 
Phosphorylation of p68 at tyrosine is found to be induced by PDGF and IL-2 and 
diminished by treatment with apoptosis agents such as TNF-α, TRAIL, and STI-571. 
However, tyrosine phosphorylation of p68 is not influenced by other anti-cancer drugs 
such as piceatannol, etoposide, and taxol. In addition, ATPase and RNA helicase 
activities are affected by tyrosine phosphorylation of p68, thereby influencing its role in 
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splicing. This suggests the potential for use of p68 phosphorylation as a diagnostic 
marker and therapeutic target for cancer diagnosis and therapy (Yang, Lin et al. 2005). 
 Another study carried out by Yang et al. demonstrated p68 phosphorylation in 
HeLa cells. TNF-α and TRAIL cause p68 to be phosphorylated at threonine and 
subsequently dephosphorylated upon longer exposure to TNF-α. Interestingly, TNF-α 
treatment causes tyrosine dephosphorylation of p68 after 15 mins of treatment. This 
result suggests that threonine or tyrosine phosphorylations of p68 react differently in 
response to TNF-α and that phosphorylation at threonine and/or tyrosine 
dephosphorylation of p68 may trigger apoptosis in the presence of TNF-α treatment 
(Yang, Lin et al. 2005). 
 
1.4.2.1 Phosphorylation of P68 by PKC 
 Protein Kinase C (PKC) is a multifunctional protein kinase that phosphorylates 
target proteins (Newton 1995). Phosphorylation of cellular proteins by PKC changes 
their activation status leading to further changes in cellular functions (Alberts et al. 
2002). PKC plays essential roles in processes such as proliferation (Murray, 
Baumgardner et al. 1993), differentiation (Cutler, Maizels et al. 1993), development 
(Otte, Kramer et al. 1991), memory (Alkon 1989) and cancer (Ashendel 1985). PKC 
enzymes are present in the cytoplasm in their inactive state and upon activation 
translocate to cell membranes or different cellular organelles (Martelli, Faenza et al. 
2003). There are atleast 10 different isoforms of PKC depending on protein structure 
and cofactor requirements. The conventional isoforms of PKC, α, βI, βII, γ, need Ca2+, 
diacylglycerol and phosphatidylglycerol for activation; the novel isoforms, δ, ε, η, θ, μ, 
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are activated by diacylglycerol and phosphatidylglycerol, but do not require Ca2+; and 
the last group, the atypical (ζ, ι) isoforms do not require Ca2+, but are stimulated by 
phosphatidylserine. Different isoforms can sometimes phosphorylate the same target 
substrate (Newton 1997). The general structure of a PKC molecule consists of a single 
polypeptide with a catalytic and a regulatory domain found at the COOH- and NH2-
terminus, respectively (Way, Chou et al. 2000). Aberrant PKC activity is linked with 
diseases of cellular dysregulation, such as diabetes and cancer. Overexpression of 
different PKC isoforms have been observed in squamous cell carcinoma (PKCε) 
(Wheeler, Martin et al. 2004), serous epithelial ovarian cancer (PKCι) (Eder, Sui et al. 
2005), breast tumor (PKCα) (Lahn, Kohler et al. 2004), non-small cell lung carcinoma 
(PKCι) (Regala, Weems et al. 2005)  and multiple myeloma (PKC δ, ι, μ ζ) (Ni, Ergin et 
al. 2003). Downregulation of PKCδ is observed in colon cancer (Cerda, Bissonnette et 
al. 2001) while PKCα and PKCδ promote cell death in androgen-dependent prostate 
cancer cells (Gavrielides, Frijhoff et al. 2004). 
 The earliest reports of p68 phosphorylation were shown by the study performed 
by Buelt et al. In vitro and immunological studies showed that p68 can be 
phosphorylated by PKC in the IQ domain in the absence of RNA and it can bind 
calmodulin in a Ca2+-dependent manner. The phosphorylation and binding to calmodulin 
block RNA-dependent ATPase activity of p68, indicating that PKC negatively regulates 
ATPase activity of p68. Thus, PKC phosphorylation regulates the RNA binding or 
helicase activity of p68 (Buelt, Glidden et al. 1994). Another study demonstrated that 
PKC phosphorylation of p68 inhibits its RNA-binding ability, while dephosphorylation 
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restores the function further substantiating the role of PKC phosphorylation in regulating 
the function of p68 (Yang, Yang et al. 2004).  
 
1.4.2.2 Phosphorylation of P68 by Tlk1 
 Mammalian Tousled-like kinase 1 (Tlk1) is a relatively recently discovered 
nuclear serine/threonine kinase that was identified in 1999. There are two known human 
Tlks that are ubiquitously expressed. They are Tlk1 and Tlk2 that share 84% amino-acid 
sequence identity and act as dimers/oligomers. Tlk1 is found to be maximally active in 
S-phase showing the potential role of Tlk1 in cell-cycle progression (Sillje, Takahashi et 
al. 1999). It is also implicated in processing replicated DNA and chromatin formation 
and this role of Tlk1 in regulating chromatin assembly was first noted by the discovery of 
human chromatin-assembly factors, Asf1a (Anti-silencing function 1) and Asf1b, as Tlk 
substrates (Sillje, Takahashi et al. 1999; Sillje and Nigg 2001). Tlk1 is activated in 
response to genotoxic stress, such as UV, ionizing radiation or treatment with 
hydroxyurea (Groth, Lukas et al. 2003; Krause, Jonnalagadda et al. 2003). DNA-
damage generates double strand breaks (DSBs) that require Ataxia Telangiectasia 
Mutated kinase (ATM) and Checkpoint protein kinase 1 (Chk1) functions. ATM 
phosphorylates Chk1, which in turn phosphorylates Tlk1 on serine 695 (S695) in vitro 
and in vivo leading to the rapid and transient deactivation of Tlk1 (Krause, 
Jonnalagadda et al. 2003). Deactivation of Tlk1 causes a delay of Tlk-dependent 
processes in S-phase, such as activation and phosphorylation of hAsf1, essential in 
DNA-repair or blockage of activation of certain transcription factors resulting in 
subsequent cell death (Groth, Lukas et al. 2003). Other downstream targets of Tlks 
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besides Asf1a and Asf1b include histone H3 and DEAD-box protein p68 (Sillje and Nigg 
2001; Kodym, Henockl et al. 2005; De Benedetti 2009).  
Like PKC, p68 gets phosphorylated by Tousled-like kinase 1 (Tlk1). In addition, 
Tlk1 phosphorylation of p68 affects its RNA-binding activity, further confirming the 
regulatory effect of phosphorylation on p68-enzymatic activity (Kodym, Henockl et al. 
2005). Tlk1 has been implicated in the UV- and ionizing-radiation-induced pathways 
(Groth, Lukas et al. 2003; Krause, Jonnalagadda et al. 2003). So, p68 phosphorylation 
by Tlk1 may potentially link p68 in the UV- or IR-induced pathways. Tlk1 is also known 
to regulate chromatin assembly (Sillje, Takahashi et al. 1999; Sillje and Nigg 2001) 
while p68 is known to function in transcriptional co-activation. These observations 
suggest that Tlk1 and p68 may participate in the chromatin remodeling process by 
regulating the expression of chromatin remodeling genes. However, the downstream 
targets and substrates are not known yet. 
 
1.4.2.3 Phosphorylation of P68 by c-abl kinase 
 C-abl belongs to the non-receptor tyrosine kinase family (Abelson and Rabstein 
1970) (Goff, D'Eustachio et al. 1982; Shaul 2000). It is ubiquitously expressed, but is 
localized at different sites including cellular membranes, cytoskeleton, and in the 
cytoplasm (cytoplasmic c-Abl), and nucleus (nuclear c-Abl). It has nuclear localization in 
the fibroblasts, while cytoplasmic localization is seen primarily in haematopoietic cells 
and neurons (Van Etten 1999). This subcellular localization and shuttling ability of c-Abl 
is due to the nuclear localization signal (NLS) and a nuclear export signal (NES) 
(Taagepera, McDonald et al. 1998). The NLSs and DNA-binding sequences in c-Abl are 
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crucial for its nuclear functions (Pendergast 2002). Alternative splicing leads to the 
formation of abl- 1a and 1b isoforms. Abl-1b isoform with predominant localization in the 
nucleus is myristoylated. Isoform 1a lacks myristoylation site and is mostly cytoplasmic 
(Kharbanda, Pandey et al. 1997). 
 The functional domains of c-Abl include a myristoylation site in the N-terminus of 
1b isoform, tyrosine-kinase region, Src homology 2 (SH2) domain and SH3-domain with 
high affinity for proline-containing regions containing the PxxP motif (Cicchetti, Mayer et 
al. 1992; Ren, Mayer et al. 1993; Songyang, Shoelson et al. 1993; Pawson 1994; 
Songyang, Shoelson et al. 1994; Cohen, Ren et al. 1995). C-Abl also has a long C-
terminal tail that consists of three PxxP motifs, three NLS and a NES, actin and DNA-
binding domains. These structural domains are responsible for the ability of c-Abl to 
regulate different cellular processes by either direct protein-protein interactions or 
diverse subcellular localization (Tybulewicz, Crawford et al. 1991; Kipreos and Wang 
1992; Van Etten, Jackson et al. 1994; Miao and Wang 1996). C-Abl has functions in cell 
growth (Sawyers, McLaughlin et al. 1994), morphogenesis and actin dynamics 
(Woodring, Hunter et al. 2003), cell homeostasis (Schwartzberg, Stall et al. 1991; 
Tybulewicz, Crawford et al. 1991), and migration (Woodring, Litwack et al. 2002; 
Woodring, Hunter et al. 2003). C-abl also regulates cell-cycle and cell-growth arrest 
(Yuan, Huang et al. 1996) and induces apoptosis (Yuan, Huang et al. 1997). Growth-
factors, including PDGF (Plattner, Kadlec et al. 1999), EGF (Plattner, Kadlec et al. 
1999), TGFβ (Wang, Wilkes et al. 2005) etc activate cytoplasmic c-Abl. C-Abl with 
cytoplasmic localization is involved in normal cell transformation and cancer progression 
specifically in chronic myeloid leukemia (Krause and Van Etten 2005). Cytoplasmic c-
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Abl kinase demonstrates kinase activities in non-small cell lung cancers (Rikova, Guo et 
al. 2007) and breast carcinoma (Srinivasan and Plattner 2006). Studies carried out by 
Yang et al. showed an unanticipated function of cytoplasmic c-Abl in epithelial-
mesenchymal transition (EMT), and p68 being a substrate of this signaling process 
(Yang, Lin et al. 2006). EMT is defined as a process in which epithelial cells loose cell 
polarity, loose cell-cell contact and acquire a fibroblastoid, invasive morphology 
essential for cell motility. They found that PDGF stimulation of HT-29 colon cancer cells 
activates c-Abl which was phosphorylated by Src. Activated c-Abl phosphorylates p68 at 
Y593 in the cell nucleus. Phospho-p68 interacts with β-catenin in the nucleus after 
translocation and displaces β-catenin from the axin destruction complex. It does this by 
blocking GSK-3β-induced β-catenin phosphorylation. Phosphorylated p68 then 
promotes nuclear translocation of β-catenin causing stimulation of the EMT process 
(Yang, Lin et al. 2006). Phosphorylated p68 also promotes cell proliferation by activating 
the transcription of proliferative genes, such as c-myc and cyclin D1 (Yang, Lin et al. 
2007). Another study showed that phosphorylated p68 at Y593 suppresses E-cadherin 
expression by activating Snail 1 transcription. It does so by displacing HDAC1 from the 
MBD3:Mi-2/NuRD nuclear-remodeling and deacetylation-complex assembled at the 
Snail 1 promoter (Carter, Lin et al. 2010). 
 
1.4.2.4 A-kinase-anchoring protein (AKAP95) 
 A-kinase-anchoring protein (AKAP95) is a nuclear protein with zinc-finger 
domain. It has a docking site for PKA kinase, nuclear matrix targeting site, two zinc-
finger motifs and a PKA-binding domain (Coghlan, Langeberg et al. 1994; Akileswaran, 
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Taraska kinase et al. 2001). By virtue of its binding to cAMP/PKA, AKAP95 regulates 
chromatin condensation during mitosis (Collas, Le Guellec et al. 1999; Steen, 
Cubizolles et al. 2000). P68 binds to AKAP95 (Akileswaran, Taraska et al. 2001). 
During interphase, interaction of p68 with AKAP leads to localization of p68 to the 
nuclear matrix, and further suggests the possibility for PKA to target p68. Since AKAP95 
has the scaffolding function and a docking site for PKA, known for its established role in 
regulating CBP/CREB transcriptional initiation complexes, (Arias, Alberts et al. 1994; 
Kwok, Lundblad et al. 1994) and p68 associates with CBP regulating CBP-mediated 
transcription (Endoh, Maruyama et al. 1999), it is quite possible for the involvement of 
this complex in the changes in chromatin structure and gene expression regulation 
(Akileswaran, Taraska et al. 2001). 
 
1.5 COLORECTAL CANCER (CRC) 
Colorectal cancer (CRC) has a very high mortality rate and more than a million 
cases are reported every year. The incidence of colorectal cancer is equally distributed 
between both the sexes. The highest rate of occurrence is seen in developed nations 
such as North America, Australia, Western Europe, most probably due to dietary factors 
(Parkin, Bray et al. 2005; Saunders and Iveson 2006). The risk factors for developing 
colorectal cancer are genetic, increasing age, colonic polyps and lifestyle factors such 
as diet (fiber deficiency, obesity, high consumption of alcohol), sedentary lifestyle, 
diabetes mellitus, and smoking (Cunningham, Atkin et al. 2010). The diagnosis of CRC 
is based on colonoscopy or sigmoidoscopy with tumor biopsy. After detection of the 
newly diagnosed cancer, physical examination and complete colonoscopy are 
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performed to detect tumor (Mauchley, Lynge et al. 2005). Approximately 70 to 80% of 
CRC patients develop localized disease and surgery is the optimum curative treatment 
(Bennouna and Douillard 2002). Adjuvant chemotherapy is used for high-risk patients 
after surgery to avoid recurrence. Nearly half of the CRC patients still develop 
disseminated, advanced disease and receive systemic chemotherapy or surgery. The 
survival rates have increased in the past few years due to large scale screening and 
early diagnosis (Saunders and Iveson 2006). Nearly 20% of CRC patients develop 
metastatic disease (mCRC) with the liver, lung, peritoneum, and retroperitoneum being 
the most common sites of CRC metastasis. The systemic chemotherapy approved by 
FDA (Food & Drug Administration) includes 5-fluorouracil (5-FU), leucovorin, 
bevacizumab, oxaliplatin, cetuximab, irinotecan, capecitabine, and panitumumab. The 
systemic therapy for CRC aims at mitigating the symptoms, increasing the life 
expectancy and regression of the tumor in liver-only metastases for surgical resection. 
Combination systemic therapy has increased the median survival of CRC patients in the 
last decade to roughly 2 years (Goodwin and Asmis 2009). Thus, combination of 
targeted treatments with conventional cytotoxic drugs and population screening has 
improved outcomes and has caused incremental survival advantage in the colorectal 
cancer treatment. 
 
1.5.1 Chemotherapy for Metastatic Colorectal Cancer 
1.5.1.1 FOLFIRI or FOLFOX Regimen 
The standard chemotherapeutic agent for metastatic CRC has been 5-
fluorouracil (5-FU) for over half a century (Krueger, Alexander et al. 2006) (Saunders 
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and Iveson 2006). The drug 5-FU is a cytotoxic thymidylate-synthase (essential for DNA 
synthesis) inhibitor and is typically administered with leucovorin. Leucovorin, a 
thymidylate-synthase modulator, also called folinic acid increases the antineoplastic 
effects of 5-FU (Goodwin and Asmis 2009). When 5-FU is administered alone, it is not 
very effective, with the response rate being just 20% in advanced disease and survival 
rate just 12 months. Leucovorin and 5-FU administered together have a slightly better 
response rates but the overall survival is 11 to 13 months. The latest combination 
therapy consisting of 5-FU-leucovorin, irinotecan or oxaliplatin has doubled the overall 
survival of 14 to 21 months in advanced disease (Grothey and Schmoll 2001; Grothey, 
Sargent et al. 2004). Irinotecan belongs to the campothecin family, and is an inhibitor of 
topoisomerase I during replication. Optimal chemotherapy for metastatic CRC includes 
administration of 5-FU (F=fluorouracil) and leucovorin (FOL=folinic acid) combined with 
either oxaliplatin (OX) or irinotecan (IRI), forming FOLFIRI or FOLFOX regimens, 
respectively (Goodwin and Asmis 2009). Studies carried out by Tournigand et al. 
reported that FOLFIRI has 56% response rate and progression-free survival (PFS) of 
8.5 months, while FOLFOX has 54% response rate and 8 months PFS concluding that 
both the regimens have similar efficacy (Tournigand, Andre et al. 2004).  
 
1.5.1.2 Targeted Therapies 
 Targeted cancer therapies utilize drugs that specifically interfere with particular 
molecules involved in tumor growth and progression. Treatment for metastatic CRC in 
the last several years has included the administration of inhibitors of vascular 
endothelial growth factor (VEGF) and of epidermal growth factor receptor (EGFR) 
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(Patiyil and Alberts 2006). Bevacizumab is a VEGF antibody that binds to VEGF-ligand 
thereby blocking and inhibiting angiogenesis. It aids in more effective delivery of 
chemotherapy to the tumor site by normalizing abnormal tumor vasculature and 
inhibiting neovacularization. It is generally given in combination with 5-FU-based 
chemotherapy regimen since being sanctioned by US Food and Drug Administration 
(FDA) in 2004 (Hurwitz, Fehrenbacher et al. 2004). According to a study carried out by 
Hurwitz et al., Bevacizumab given with FOLFIRI regimen increases the RR of patients 
from 35% to 45% (Hurwitz, Fehrenbacher et al. 2004). Bevacizumab administered with 
FOLFOX regimen does not cause any change in RR (Goodwin and Asmis 2009). 
Panitumumab, a fully humanized (not chimeric) monoclonal antibody for EGFR was 
approved by FDA in 2006. It is normally given to patients following 5-FU, oxaliplatin and 
irinotecan regimens. Panitumumab has a RR of 10% and does not cause much serious 
infusion reactions as seen with cetaximab (3%) (Van Cutsem, Peeters et al. 2007). 
However, the efficacy of panitumumab when given with systemic chemotherapy or its 
effect in comparison to cetaximab is still not known. 
 
1.5.1.3 Oxaliplatin 
 Oxaliplatin is a platinum-based agent containing a 1,2-diaminocyclohexane 
ligand. It is used in colorectal cancer chemotherapy (Jung and Lippard 2007). 
Oxaliplatin administered as a single agent has low activity in many tumors and is 
generally given in combination therapy with 5-FU and leucovorin. Exact mechanism of 
oxaliplatin in this complex is not known, however, it is suggested that it can 
downregulate dihydropyrimidine dehydrogenase, slowing the catabolism of 5-FU 
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(Fischel, Formento et al. 2002). Cellular uptake of oxaliplatin occurs through passive 
diffusion and carrier-mediated transport systems (Ghezzi, Aceto et al. 2004; Safaei and 
Howell 2005). Oxaliplatin exerts its cytotoxic effect by causing DNA-damage brought 
about by platinum DNA-adducts formed by binding of oxaliplatin to guanine residues of 
DNA (Raymond, Faivre et al. 2002; Chaney, Campbell et al. 2005; Hah, Sumbad et al. 
2007). The DNA lesions lead to inhibition of DNA replication resulting in cell-cycle arrest 
and apoptosis (Di Francesco, Ruggiero et al. 2002). It also causes inhibition of RNA 
synthesis and triggers immunologic reactions causing immunogenic death of colon 
cancer cells (Todd and Lippard 2009; Tesniere, Schlemmer et al. 2010). In terms of 
toxicity caused by oxaliplatin, it is less neurotoxic than other platinum compounds, but 
still causes adverse reactions specifically in the haematopoietic system, the peripheral 
nerves, and the gastrointestinal system (Donzelli, Carfi et al. 2004; Alcindor and 
Beauger 2011). 
 Oxaliplatin causes cell death through DNA-platinum adducts, which trigger 
massive apoptosis (Faivre, Chan et al. 2003). γ-H2AX, a marker of double-strand 
breaks and factor in DNA-repair process, is found to be induced by oxaliplatin via p53-
dependent and -independent pathways (Chiu, Lee et al. 2009). The molecular 
mechanism of oxaliplatin action involves G/M arrest and apoptosis. G2/M arrest leads to 
reduction in both cyclin B1 expression and phosphorylated-CDC2 (Arango, Wilson et al. 
2004; Chiu, Lee et al. 2009). Treatment of HCT116 colorectal cancer cells with 
oxaliplatin activates intrinsic-mediated apoptosis. Subsequently, there is caspase-3 
activation followed by cellular apoptosis (Arango, Wilson et al. 2004). The cytotoxic 
effects of oxaliplatin are p53 status-dependent. One study demonstrated that p53 wild-
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type cells, including HCT116 cells, are sensitive to oxaliplatin while p53-mutated cells 
are resistant to its action. Oxaliplatin effects are influenced by p21, a cyclin-dependent 
kinase inhibitor regulated by p53, gene status. Oxaliplatin strongly induces p21 
expression and G0-G1 arrest in p53 wild-type cells (Hata, Yamamoto et al. 2005). 
Oxaliplatin is also known to deactivate ERK, which induces PUMA (p53 up-regulated 
modulator of apoptosis), involved in apoptosis through the intrinsic pathway (Wang, Li et 
al. 2006). Oxaliplatin is also found to inhibit survivin expression, a protein that protects 
cell from apoptosis. Furthermore, the mechanism of reducing survivin expression is 
through p38 MAPK pathway. Oxaliplatin treatment causes activation and 
phosphorylation of p53, which in turn activates and phosphorylates p38 MAPK. 
Phosphorylated p38 reduces survivin protein level to enhance oxaliplatin-induced 
cancer cell death (Liu, Hu et al. 2010; Sohn, Lee et al. 2010).  
 
1.5.2 Phosphorylation of P68 by P38MAPK 
 The transmission of wide-array of extracellular stimuli to their intracellular targets 
is mediated through intracellular mitogen-activated protein kinase (MAPK) pathways. 
MAPKs relay, amplify, and integrate these stimuli to produce required physiological 
responses, such as inflammation, cellular proliferation, and apoptosis (Rouse, Cohen et 
al. 1994). The MAPK-cascade consists of 3 canonical, parallel, serine/threonine-kinase 
cascades: (1) extracellular signal-regulated kinases (ERKs), (2) c-jun N-terminal or 
stress-activated protein kinases (JNK/SAPK), and (3) p38-group of protein kinases. 
ERK promotes cellular proliferation and inhibit cell death. JNK and p38-MAPK promote 
cellular inflammation or programmed cell-death (Galcheva-Gargova, Derijard et al. 
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1994; Xia, Dickens et al. 1995). These MAPKs are expressed in all eukaryotic 
organisms in an inactive state (non-phosphorylated form). The MAPK pathway consists 
of three kinase cascades made up of Mitogen-activated protein kinase, Mitogen-
activated protein kinase kinase and Mitogen-activated protein kinase kinase kinase. 
Each MAPK is tightly regulated in the cells (Cobb and Goldsmith 1995). 
P38 MAPK was first isolated after LPS stimulation (Han, Lee et al. 1993; Han, 
Lee et al. 1994). P38 MAPK is activated by dual phosphorylation of two TGY motifs by 
upstream MAPKK-3 and MAPKK-5 in response to cellular stresses including 
proinflammatory cytokines, such as TNF-α, IL-1, heat shock, UV-irradiation, high 
osmotic stress, LPS, protein synthesis inhibitors such as anisomycin, arsenite, H2O2, 
anti-cancer drugs, such as cisplatin, oxaliplatin, and certain mitogens such as GM-CSF, 
FGF etc (Raingeaud, Gupta et al. 1995; Jiang, Chen et al. 1996; Cuenda, Cohen et al. 
1997; Jiang, Gram et al. 1997). Activated phosphorylated p38 is subsequently 
inactivated by dephosphorylation by protein phosphatase 2A, MAPK phosphatase etc 
(Barancik, Htun et al. 1999; Lee, Kim et al. 2003; Levy-Nissenbaum, Sagi-Assif et al. 
2003). There are four different isoforms of p38: α, β, γ and δ isoforms (Han, Lee et al. 
1994; Lee, Laydon et al. 1994; Jiang, Chen et al. 1996; Lechner, Zahalka et al. 1996; Li, 
Jiang et al. 1996; Cuenda, Cohen et al. 1997; Jiang, Gram et al. 1997; Kumar, 
McDonnell et al. 1997; Enslen, Raingeaud et al. 1998). P38 α- and β-isoforms are found 
in all cell-types (Jiang, Chen et al. 1996) while γ and δ isoforms have a limited 
expression depending on the tissue type. The γ-isoform is mostly found in the skeletal 
muscle cells (Lechner, Zahalka et al. 1996; Li, Jiang et al. 1996; Jiang, Gram et al. 
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1997) whereas the δ-isoform is found in the small intestine, lungs, kidneys, testis, and 
pancreas (Jiang, Gram et al. 1997; Kumar, McDonnell et al. 1997).  
P38α is belongs to the p38 MAPK family. Activated p-p38α MAPK 
phosphorylates and activates a number of downstream targets, notably protein kinases 
such as MNK1 (Fukunaga and Hunter 1997; Waskiewicz, Flynn et al. 1997), p38 
regulated/activated kinase (PRAK) (New, Jiang et al. 1998), or Mitogen-and stress–
activated protein kinase-1 (MSK1) (Deak, Clifton et al. 1998), transcription factors, such 
as SRF accessory protein (Sap1) (Janknecht and Hunter 1997), growth arrest and 
DNA-damage inducible gene 153 (CHOP) (Wang and Ron 1996), activating 
transcription factor (ATF-1/2/6) (Tan, Rouse et al. 1996), p53 (Huang, Ma et al. 1999), 
myocyte enhance factor 2C (MEF2C) (Han, Jiang et al. 1997), and high-mobility group-
box protein 1 (HBP1) (Yee, Paulson et al. 2004). Other p38 substrates include cPLA2 
(Kramer, Roberts et al. 1996), tau (Reynolds, Nebreda et al. 1997), keratin 8 (Feng, 
Zhou et al. 1999), and stathmin (Parker, Hunt et al. 1998).  
P38 plays important roles in differentiation, apoptosis, inflammation, 
development, and cell cycle. P38 is found to be activated by a number of anti-cancer 
agents to trigger apoptosis. Treatment of Rat-1 cells with cisplatin induces p38 
phosphorylation which leads to heat-shock protein 27 phosphorylation and subsequent 
apoptosis (Deschesnes, Huot et al. 2001). Retinoid CD437 induces extensive p38-
mediated apoptosis in CA-OV-3 ovarian carcinoma cells (Holmes, Soprano et al. 2003). 
P38 is also known to participate in G1 and G2/M cell cycle phases (Takenaka, 
Moriguchi et al. 1998; Wang, McGowan et al. 2000). Activation of p38 is required for 
Cdc-42 induced G1 arrest in the NIH3T3 cells (Wang, McGowan et al. 2000). 
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Furthermore, G2 cell cycle arrest induced by UV light is p38-dependent (Wang, Huang 
et al. 1998). P38 is implicated in cellular differentiation such as differentiation into 
adipocytes, cardiomyocytes, chondroblasts, erthyroblasts, myoblasts and neurons 
(Nebreda and Porras 2000). Specifically, p38 is essential for the differentiation of PC12 
cells into neuronal cells,  mouse 3T3-L1 cells into adipocytes, and SKT6 cells into 
haemoglobinised cells (Engelman, Lisanti et al. 1998; Nagata, Takahashi et al. 1998; Li, 
Jiang et al. 2000). P38 involvement in senescence is also reported (Bulavin, Demidov et 
al. 2002; Haq, Brenton et al. 2002; Wang, Chen et al. 2002). P38 has also been 
associated with tumorigenesis in certain cells. One study demonstrated that decreased 
activation of p38 in tumors results in increased proliferation and tumorigenic conversion 
of the cells (Brancho, Tanaka et al. 2003). P38 is also implicated in placental 
angiogenesis and erythropoiesis suggesting the differential role of p38 in development 
(Nagata and Todokoro 1999; Mudgett, Ding et al. 2000). P38 is also implicated in 
inflammation and is associated with diseases such as Rheumatoid arthritis, Alzheimer’s 
disease, and inflammatory bowel disease (Perregaux, Dean et al. 1995; Johnson and 
Bailey 2003; Hollenbach, Neumann et al. 2004). 
In vitro studies carried out by Yang et al showed that p68 is a cellular target of 
p38 (Yang, Lin et al. 2005). They observed threonine phosphorylation of p68 following 
TNF-α treatment which was inhibited with the exposure to increasing concentrations of 
SB203580. SB203580 is a pyridinyl imidazole inhibitor that inhibits the phosphorylation 
and the activation of p38 (Cuenda, Rouse et al. 1995). In vitro kinase assay also 
demonstrated that p68 is phosphorylated by p38. All these results confirm the p68 
threonine phosphorylation. This is in consistence with the fact that p38 usually 
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phosphorylates and activates transcription factors and protein kinases and p68 is a well 
known transcriptional co-activator. However, whether p38 phosphorylates p68 in vivo 
and the biological consequence of this phosphorylation is still unknown and warrants 
further investigation. 
 
1.6 CYTOSKELETON 
Cytoskeleton is an interconnected, dynamic, and adaptive filamentous network of 
polymeric proteins that regulate cell structure, shape, and function (Fletcher and Mullins 
2010). It consists of F-actin, microtubules, and intermediate filaments which are in turn 
made up of chemically distinct subunits, actin, tubulin, and intermediate protein (Janmey 
1998). Cytoskeleton integrates the activity of these proteins to carry out three main 
functions of sensing extracellular stimuli to respond to transmembrane receptors and 
intracellular signals, organizing the contents of the cell spatially and modulating the 
mechanical properties of the cell required for locomotion and cytokinesis (Condeelis 
1993; Cornet, Ubl et al. 1993; Stossel 1994; Fishkind and Wang 1995). The cytoskeletal 
network generates forces that provide scaffolding on which molecular motors move 
organelles or generate internal stress. There are many regulatory proteins that control 
the cytoskeletal network formed by the polymers.  
 
1.6.1 Actin 
Actin is the most highly expressed protein in the eukaryotic cells and is 
composed of actin monomers. It is composed of three main actin isoforms: α-isoforms 
of skeletal, cardiac, and smooth muscles and β- and γ-isoforms of nonmuscle and 
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muscle cells. It is highly conserved and can transit between monomeric and filamentous 
states and associate with actin-binding proteins (Herman 1993; Dominguez and Holmes 
2011). Bundles of actin filaments give support to filopodia essential during chemotaxis, 
cell motility, and cell-cell communication and provide polarity to the regulation of 
transcription (Dominguez and Holmes 2011).  
 
1.6.2 Intermediate Filaments 
 Intermediate filaments belong to a class of cytoskeletal proteins that have an 
average diameter of 10 nm. They get their name from their diameter as their average 
diameter is between those of actin (7 nm) and microtubules (25 nm) (Ishikawa, Bischoff 
et al. 1968). They are mostly cytoplasmic with one exception of lamins that are nuclear. 
Intermediate filaments are present only in multinuclear eukaryotes whereas actins and 
microtubules are expressed in eukaryotic and prokaryotic organisms (Erber, Riemer et 
al. 1998). There are atleast 65 functional genes encoding intermediate filament proteins 
(Hesse, Magin et al. 2001). They are classified into 6 types: from type I to type VI. 
Intermediate proteins contain α-helix rod domain and have a coiled-coil structure (Fuchs 
and Cleveland 1998; Herrmann, Hesse et al. 2003). A protein called plectin links 
intermediate filaments to each other as well as to actin and microtubules (Wiche 1998). 
Keratins help the cells to resist shear stress while lamins provide mechanical strength to 
the nucleus and trigger nuclear membrane breakdown at the beginning of mitosis. 
However, intermediate filaments cannot provide directional movement of molecular 
motors as they are not polarized (Tsai, Wang et al. 2006; Flitney, Kuczmarski et al. 
2009).  
 40 
1.6.3 Microtubules 
Microtubules are filamentous, tubulin-containing proteins representing important 
part of the cytoskeleton. Microtubules are made up of α- and β- tubulins that can grow 
as long as 25 μm and are highly dynamic. They are involved in maintaining cell shape 
and structure, in the vesicular and mitochondrial transport, in the formation of spindle 
during mitosis and cell division and in cell signaling (Jordan and Wilson 2004). 
Dynamics of microtubule polymerization are tightly regulated and many regulatory 
proteins such as microtubule-associated proteins (kinesin, dynein, katanin) bind to 
microtubules for regulating microtubule dynamics. The functional diversity of 
microtubules is also regulated by the expression and functions of different tubulin 
isoforms, and several modifications of tubulin at the post-translational level including 
polyglutamylation, polyglycylation, phosphorylation, and acetylation (Desai and 
Mitchison 1997; Luduena 1998; Verdier-Pinard, Wang et al. 2003). 
Microtubule nucleus is generated by α- and β- tubulin heterodimers which is 
extended by polymerization of tubulin dimers end to end to form a cylinder. This cylinder 
has 13 protofilaments of tubulin heterodimers. Protofilaments form the building block of 
the microtubule structure which can be extended by the addition of more protofilaments. 
Microtubules have a distinct polarity with α-subunit [designated (-) minus end] of one 
tubulin dimer linked to the β-subunit [designated (+) plus end] of the next dimer. (Jordan 
and Wilson 2004) (Desai and Mitchison 1997).  
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1.7 TPPP/P25 
TPPP/p25 (Tubulin polymerization promoting protein/p25), also known as p25α, 
is a small, basic, heat resistant, 219 amino-acid containing protein. It was initially 
purified from bovine brain in tau protein kinase II (TPKII) fraction (Takahashi, Tomizawa 
et al. 1991). TPPP/p25 is evolutionary conserved among mammalian species with the 
human homolog of TPPP/p25 sharing 90% homology with bovine TPPP/p25. TPPP/p25 
is located on chromosome 5 (Seki, Hattori et al. 1999). It is found only in animals but not 
in prokaryotes, plants and fungi (Orosz and Ovadi 2008). It is a newly discovered tubulin 
targeting protein and functionally, it closely resembles the characteristics of microtubule-
associated proteins (MAPs) by binding to tubulin (Hlavanda, Kovacs et al. 2002). 
TPPP/p25 is also called as p25α because it binds to α-synuclein, a protein that 
accumulates as insoluble aggregate in cytoplasmic inclusions in Parkinson’s disease 
and other α-synucleinopathies (Gai, Power et al. 1999; Lindersson, Lundvig et al. 2005). 
It is also described as p24 due to its function as a glycogen synthase kinase-3 inhibitor 
(Martin, Vazquez et al. 2002). 
 
1.7.1 Structure and Expression 
TPPP/p25 has a α-helical content of 4% as against the predicted values of 30-
43% (Hlavanda, Kovacs et al. 2002). It is natively folded under physiological conditions 
but has a flexible structure that unfolds co-operatively under equilibrium conditions 
(Otzen, Lundvig et al. 2005). However, there is a disagreement about the structure of 
TPPP/p25 with another group reporting that TPPP/p25 is an unfolded protein. It has a 
well defined 3D structure only when it is associated with specific binding proteins such 
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as chaperones (Hlavanda, Kovacs et al. 2002; Tirian, Hlavanda et al. 2003; Orosz, 
Kovacs et al. 2004). It shows an abundance of “disorder promoting amino-acids” such 
as Q,S,P,E,K,A,R,G but does not contain “order promoting amino-acids” such as 
W,C,F,I,Y,L,N,V. TPPP/P25 has an N-terminal region which is disordered, consisting of 
50 amino-acids followed by a highly flexible ordered core of 40 residues consisting of β-
structure. TPPP/p25 is not very hydrophobic and has a high net charge with a pI of 9.5 
(Orosz, Kovacs et al. 2004). 
There are two shorter homologs of TPPP/p25 with which it shares roughly 60- 
75% homology. They are TPPP/p18 consisting of 170 amino-acids with the gene name 
p25β and TPPP/p20 consisting of 176 amino-acids and having the gene name CGI-38. 
TPPP/p18 and TPPP/p20 lack the unstructured N-terminal region (from 3-43) of 
TPPP/p25 and demonstrate extensive homology in the middle and C-terminal regions 
including the conserved Rossmann motif GXGXXG (Shiratsuchi, Sato et al. 1995; Seki, 
Hattori et al. 1999; Zhang, Wu et al. 2002; Vincze, Tokesi et al. 2006). TPPP/p18 is 
more ordered and shares 57% identity with TPPP/p25 with high expression in the liver 
and pancreas and is moderately expressed in the heart, kidney and skeletal muscle. 
Interestingly, its transcript is detected only in the fetal brain. It is also detected only in 
breast carcinoma, pancreas adenocarcinoma and occasionally, colon adenocarcinoma 
(Zhang, Wu et al. 2002). TPPP/p18 is distributed homogenously in the cytoplasm. It is 
more ordered and does not crosslink microtubules like TPPP/p25 implying that 
TPPP/p18 does not influence microtubule network. TPPP/p20, on the other hand, 
behaves like a disorganized protein and has a very high microtubule bundling ability 
(Vincze, Tokesi et al. 2006). 
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TPPP/p25 was first detected in the bovine brain specifically in the 
oligodendrocytes of the nervous tissue (Takahashi, Tomizawa et al. 1991; Takahashi, 
Tomizawa et al. 1993; Kovacs, Laszlo et al. 2004). Rat brain homogenates showed that 
TPPP/p25 expression begins to be detectable on E20 (embryonic day 20) in myelinating 
oligodendrocytes and gradually increases in the brain from 1-2 years of age to 
adulthood (Skjoerringe, Lundvig et al. 2006).  However, Seki et al. demonstrated that 
TPPP/p25 mRNA is found in various tissues (Seki, Hattori et al. 1999). Acevedo et al 
showed that TPPP/p25 is not exclusively expressed in the brain inspite of its high 
expression in the brain. They detected TPPP/p25 expression in the liver, lung and heart 
tissue extracts. Immunoblot analysis revealed high expression in the brain, testis, heart, 
skeletal muscle, and eyes (Table 1.1) (Acevedo, Li et al. 2007). In the mouse brain, 
specifically, TPPP/p25 is found in the oligodendrocytes and in the axons of myelinated 
neurons of the white matter of the cerebellum and nuclei of the granule cells of the 
cerebellum. TPPP/p25 is also found in the neuroglia and the neuropil and pyramidal 
neurons of the cerebral cortex. However, it is not expressed in the hippocampus 
(Acevedo, Li et al. 2007). TPPP/p25 gene is not present in the non-ciliated organisms 
but is conserved in the ciliated organisms. In these ciliated organisms, TPPP/p25 could 
be involved in the motile or sensory functions of the cilia/basal bodies. Basal bodies are 
the microtubule rich cellular elements that resemble centrioles (microtubule organizing 
centers, MTOC). Very high concentration of TPPP/p25 is seen in the MTOC and 
cytokinetic cleavage furrow suggesting the TPPP/p25 involvement in the cell cycle 
process (Orosz and Ovadi 2008). 
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At the subcellular level, nuclear and cytoplasmic localization of TPPP is observed 
in the cells such as HUVEC, HeLa and NIH3T3 and it co-localizes specifically with the 
stabilized microtubules in the cytoplasm. However, in the migratory cells, it is detected 
only in the cytoplasm co-localized with the microtubules and around the nucleus 
(Acevedo, Li et al. 2007). Over-expression of TPPP/p25 causes dramatic changes in 
the cellular morphology and leads to the formation of two major types of structures: the 
aggresome and the perinuclear cage observed in pathological brain tissues. The 
nucleus becomes bi- or multilobed in highly expressing cells with a bright aggregate of 
the protein and a dense network of disordered bundles of microtubules and intermediate 
filaments interdispersed with small cisternae of RER. These round juxtanuclear bodies 
are called aggresomes which are pathological inclusion like structures observed near 
the microtubule-organizing center (MTOC). Such superstructures (aggresome/inclusion 
body) may either lead to cell death or provide cytoprotecting mechanism evading cell 
death (Lehotzky, Tirian et al. 2004). 
 
1.8 FUNCTIONS OF TPPP/P25 
1.8.1 Cellular Functions of TPPP/p25 
Tubulin/microtubule system is the main target of TPPP/p25. Brain extract 
harboring increased TPPP/p25 protein levels demonstrated increased tubulin 
polymerization activity in comparison to the muscle extract which did not exhibit any 
activity while neuroblastoma cells showed ~10 fold lesser activity in comparison to the 
brain extract (Hlavanda, Kovacs et al. 2002; Tirian, Hlavanda et al. 2003). The C-
terminal has a segment that is also present in the protein tau which is the tubulin 
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binding region of tau and consequently, may also be the region where TPPP/p25 binds 
to tubulin (Himmler, Drechsel et al. 1989; Lee, Neve et al. 1989; Hlavanda, Klement et 
al. 2007). TPPP/p25 binds to both tubulin and microtubules in vitro and in the cells and 
perturbs the physiological tubulin assemblies and microtubular ultrastructures. In vitro 
binding of TPPP/p25 to tubulin, most probably, tubulin dimers influences microtubule 
assembly by promoting the formation of tubulin assemblies while binding to 
microtubules alters microtubule ultrastructures by inducing strong bundling of 
microtubules. TPPP/p25, at substoichiometric concentration, interacts with tubulin to 
cause its polymerization into intact-like microtubules, polymorphic aggregates, and 
bundling of paclitaxel stabilized microtubules (Hlavanda, Kovacs et al. 2002; Tirian, 
Hlavanda et al. 2003).  
 At low expression levels in the eukaryotic cells, TPPP/p25 co-localizes with the 
microtubule network maintaining its physiological integrity. This co-localization is 
dynamic and alters during mitosis without affecting the cell cycle process. TPPP/p25 
also causes bundling of microtubules in the eukaryotic cells similar to that observed in in 
vitro studies and the bundled microtubules counteract and resist the destabilizing 
function of vinblastine, a specific microtubule destabilizing agent. The stabilization of 
microtubule filaments/bundles mediated by TPPP/p25 denotes the basic physiological 
function of TPPP/p25 to strike a balance between stabilization of microtubules and their 
polymerization dynamics which, in fact, could play an important role during 
oligodendrocyte differentiation. This microtubule specific function of TPPP/p25 along 
with its interaction suggests that it is a microtubule associated protein (MAP) like tau 
protein (Lehotzky, Tirian et al. 2004). In contrast, high expression levels of TPPP/p25 
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are observed in the pathological conditions. Overexpression of TPPP/p25 rearranges 
microtubule network into aggresome like structure consisting of TPPP/p25 accumulation 
around the centrosome, protruding into the nucleus and perinuclear cage consisting of 
TPPP/p25 forming a filamentous cage of microtubules surrounding the nucleus. These 
aberrant structures interfere with the intracellular transport processes, inhibiting cell 
division and ultimately, leading to cell death (Lehotzky, Tirian et al. 2004). In fact, 
introduction of bovine TPPP/p25 into Drosophila embryos blocks formation of mitotic 
spindles and breakdown of nuclear envelop during mitosis without affecting centrosome 
duplication and separation, nucleation of microtubules, and nuclear growth (Hlavanda, 
Kovacs et al. 2002). However, GTP can modulate and inhibit the interaction of tubulin 
and TPPP/p25, thereby, inhibiting TPPP/p25-induced tubulin polymerization. GTP 
interacts with tubulin and serves as a main regulator of microtubules in brain. In 
addition, TPPP/p25 has GTP binding motifs and Mg2+ dependent GTPase-activity by 
virtue of which it specifically hydrolyzes GTP suggesting its potential role in different 
physiological processes (Hlavanda, Kovacs et al. 2002; Tirian, Hlavanda et al. 2003; 
Zotter, Bodor et al. 2011). 
Studies by Acevedo et al showed that TPPP/p25 functions in the stabilization and 
maintainence of the integrity of the microtubular network. They found that reduction of 
TPPP/p25 by siRNA decreases acetylated tubulin and also reduces microtubule 
concentration affecting the ultrastructure of the microtubule network. They also found 
that cells stably expressing TPPP/p25 are larger in size as a consequence of greater 
amount of acetylated microtubules. Thus, down-regulation of TPPP/p25 decreases 
microtubule levels while overexpression increases stable microtubules and cell size 
 47 
(Acevedo, Li et al. 2007). The mechanism by which TPPP/p25 enhances tubulin 
acetylation involves inhibition of HDAC6 which is an enzyme responsible for tubulin 
deacetylation. TPPP/p25 interacts with HDAC6 and inhibits its deacetylase activity and 
in turn promotes acetylation of the microtubule network. However, stabilization of 
microtubules by TPPP/p25 cannot be completely attributed to tubulin acetylation alone 
but also to its bundling activity (Tokesi, Lehotzky et al. 2010). TPPP/p25 decreases the 
growth of microtubule plus ends thereby influencing microtubule derived cell motility. 
However, the precise mechanism by which it affects the cell motility is not known 
(Tokesi, Lehotzky et al. 2010). 
Phosphorylation of TPPP/p25 prevents microtubule assembly (Hlavanda, Kovacs 
et al. 2002; Tirian, Hlavanda et al. 2003; Acevedo, Li et al. 2007). Phosphorylation of 
TPPP/p25 specifically in its N-terminal region dramatically affects its tubulin 
polymerization ability leading to the formation of only aberrant microtubules (Hlavanda, 
Kovacs et al. 2002; Tirian, Hlavanda et al. 2003). LIMK1 phosphorylates TPPP/p25 to 
affect its ability to promote polymerization of tubulin resulting in microtubule-dissembly 
(Acevedo, Li et al. 2007). ERK2 and Cdk5-mediated phosphorylation also blocks tubulin 
assembly mediated by TPPP/p25. Phosphorylation causes some structural changes in 
the tubulin binding interface of TPPP/p25 due to which it is unable to induce appropriate 
conformation required for the tubulin assembly into microtubules (Hlavanda, Klement et 
al. 2007). 
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1.8.2 Role of TPPP/p25 in Differentiation 
 TPPP/p25 was first found to be expressed in the oligodendrocytes of most 
regions of the adult brain as a tubulin binding protein (Takahashi, Tomizawa et al. 1991; 
Takahashi, Tomizawa et al. 1993; Vincze, Tokesi et al. 2006). Oligodendrocytes are a 
type of brain cells required for axon and myelin sheath development that insulate the 
axons in the central nervous system (Baumann and Pham-Dinh 2001). They extend 
their filopodial processes to ensheath axons with myelin which consists mostly of lipids 
and some proteins. Myelin consists of myelin basic protein (MBP) as the main protein 
component during differentiation of oligodendrocytes (Hardy and Reynolds 1991; Schiff 
and Rosenbluth 1995; Akiyama, Ichinose et al. 2002). Oligodendrocyte progenitor cells 
give rise to pre-myelinating oligodendrocytes which in turn differentiate into myelin-
forming oligodendrocytes with long, arborized, microtubule containing projections. Pre-
myelinating oligodendrocytes do not express myelin proteins but express proteins like β-
IV-tubulin essential for  the transport of myelin components (Barres and Raff 1994; 
Trapp, Nishiyama et al. 1997; Terada, Kidd et al. 2005). TPPP/p25 is expressed by 
myelin-forming oligodendrocytes and thus, can be a marker of myelinating 
oligodendroglia. Oligodendrocyte progenitor cells show low expression of TPPP/p25 
where it is confined to the centrosome and MTOC. It is upregulated during 
differentiation of oligodendrocyte progenitor cells to oligodendrocytes being found 
around the nucleus, in the cytoplasm and along the microtubules. It co-localizes with 
MBP that is specifically expressed during oligodendrocyte differentiation (Goldbaum, 
Jensen et al. 2008). TPPP/p25 knockdown by siRNA decreases oligodendrocyte 
differentiation (Lehotzky, Lau et al. 2010). In summary, TPPP/p25 expression during 
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differentiation and its interaction with tubulin before myelin development may be 
essential in the formation of tubulin-related processes and microtubule network required 
for transport of lipids and proteins for myelin formation in differentiating 
oligodendrocytes. 
 
1.8.3 Involvement of TPPP/p25 in Different Diseases 
TPPP/p25 is implicated in several neuro-degenerative diseases and could serve 
as a novel marker of alpha-synucleinopathies (Kovacs, Laszlo et al. 2004). Neuro-
degenerative diseases are characterized by accumulation of proteinaceous aggregates 
of α-synuclein or hyperphosphorylated tau (Goedert, Spillantini et al. 1998; Goedert 
2001). Accumulation of neuron-specific protein, α-synuclein is typical of 
neurodegenerative diseases such as alpha-synucleinopathies like Parkinson’s Disease 
(PD), Multiple System Atrophy (MSA), Diffuse Lewy Body Disease (DLBD) etc 
(Spillantini, Schmidt et al. 1997; Wakabayashi, Yoshimoto et al. 1998; Gai, Power et al. 
1999). Tauopathies include progressive supranuclear palsy (PSP), Pick’s Disease 
(PiD), corticobasal degeneration (CBD), Alzheimer’s Disease (AD) etc (Arai, Ikeda et al. 
2001; Dickson 2009). TPPP/p25 is abnormally found in the degenerating 
oligodendrocytes and neurons in alpha-synucleinopathies and is identified as α-
synuclein filament-binding protein. It binds to α-synuclein and participates in the tubulin-
induced alpha-synuclein aggregation and fibril formation. This contributes to the 
degenerative process which is accompanied by cytoskeletal disruption including the 
microtubular system (Lindersson, Lundvig et al. 2005). In MSA, there is an altered 
expression of α-synuclein and α-synuclein is localized with TPPP/P25. TPPP/p25 and 
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α-synuclein are also detectable in the neuronal Lewy body inclusions of PD and Lewy 
body dementia (Lindersson, Lundvig et al. 2005). Unlike α-synuclein, TPPP/p25 is not 
linked with the phosphorylated tau and does not stimulate its aggregation in tauopathies 
including AD. However, high expression of TPPP/p25 is seen in the granules of 
granulovacuolar degeneration and is found deposited near the tau filaments in AD brain 
(Kovacs, Laszlo et al. 2004). 
Immunohistochemical analysis of oligodendroglial neoplasms such as 
oligodendroglioma, oligoastrocytoma, and central neurocytoma showed that these 
tumor cells lack TPPP/p25 expression. Absence of TPPP/p25 in these cells suggests 
that the brain tumor cells may either loose TPPP/p25 expression during histogenesis of 
oligodendroglial neoplasms or they may arise from TPPP/p25 immuno-negative 
progenitor cells (Preusser, Lehotzky et al. 2007). This shows that TPPP/p25 is not 
required for providing the tubulin-related processes or stabilization of microtubules in 
oligodendroglial neoplasms. 
 
1.9 AIMS AND SIGNIFICANCES OF THE DISSERTATION 
The purpose of this dissertation is to characterize the functional role of threonine 
phosphorylation of p68 and study the transcriptional regulation function of p68 in 
regulating the cytoskeletal gene, TPPP.  
P68 RNA helicase is involved in several cellular processes from pre-mRNA 
splicing, transcription etc. to cell proliferation and differentiation (Liu 2002) (Endoh, 
Maruyama et al. 1999) (Stevenson, Hamilton et al. 1998). P68 is also found to be 
overexpressed in colon cancer (Causevic, Hislop et al. 2001). Previous studies 
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demonstrated phosphorylation of p68 at several residues (Yang and Liu 2004). P68 is 
tyrosine-phosphorylated in several cancer cells (Yang, Lin et al. 2005). PDGF-
stimulation of HT-29 cells lead to tyrosine phosphorylation of p68 at Y593 by c-abl 
(Yang and Liu 2006). Also, studies by Yang et al. showed that TNF-α treatment of HeLa 
cells phosphorylates p68 at threonine and dephosphorylates p68 at tyrosine residues 
indicating that TNF-α treatment reciprocally regulates the threonine and tyrosine 
phosphorylations of p68 (Yang, Lin et al. 2005). All these studies imply that p68 is a 
pleiotrophic protein that has different biological roles in multiple cellular pathways and 
that phosphorylation of p68 regulates the enzymatic activity and cellular functions of p68 
in different pathways in response to different external stimuli. In this dissertation study, 
we found that p68 gets phosphorylated at threonine residue(s) (T564 and/or 446) under 
the treatment of anti-cancer drug oxaliplatin in colon cancer cells. The protein is 
phosphorylated by p38 MAP-kinase upon the drug treatment. Further characterization of 
the role of threonine phosphorylation of p68 showed that it mediates, at least partially, 
the effects of the drug on apoptosis induction. Thus, the phosphorylation of p68, effect 
of phosphorylation on its cellular function, and the signaling pathway causing the 
phosphorylation are studied. This study shows an important mechanism of action of the 
anti-cancer drug which could be used for improving cancer treatment.  
The second part of the dissertation involves studying the role of p68 in the 
transcriptional regulation of TPPP. Numerous studies have shown that p68 functions as 
a transcriptional co-activator for a number of genes (Endoh, Maruyama et al. 1999). 
Previous reports demonstrated that p68 may regulate the expression of several genes 
that regulate the stability and dynamics of different cytoskeletal elements. In this 
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dissertation, the involvement of p68 in regulating TPPP expression is characterized. 
P68 is found to interact with the promoter region of TPPP and regulate its mRNA and 
protein expression. Control of TPPP expression by p68 is found to be an important 
event for neuronal differentiation. Expression of TPPP is important for cellular 
differentiation while its loss contributes to the development and progression of cancer. 
Our studies reveal an important mechanism that is critical for cellular differentiation. 
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Figure 1.1 DEAD-box RNA helicases in multiple cellular processes. 
DEAD-box RNA helicases are involved in ribosome biogenesis (Fal1, Rok1, Spb4 and 
Dbp10), pre-mRNA splicing (Prp28, Prp5 and Sub2), mRNA export (Dbp5 and Sub2), 
translation initiation (eIF4A, Ded1 and Vasa), organellar gene expression (Mss116, 
Mrh4 and Cyt-19), and RNA decay (RhlB, Dbp2 and Dhh1). Some of these RNA 
helicases is involved in two or more biological processes serving as a consequent link 
or control element for those processes. [Figure taken from Rocak et al. (2004). Nature 
reviews molcellbio. 5:232-241]. (Rocak and Linder 2004). 
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Figure 1.2 Drawing of the structure of full-length p68.  
The figure shows typical DEAD-box structure and it is refined to 2.6Aₒ resolution. The 
DEAD domain has a central 8-stranded β-sheet between 5 α-helices on each face and 
ADP molecule in the nucleotide binding pocket. [Figure taken from SGC - 
http://www.thesgc.org/structures/details?pdbid=3FE2/] 
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Figure 1.3a Structure of the human p68 gene (EMBL accession no. AF015812) 
with the distribution of exons and introns along with conserved DEAD-box motifs. 
Filled boxes with roman numbers on the top denote exons while introns and flanking 
regions are represented by thin lines (bar=500nt). The amino-acid sequences of 
conserved motifs are given in single letter code. [Figure taken from Rossler et al. 
(2000). Nucleic acids Research. 28(4): 932-939]. (Rossler, Hloch et al. 2000). 
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Figure 1.3b Schematic depiction of domains of p68 RNA helicase 
P68 is a 614 amino-acids containing protein. The bottom panel represents the domain 
structure of p68 consisting of N-terminal, C-terminal and helicase core region. Different 
sequence motifs are labeled while amino-acids are represented by numbers. The panel 
on the top denotes the core domain of p68 (134-430 amino-acid). [Figure taken from 
Yang et al. (2004). Biochemical and Biophysical Research Communications. 314: 622-
630]. (Yang and Liu 2004). 
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Figure 1.4 GTF assembly at a typical eukaryotic promoter 
The assembly of the basal transcription machinery is depicted here. A general 
eukaryotic promoter with a TATA box (TATA), an initiator motif (INR), which overlaps 
the transcription initiation site (arrow), and two GAGA elements (GAGA, not coloured) is 
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depicted. TBP (pink) is assembled when one or more GAGA factors interact with one or 
more GAGA elements. Several TAFs (pale pink) then join the basal complex followed 
by TFIIA (TFs not coloured). Stepwise addition of TFIIB, RNA pol IIa (red)±TFIIF dimer, 
TFIIE, TFIIH and the mediator (dark pink) complex takes place after isomerisation of the 
TFIIA±TFIID complex. This pre-formed RNA pol II holoenzyme increases the frequency 
of transcription initiation. Next step involves DNA melting and CTD phosphorylation in 
order for elongation to take place. Recycling of the various parts of the spent GTFs 
(broken arrows) helps to increase the rate of re-initiation. [Figure taken from Ogbourne 
et al. (1998). Biochem Journal. 331: 1-14]. (Ogbourne and Antalis 1998). 
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Figure 1.5 Depiction of functional interactions that affect basal (Upper) and 
activator-dependent transcription (Lower).  
The “pol II holoenzyme” components are denoted by square brackets while the basal 
coactivators (TBP, TFIIB, TFIIF, TFIIE, and TFIIH and pol II) are shown in yellow 
symbols. [Figure taken Nikolov et al. (1997). PNAS. 94:15-22]. (Nikolov and Burley 
1997).  
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Figure 1.6 Proteins interacting with p68/Dbp2 and the different biological 
functions carried out by them. 
The different roles of the DExD/H box protein are shown here. P68 found to co-purify 
with spliceosomes has an important function in the splicing process. P68 
transcriptionally coactivates a number of genes including ERα, Smad3, SRA, SRC1, 
RNA Pol II/CBP/p300 and functions as a transcriptional repressor for HDAC1 mediated 
transcription. P68 is also found to be involved in rRNA processing, mRNA decay and 
RNAi but the precise role is not yet known. [Figure taken Fuller-Pace et al. (2006). 
Nucleic Acids Research. 34(15):  4206-4215]. (Fuller-Pace 2006). 
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Table 1.1 Expression of TPPP/p25 in mouse tissues 
The table summarizes the different regions or cell types with TPPP/p25 expression. It is 
expressed both in the nucleus and the cytoplasm. “+” represents low levels of 
expression while “++” and “+++” denotes moderate and high levels respectively. Tissues 
without TPPP/p25 expression are as −. [The table is taken from Acevedo et al. (2007). 
Experimental Cell Research. 313(20): 4091-4106]. (Acevedo et al. 2007). 
 
 
Tissue 
 
IB 
 
IHC 
 
Cell-type or region 
Brain +++ +++ Neuropil, neuroglia, cortical neurons 
Heart ++ +++ Cardiac muscle cells 
Kidney − − Glomeruli, distal and proximal convoluted tubules 
Lung ++ ++ Bronchiole epithelium, alveolar cells 
Liver ++ − − 
Stomach + ++ Parietal cells in funding glands 
Intestine ++ ++ 
Crypts of Lieberkühn, lamina propria containing smooth muscle 
bundles, muscularis mucosae 
Spleen ++ ++ B lymphocytes (lymphoid follicles) 
Testis − +++ elongated spermatids, spermatocytes, early spermatids 
Ovaries − +++ 
Follicles—oocytes, granulosa cells, follicular epithelium, corpus 
luteum—granulosa lutein cells 
Skeletal 
Muscle 
− +++ Dark and light striations in muscle fibres 
Eye − +++ 
Retina—photoreceptors (cones and rods), outer and inner 
plexiform layer and ganglion cell fibre layer 
   Lens—anterior epithelium and lens fibres 
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CHAPTER 2 
PHOSPHORYLATION OF P68 RNA HELICASE BY P38 MAP-KINASE 
CONTRIBUTES TO COLON CANCER CELLS APOPTOSIS INDUCED BY 
OXALIPLATIN 
 
This chapter is published in BMC Cell Biol. 2012 Oct 31; 13(1):27. 
 
2.1 ABSTRACT 
It was shown initially that phosphorylation of p68 at threonine was associated 
with cancer cell apoptosis under the treatments of TNF-α and TRAIL (Yang, Lin et al. 
2005). The role of p68 phosphorylation in apoptosis induction following the treatment of 
colon cancer cells in culture with oxaliplatin was investigated in this study. Our data 
indicated that oxaliplatin treatment activates p38 MAP-kinase, which subsequently 
phosphorylates p68 at T564 and/or T446. P68 phosphorylation, at least partially, 
mediates the effects of the drug on apoptosis induction, as mutations at these two sites 
greatly reduce the cancer cell death. This study shows an important mechanism of 
action of the anti-cancer drug which could be used for improving cancer treatment. 
 
2.2 INTRODUCTION 
Oxaliplatin belongs to a new generation of platinum compounds currently used in 
the front line for human colorectal cancer and other cancers treatment (Raymond, 
Faivre et al. 1998). The therapeutic functions of oxaliplatin are from the DNA damage 
caused by the compound, which leads to arrest of the cell cycle and apoptosis (Faivre, 
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Le Chevalier et al. 2002; Rakitina, Vasilevskaya et al. 2007). The compound can 
damage DNA by crosslinking DNA thereby blocking DNA replication and transcription 
(Faivre, Le Chevalier et al. 2002; Fischel, Formento et al. 2002; Ang, Myint et al. 2010). 
It activates multiple signaling pathways in mediating apoptosis induction (Wang, Li et al. 
2006; Chiu, Lee et al. 2009). Oxaliplatin treatment causes activation of p38 and/or JNK 
kinases, which subsequently targets a number of downstream effector molecules 
leading to cancer cell apoptosis. Although the mechanism underlying the tumor 
apoptosis induced by the drug has been intensively studied, the detailed mechanism, 
especially the cellular molecules that contribute to the effects of the drug, is not fully 
understood. P38 is a stress-activated MAP-kinase that is activated by cellular stresses 
such as oxidative stress and toxic chemicals (Gould, Cuenda et al. 1995; Lu, Rau et al. 
2011). Activated p38 relays stress signals in the induction of cell apoptosis (Xia, 
Dickens et al. 1995; Zarubin and Han 2005). A number of anti-cancer agents act via 
activation of p38, such as platinum compounds (Wang and Lippard 2005), etoposide 
(Wood, Nail et al. 2006), and taxol (Shtil, Mandlekar et al. 1999). Phosphorylation of p38 
MAP-kinase at Thr180 and Tyr182 residues in its conserved TGY motif leads to its 
activation (New and Han 1998; Gong, Ming et al. 2010). The p38 MAP-kinase targets a 
number of very important downstream proteins to exert its effects on apoptosis 
induction. It is reported that phosphorylation of p53 on Ser46 by p38 is essential for 
apoptosis induction by several anti-cancer drugs or by certain viruses (Perfettini, 
Castedo et al. 2005; Perfettini, Castedo et al. 2005). Oxaliplatin treatment of colon 
cancer cells leads to activation of p38 MAP-kinase, which subsequently phosphorylates 
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gamma-H2AX and securin. These phosphorylation events lead to cancer cell apoptosis 
caused by oxaliplatin (Chiu, Chao et al. 2008; Liu, Liu et al. 2010). 
P68 RNA helicase is a RNA helicase with a DEAD-box motif (Lane and Hoeffler 
1980; Crawford, Leppard et al. 1982). It is implicated in cellular proliferation, 
differentiation (Stevenson, Hamilton et al. 1998) and cancer progression (Causevic, 
Hislop et al. 2001). P68 RNA helicase gets phosphorylated at several residues (Yang, 
Lin et al. 2005). Tyrosine phosphorylation of p68 is demonstrated in several cancer 
cells. C-abl phosphorylates p68 in HT-29 cells following PDGF-BB stimulation. P68 
phosphorylation at Y593 promotes EMT by allowing nuclear translocation of β-catenin 
(Yang, Lin et al. 2006). P68 phosphorylation in T98G glioblastoma cells causes 
resistance to apoptosis induced by TRAIL. Interestingly, when the cancer cells become 
apoptotic resistant, the double tyrosine phosphorylations of p68 increase while the 
phosphorylation of p68 at threonine decreases implying that phosphorylation of p68 at 
threonine may be important in the induction of apoptosis induced by the anti-cancer 
drug (Yang, Lin et al. 2005). We report here that, upon the anti-cancer drug oxaliplatin 
treatment, p68 RNA helicase becomes threonine-phosphorylated in colon cancer 
HCT116 cells. Oxaliplatin treatment activates p38 MAP-kinase in the cells, which 
subsequently phosphorylates p68 at T564 and/or T446. The phosphorylation of p68 at 
T564 and/or T446 is found to be important for the apoptosis induction by the drug. This 
study demonstrates an important factor responsible for the effects of oxaliplatin in 
apoptosis induction and may suggest a potential therapeutic strategy for cancer 
treatment. 
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2.3 RESULTS 
2.3.1 Oxaliplatin treatment of colon cancer cells induced p68-threonine 
phosphorylation 
A previous study showed that p68 tyrosyl-phosphorylation is associated with 
tumor development (Yang, Lin et al. 2005). In studying the effects of several anti-cancer 
drugs and p68 phosphorylation status, p68 threonine phosphorylation was reported in 
the colon cancer cells following the treatment with those anti-cancer drugs (Yang, Lin et 
al. 2005). So, the next question is whether p68 phosphorylation at threonine plays a role 
in mediating the anti-cancer drug effects. We used oxaliplatin which is used in the 
treatment of colon cancer patients and HCT116 as the study system. HCT116 is a colon 
cancer cell-line with a positive expression for transforming growth factor-beta. It has a 
mutation in the β-catenin gene (gain of function mutation). This mutation causes 
constitutive activation of a number of β-catenin-regulated downstream genes as a result 
of prevention of degradation of β-catenin. It also contains a homozygous mutation in 
mismatch repair gene hMLH1 (mutL homolog1), a gene whose mutation increases 
susceptibility to sporadic colorectal cancer. HCT116 cells has wild-type p53 gene and 
undergo apoptosis in a p53-responsive manner after exposure to different anti-cancer 
agents (Vikhanskaya, Colella et al. 1999). Treatment of HCT116 cells with different 
dosages of oxaliplatin for 24 hours induced cell-death. The cells showed roughly 30 to 
32% cell death at 20 μM concentration while 50% of the cells died at 40 μM drug 
concentration (Figure 2.1A). We then examined the threonine phosphorylation of p68 by 
using anti-phospho-threonine antibody and using the procedure reported in previous 
studies (Yang, Lin et al. 2005; Yang, Lin et al. 2007). Oxaliplatin treatment 
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demonstrated increased p68 phosphorylation at threonine (Figure 2.1B). This 
phosphorylation increase was observed with both the detached cells and the cells that 
were still attached to the culture plate following 24 hours of drug treatment (Figure 
2.1C). We subsequently tested the timing of the p68 threonine phosphorylation following 
oxaliplatin treatment. It was evident that the p68 threonine phosphorylation reached a 
peak around 4 – 6 hours of 20 μM treatment and the phosphorylation decreased 
thereafter (Figure 2.1D). 
 
2.3.2 P68 is phosphorylated by p38 MAP-kinase at T564 and T446 upon the drug 
treatment 
We next sought to investigate the protein kinase that phosphorylates p68 in 
response to oxaliplatin. It is very well known that oxaliplatin treatment of colon cancer 
cells activates p38 MAP-kinase which is critical for apoptosis induction in cancer cells 
(Xia, Dickens et al. 1995; Holmes, Soprano et al. 2003). To investigate the relation of 
p68-threonine phosphorylation and p38 MAP-kinase activation, we simultaneously 
probed threonine phosphorylation of p68 and phosphorylation of p38 MAP-kinase at the 
TGY motif using an antibody against phospho-threonine (14B3) after 
immunoprecipitating p68 (using p68 antibody) and phosphorylated/activated p38 (p-p38 
antibody) respectively in the HCT116 cells. It was clear that p38 MAP-kinase was 
activated upon the oxaliplatin treatment (Figure 2.2A). Interestingly, the timing of p38 
MAP-kinase activation/phosphorylation correlated with the p68-phosphorylation at 
threonine with the oxaliplatin treatment, atleast upto 4 hours (Figure 2.2A); indicating 
the possibility that p68 is a substrate of p38 MAP-kinase following oxaliplatin treatment. 
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This possibility was tested by examining the interaction of p68 and p38 MAP-kinase by 
co-immunoprecipitation. HCT116 cells expressing endogenous p68 and p38 were 
treated with 20 μM oxaliplatin for 4 hours. P68 was immunoprecipitated from the 
oxaliplatin-treated cell lysate using anti-p68 antibody. It was evident that p38 MAP-
kinase coimmunoprecipitated with p68 (Figure 2.2B). We then further verified the 
phosphorylation of p68 by performing in vitro kinase assay with recombinant p68 and 
p38 MAP-kinase. It was clear that the recombinant p38 MAP-kinase phosphorylated 
recombinant p68. As a control, BSA was not phosphorylated by the recombinant MAP-
kinase (Figure 2.2C). To further confirm that p38 phosphorylated p68 at threonine, a 
constitutively activated p38 MAP-kinase-mutant D176AF327L was generated by 
QuickChange site-directed mutagenesis (Diskin, Askari et al. 2004). D176A-F327L is a 
constitutively activated p38 MAP-kinase mutant with double mutations at D176 and 
F327 sites that induce conformational changes mimicking the naturally imposed 
changes by dual phosphorylation in the loop region between kinase domains of p38 by 
upstream p38 MAP-kinase activators. The double mutations render p38 MAP-kinase 
constitutively active with high intrinsic activity independent of upstream activation and 
regulation. This mutant retains the ability to phosphorylate and activate downstream p38 
substrates (Diskin, Askari et al. 2004). Thereafterm, D176A-F327L was expressed in 
HCT116 cells. P68 threonine phosphorylation in the cells was examined by the 
immunoprecipitation with the anti-p68 antibody and immunoblot procedures with anti-
phospho-threonine and anti-p68 antibodies. Apparently, phosphorylation of p68 at 
threonine was increased upon the p38 MAP-kinase-mutant expression (Figure 2.2D). 
We, thus, concluded from our studies that p38 MAP-kinase phosphorylates p68. 
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We next determined the p68 phosphorylation sites recognized by p38 MAP-
kinase. Phosphorylation-site search using a web-based program, NetPhos 2.0 was 
performed. The consensus phosphorylation-site search indicated several potential S/T 
phosphorylation sites on p68 by p38 MAP-kinase (Figure 2.3A). Based on the 
phosphorylation-site predictions, several mutants were generated where the threonine 
(T) residue at the predicted phosphorylation-sites was mutated to alanine (A) by Quick-
change site-directed mutagenesis. This mutation abolished the ability of the mutants to 
be phosphorylated as alanine did not have any phosphoacceptor site for phoshorylation 
by p38 MAP-kinase (Figure 2.3A). Data from in vitro phosphorylation reactions with the 
generated mutants using the recombinant p38 suggested that there was a decrease in 
p68-phosphorylation with the mutant T564A, while there was almost no change with 
other mutants (Figure 2.3B, Upper panel), suggesting that T564 phosphorylation may 
result from activated p38 MAP-kinase. To verify whether the T564 is the 
phosphorylation site, the T564A mutant or other mutants were transfected in the 
HCT116 cells and the phosphorylation of the p68 mutant at threonine was examined 
after treating the cells with oxaliplatin. Surprisingly, there was no change in p68 
threonine phosphorylation with wild-type and any mutant (Figure 2.3C Upper panel). 
One possible explanation is that p68 may have additional sites that are phosphorylated 
by p38 MAP-kinase as p38 is known to often phosphorylate its targets at multiple sites 
(Yang, Xiong et al. 2002; De Chiara, Marcocci et al. 2006). To confirm this, we created 
two p68-double mutants, T564/446A and T446/224A.  T564/446A has mutations at 
T564 and T446 sites where threonine (T) residue is mutated to alanine (A). Apart from 
T564 phosphorylation site, p38 may be phosphorylating p68 at additional minor sites to 
 110 
achieve maximal phosphorylation. T446 and T224 have the p38 consensus sequence 
and show higher possilbity of being phosphorylated by bioinformative analysis. Hence, 
double mutants, T564/446A and T446/224A were generated and in vitro 
phosphorylation was performed with these two mutants. It was clear that p38 MAP-
kinase induced phosphorylation of T564/446A was reduced, while the phosphorylation 
of T446/224A had very minor reduction (Figure 2.3B Lower panel). The in vitro 
phosphorylation results suggested that it is likely that the T564 and T446 of p68 are the 
sites phosphorylated by p38. To verify that T564 and T446 are the phosphorylation 
sites, HA-tagged p68-wild-type (wt), T564/446A, and T446/T224A mutants were 
expressed in HCT116 cells followed by oxaliplatin treatment. Phosphorylation of the HA-
tagged p68-wt and the mutants were examined. Clearly, phosphorylation of 
T446/T224A experienced a minor decrease, while phosphorylation of T564/446A was 
almost abolished (Figure 3.3C Lower panel). The results strongly suggest that p38 
phosphorylated p68 at T564 and T446 by the anti-cancer drug.  
 
2.3.3 Phosphorylation of p68 at threonine mediates the effects of oxaliplatin in the 
induction of apoptosis 
We next investigated whether p38 MAP-kinase-induced p68 threonine- 
phosphorylation is involved in the oxaliplatin-mediated pathway. The HA-tagged wt p68 
or T564/446A was expressed in HCT116 cells after knocking down endogenous p68 
(Figure 2.4A). The cells were then subsequently treated by oxaliplatin for 24 hrs at a 
concentration of 10 μM. Cellular apoptosis was measured using caspase-3 colorimetric 
assay as caspase-3 is an important factor for detection of apoptosis. Caspase-3 
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cleavage and subsequent activation is a primary hallmark of apoptosis mediated by 
both intrinsic and extrinsic apoptotic pathway. There were no significant changes in cell 
apoptosis without oxaliplatin treatment. However, oxaliplatin-induced apoptosis was 
reduced with the T564/446A-expressing cells. This effect was not observed with the wt 
p68-expressing cells (Figure 2.4B). Similar results were observed with MTT assays 
(Figure 2.4C). Thus, we conclude that phosphorylation of p68 at T564/446, at least 
partially, mediates the effects of oxaliplatin on apoptosis induction. 
 
2.4 DISCUSSION 
We found in this study that p68 gets phosphorylated at T564 and/or T446 in 
HCT116 colon cancer cells following oxaliplatin treatment. P38 MAP-kinase 
phosphorylates p68 following the drug treatment. The phosphorylation(s) of p68 
appears to be essential for caspase-3 cleavage, an event which culminates in 
apoptosis. These results echo a report from Yang and colleagues that the loss of p68 
threonine phosphorylation correlates with cancer cell TRAIL- resistance (Yang, Lin et al. 
2007). Thus, phosphorylation of p68 at T564 and T446 may represent a common 
molecular mechanism that acts in multiple pathways of apoptosis induction.  
Activated p38 MAP-kinase is a common factor in multiple apoptosis induction 
with a number of anti-cancer drugs with different molecular mechanisms (Wang, Li et al. 
2005; Wang, Li et al. 2006; Wood, Nail et al. 2006), oxidative stresses (Lu, Rau et al. 
2011), cells damaged by UV light (Tanos, Marinissen et al. 2005). Moreover, the 
downstream substrates of p38 MAP-kinase that execute the apoptosis effects is not 
very clear. In fact, only a few substrates of p38 MAP-kinase involved in cell apoptosis 
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induction, including p53 (Perfettini, Castedo et al. 2005) and HSP27 (Deschesnes, Huot 
et al. 2001; Gonzalez-Mejia, Voss et al. 2010) are known. The mechanism by which 
phosphorylation of these substrates mediates the effects of apoptosis induction is not 
fully known. 
How the p68 phosphorylation at T564 and T446 mediates cell apoptosis is an 
open question. One plausible explanation is that the phosphorylated p68 may change 
p68-interacting partners in the cells, which allows p68 to target a specific apoptosis- 
mediating protein or complex. The consequence for the p68-targeting is activation of 
apoptotic function of the targeted protein or complex. Some DEAD-box RNA helicases 
associate with apoptosis induction protein or complex. For example DDX42 modulates 
the apoptotic function of ASPP2 by direct interaction with it (Uhlmann-Schiffler, 
Kiermayer et al. 2009). Interaction between GABA-receptor associated protein 
(GABARAP) and DDX47 is required for induction of neuronal cell apoptosis (Lee, Rho 
et al. 2005). However, the mechanism by which this DEAD-box RNA helicase regulates 
the apoptotic process is not known. Thus, it will be very interesting to find whether p68 
phosphorylation at T564 and/or T446 mediates the association of the protein with a 
particular apoptosis inducing complex to activate the complex. 
 
2.5 MATERIALS AND METHODS 
2.5.1 Cell Culture and Antibodies 
HCT116 cells (Catalog # CRL-247) were obtained from ATCC (Manassas, VA, 
USA). They were cultured according to the vendor’s instruction. Antibodies against p68 
were raised against C-terminal domain (a.a.437-614) of human p68 (Invitrogen, Grand 
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Island, NY, Carlsbad, CA, USA, and Auburn University Hybridoma Facility). The 
antibodies used were: anti-phospho-threonine (14B3) antibody (Calbiochem, Billerica, 
MA), p38 and phospho-p38 antibodies (Cell Signaling Technology, Beverly, MA), anti-
HA antibody (Abcam, Cambridge, MA and Georgia State University, Animal Center 
Facility, Atlanta, GA), anti-GAPDH antibody (Millipore, Billerica, MA) and Flag antibody 
(Sigma, St. Louis, MO). 
 
2.5.2 Drug Treatment, DNA constructs, Transfections, and siRNA Interference 
Oxaliplatin was bought from Sigma (Sigma, St. Louis, MO). It was diluted with 
medium to prepare working concentrations. The cDNA of p68 ORF was subcloned into 
pHM6 vector at HindIII site to get HA-tagged p68 expression vector. The various p68 
single and double threonine mutants (threonine replaced by alanine) were made using 
Quick-Change mutagenesis kit (Stratagene, Cedar reek, TX) and the mutations were 
confirmed by DNA sequencing. P38α cDNA (Origene, Rockville, MD) was subcloned 
into p3XFLAG-myc-CMV™-24 Expression Vector (Sigma, St. Louis, MO). A number of 
mutations to obtain the constitutively activated p38 MAP-kinase was done according to 
the studies performed by Diskin and colleagues (Diskin, Askari et al. 2004). All DNA 
transfections were done using fugene HD and lipofectamine 2000 (Invitrogen, Grand 
Island, NY) while siRNA knockdown was done with lipofectamine RNAimax (Invitrogen, 
Grand Island, NY). SiRNA against p68 was purchased from Dharmacon (Thermo Fisher 
Scientific Dharmacon, Lafayette, CO), and the sequence was as follows: siRNA 
oligonucleotides against p68 (sense: 5’-GCAAGUAGCUGCUGAAUAUUU-3’; antisense: 
5’-AUAUUCAGCAGCUACUUGCUU-3’). Cells were transfected after p68-siRNA 
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knockdown and further treated with the drug for 24 hrs. The cells were then harvested 
for nuclear extract preparation as p68 is a predominantly nuclear protein using a kit from 
Active motif (Active motif, Carlsbad, CA). 
 
2.5.3 Protein Expression and Purification 
The procedure used to express and purify p68 was similar to the procedure 
reported previously. P68 ORF was cloned as well as various mutants into expression 
vector pET-30a+ using the restriction sites Bam HI/Hind III and subsequently used to 
transfer on E.coli BL21-CodonPlus bacteria (Stratagene, Cedar Reek, TX) to express 
protein. The bacteria were subcultured in fresh sterile Luria Bertani (LB) broth until 
optical density at A600 reached around 0.6. Bacteria were subsequently induced with 
IPTG at 16°C overnight for protein expression. The cells were pelleted and stored. The 
cells were then lyzed by freeze-thaw cycle at -80°C and further lysed in lysis buffer (50 
mM Tris-HCl pH 8.0, 300 mM NaCl, 1 mM DTT, 10 mM PMSF, 10% glycerol). They 
were then subjected to lysozyme (0.5 mg/ml) digestion to ensure complete lysis of the 
cells. DTT and PMSF were also added at 1 mM final concentration. DTT reduces the 
disulphide bonds of proteins thereby preventing them from linking the cysteine residues 
of proteins while PMSF inactivates proteases that digest proteins after cell lysis. The 
cells were further subjected to ultrasonication and pelleted. After centrifugation, the 
expressed protein was precipitated which was dissolved in denaturing buffer containing 
8 M urea, 250 mM NaCl, 50 mM Tris-HCl pH 8.0, and 0.2% Triton-100. The lysate was 
passed through Ni-NTA column for purification of recombinant protein by affinity 
separation and was washed with the denaturing wash buffer (8 M urea, 50 mM Tris-HCl 
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pH 8.0, 250 mM NaCl, 0.2% Triton-100 and 20 mM imidazole pH 8.0). Elution buffer 
(250 mM imidazole, 8 M urea, 50 mM Tris-HCl pH 8.0, 250 mM NaCl, 0.2% Triton-100, 
0.5 mM DTT and 10% glycerol) was used to elute the protein. The eluted protein 
solution was refolded using stepwise dialysis procedure (8M→ 6M→ 4M→ 2M→ 0M) to 
remove urea using refolding buffer (200 mM arginine, 50 mM Tris-HCl pH 8.0, 250 mM 
NaCl, 0.2% Triton-100, 0.5 mM DTT and 10% glycerol) and preserved in further 15 to 
20% glycerol. 
 
2.5.4 In Vitro Kinase Assay 
In the kinase assay, the 25 μl reaction consisted of 1 μg of purified proteins, 200-
250 ng of p38α/SAPK2a enzyme (Upstate cell signaling, Beverly, MA), 10 μCi/μl of [γ-
32P]ATP, 5X buffer (125 mM Tris-HCl, pH 7.5 and 0.1 mM EGTA), and 
Magnesium/ATP cocktail (75 mM MgCl2 and 500 μM ATP in 20 mM MOPS, pH 7.2, 25 
mM β-glycerol phosphate, 1 mM sodium orthovanadate, 5 mM EGTA, and 1 mM DTT).  
The 5X-loading buffer (Fermentas, Glen Burnie, MA) was added after incubation of the 
reaction mixtures at 30°C for 30 mins. Two 10% SDS-PAGE gels were run to analyse 
the samples. One of the gels was subjected to autoradiography while other one was 
treated with Coomassie blue solution followed by destaining. 
 
2.5.5 Cell Viability and Apoptosis Assay 
Cell viability of HCT116 cells was analyzed by MTT (Sigma, St. Louis, MO) 
assay. 4000 cells were seeded 24 hrs before either knockdown or transfection of cells 
with vectors containing p68 and the mutants. Subsequently, 24 hrs after transfection, 
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the cells were induced for apoptosis by oxaliplatin treatment. The next day, 
reconstituted MTT-reagent was added in an amount equal to 10% of the volume of the 
cell culture medium and incubated at 37°C. MTT Solubilization solution used to dissolve 
the formazan crystals formed during incubation was subsequently added. Cell viability 
was determined spectrophotometrically by measuring absorbance at A570. Cells plated 
on 6-well plates were treated with 10 μM oxaliplatin after p68 knockdown and 
transfection and caspase-3/CPP32 colorimetric assay kit (Biovision Research Products, 
Milpitas, CA) was used for measuring caspase-3 cleavage. Briefly, after apoptosis 
induction, the cells were lyzed in Cell Lysis Buffer for 10 mins, centrifuged and 
subjected to cleavage assay. The reaction consisted of cell lysate diluted in Cell Lysis 
Buffer, 2X Reaction buffer, and 4 mM DEVD-pNA substrate. The samples were read at 
A405 using a microtiter plate reader. FITC-Annexin V Apoptosis Detection Kit 
(BDBiosciences, San Jose, CA) was also used to measure apoptosis induced by 
oxaliplatin.  
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Figure 2.1. Threonine phosphorylation of p68 in HCT116 cells following 
oxaliplatin (Oxa) treatment. 
(A) Apoptosis of HCT116 cells induced by different concentrations of oxaliplatin was 
measured and presented as percent of apoptotic cells after 24 hours treatment. Error 
bars represented standard deviations of four independent experiments.  
(B), (C), and (D) Threonine phosphorylations of p68 measured by immunoblotting using 
anti-phospho-threonine antibody (14B3) (1:1000 dilution) in HCT116 cells that were 
treated with different oxaliplatin concentration (B) and (C), or 20 μM of oxaliplatin for 
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different times (D) were analyzed by immunoblotting the p68 that was 
immunoprecipitated (IP: p68) using antibody against anti-phospho-threonine (IB: 14B3). 
The immunoblot of p68 (IB: p68) in the immunoprecipitates represented the amount of 
p68 that was precipitated. In (C), the analyses were carried out with the cells that were 
already detached and the cells that were still adherent following the treatment for 24 
hours.  
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Figure 2.2 P68 Phosphorylation by p38 MAP-kinase 
(A) Threonine phosphorylation of p68 in HCT116 cells following treatment of the cells 
with 20 μM of oxaliplatin for different times were analyzed by immunoblotting the p68 
that was immunoprecipitated (IP: p68) using antibody against phospho-threonine (IB: 
14B3) from the cell lysates. Phosphorylation of p38 MAP-kinase during the same 
treatment was analyzed by immunoblot of cell lysates using antibody against the 
phosphorylated p38. The immunoblot of p68 (IB: p68) in the immunoprecipitates 
represented the amount of p68 that was precipitated. The immunoblot of p38 in the cell 
lysate (IB: p38) indicated the cellular levels of p38 as a control.  
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(B) Coimmunoprecipitation of p38 and p68 in the cell extracts of HCT116 cells 
with/without oxaliplatin treatment (Oxa, +/-) was analyzed by p68 immunoblot with p68 
antibody after immunoprecipitation (IP: p68) and by using antibody against p38 (IB: 
p38). The immunoblot of p68 (IB: p68) from the immunoprecipitates represented the 
amount of p68 that was precipitated. The IP: IgG was the immunoprecipitation using 
rabbit IgG, serving as a negative control IP.  
(C) Phosphorylation of recombinant His-p68, or BSA as a control, by recombinant p38 
was demonstrated by autoradiography. The amount of protein used in the 
phosphorylation reactions was shown by Coomassie Blue Staining (CBS).  
(D) Phosphorylation of p68 by overexpression of Flag-tagged p38 MAPK, wild-type and 
constitutively active mutant D176A-F327L, in HCT116 cells was analyzed by 
immunoblotting the p68 that was immunoprecipitated (IP: p68) using antibody against 
phospho-threonine (IB: 14B3). The immunoblot of p68 (IB: p68) in immunoprecipitates 
represented the amount of p68 that was precipitated. The immunoblot of Flag-tag (IB: 
FLAG) indicated the overexpressed p38 levels. The immunoblot of GAPDH (IB: 
GAPDH) served as a loading control. 
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Figure 2.3 Phosphorylation site(s) of p68 by p38 MAPK 
(A) Prediction of potential p38 MAP-kinase-induced phosphorylation site(s) in the p68-
reading frame and compared to consensus p38 MAPK phosphorylation sites of several 
authentic p38 MAP-Kinase substrates by a web-based phosphorylation-site prediction 
program NetPhos 2.0, (B) Phosphorylation of recombinant His-p68 and mutants with 
single site mutation (Upper) and double site mutations (Lower) by recombinant p38 was 
demonstrated by autoradiography. The amount of protein used in the phosphorylation 
reactions was shown by Coomassie Blue Staining (CBS). (C) Phosphorylation of 
overexpressed HA-p68s, wild type (WT) and mutants (Single site mutation, Upper, and 
Double site mutations, Lower), in HCT116 cells with/without oxaliplatin treatment (Oxa, 
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+/-) was analyzed by immunoblotting the p68 that was immunoprecipitated (IP: p68) 
using antibody against phospho-threonine (IB: 14B3). The immunoblot of p68 (IB: p68) 
from immunoprecipitates represented the amount of p68 that was precipitated. 
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Figure 2.4 Effects of p68 phosphorylation on cell apoptosis 
(A) HCT116 cells were treated by non-targeting siRNA (NT) or siRNA targeting p68 
(p68) to knockdown p68 for 24 hours. Wild type and the different mutants of p68 were 
overexpressed in the p68 knockdown cells. P68 (IB: p68) immunoblot represented the 
cellular levels of p68 (both endogenous and overexpressed). The immunoblot of 
GAPDH (IB: GAPDH) served as a loading control.  
Cell apoptosis (B) and viability (C) of the cells in (A) that were treated or untreated with 
oxaliplatin were measured by a caspase-3 apoptosis kit (B) or MTT assay (C). The cell 
apoptosis and viability were presented as relative apoptosis and relative viability by 
defining the apoptosis and viability of the vector expressing cells without oxaliplatin 
treatment as 1. Error bars represented standard deviations of four independent 
experiments. 
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CHAPTER 3 
P68 RNA HELICASE REGULATES THE EXPRESSION OF TUBULIN 
POLYMERIZATION PROMOTING PROTEIN INVOLVED IN NEURITE 
OUTGROWTH AND GLIOMA SUPPRESSION 
 
3.1 ABSTRACT 
P68 RNA helicase is a RNA helicase with DEAD-box motif. It functions in the 
regulation of gene transcription. Previous studies revealed that p68 regulates the 
expression of several genes whose products are required in controlling the stability and 
dynamics of different cytoskeleton.  Experiments were designed to characterize the 
function of p68 in transcriptional regulation of tubulin polymerization-promoting protein 
(TPPP/p25). P68 is shown to mediate transcriptional regulation of TPPP/p25 gene by 
associating with TPPP/p25 gene promoter. Expression of TPPP/p25 and its regulation 
by p68 is found to be an important event for cell differentiation and neurite outgrowth. 
Loss of TPPP/p25 expression contributes to the development and progression of 
gliomas. The studies performed reveal an important molecular factor that regulates 
TPPP/p25 to mediate the regulation of differentiation induced by the growth-factor. 
 
3.2 INTRODUCTION 
 TPPP/p25 was thought to be expressed only in nervous tissues, including in 
neural cells and myelinating oligodendrocytes (Takahashi, Tomizawa et al. 1993) 
(Takahashi, Tomizawa et al. 1991) (Kovacs, Laszlo et al. 2004). Careful analyses 
revealed that TPPP/p25 is expressed in many tissue types, including liver, heart, and 
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lung tissues (Acevedo, Li et al. 2007). However, the elevated levels of the protein are 
only observed in a few specific tissue types. The detailed cellular function of TPPP/p25 
is not yet well defined. It is believed that the protein is likely involved in stabilizing the 
microtubular structure/network to maintain specific cell shape or morphology (Lehotzky, 
Tirian et al. 2004) (Hlavanda, Kovacs et al. 2002). Abnormal expression of TPPP/p25 
has been associated with a number of pathological conditions (Kovacs, Laszlo et al. 
2004). Abnormally high levels of TPPP expression that lead to protein deposition is an 
important characteristic of several neurodegenerative diseases, such as multiple system 
atrophy (MSA) and Parkinson’s disease (Kovacs, Laszlo et al. 2004) (Kovacs, Gelpi et 
al. 2007) (Lindersson, Lundvig et al. 2005). Very high levels of TPPP/p25 have been 
observed to closely correlate with multiple sclerosis (MS) progression (Vincze, Olah et 
al. 2011). TPPP/p25 expression is almost completely lost in oligodendrogliomas, 
indicating a critical role of the protein in the disease development and progression 
(Preusser, Lehotzky et al. 2007).    
P68 RNA helicase is a RNA helicase with DEAD-box motif (Lane and Hoeffler 
1980; Crawford, Leppard et al. 1982). It is implicated in cellular proliferation and 
differentiation (Stevenson, Hamilton et al. 1998), and its abnormal expression is linked 
to cancer progression (Causevic, Hislop et al. 2001). It is implicated by several 
independent studies that p68 is involved in regulating the transcription of several genes, 
including estrogen receptor alpha (ERα) (Endoh, Maruyama et al. 1999), and p53-
regulated genes (Bates, Nicol et al. 2005). It interacts with RNA Pol II and p300/CBP 
(Rossow and Janknecht 2003). However, molecular mechanism of p68 to execute 
transcriptional regulation is not well understood. P68 interacts with histone deacetylase 
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1 (HDAC1) to functionally regulate gene expression (Wilson, Bates et al. 2004). Studies 
suggested the functional involvement of p68 in chromatin remodeling through 
modulation of various protein interactions in the large, assembled chromatin 
remodeling-complex, Mi-2/NuRD. This suggests a novel mechanism by which p68 RNA 
helicase regulates gene expression (Carter, Lin et al. 2010). In this study, p68 is found 
to be functionally involved in regulating TPPP/p25 expression. P68 regulates the 
expression of TPPP/p25, and thus, consequently, controls the differentiation of neuronal 
cells. TPPP/p25 has been shown to be dramatically downregulated in human brain 
tumors (Preusser, Lehotzky et al. 2007). Our results show that expression of TPPP/p25 
in glioma cells significantly reduces the cell growth, indicating a therapeutic potential of 
this protein. 
 
3.3 RESULTS 
3.3.1 P68 RNA helicase regulates transcription of TPPP/p25 gene. 
 P68 RNA helicase transcriptionally regulates several genes (Endoh, Maruyama 
et al. 1999) (Bates, Nicol et al. 2005) (Rossow and Janknecht 2003). To further 
understand the function of p68 in transcription regulation, we carried out a ChIP–on-
Chip study with SW620 colon cancer cells using antibody against p68 and human 
promoter Tiling 1.0R array (Affymetrix, Santa Clara, CA) which is a single array 
consisting of probes spanning a subset of human promoter regions selected from NCBI 
human genome assembly. ChIP-on-Chip analysis indicated that p68 interacted with the 
promoters of a number of cytoskeleton-regulating genes (Table 3.1). Tubulin 
Polymerization Promoting Protein (TPPP/p25) showed a high affinity for the p68 
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promoter from the ChIP-on-ChIP results. Subsequently, ChIP experiments were 
performed to confirm data from the ChIP-on-Chip analyses of TPPP/p25 promoter using 
antibody against p68, and suggested that p68 interacted with the TPPP/p25 promoter 
(Fig 3.1A). To further confirm the data from ChIP that p68 RNA helicase indeed 
regulated TPPP/p25 expression, we used RT-PCR analysis to probe the effects on 
TPPP/p25 gene expression by knocking down p68 from the cells by siRNA. Data from 
these analyses indicated that p68 knockdown down-regulated the expression of 
TPPP/p25 (Fig 3.1B). Quantitative RT-PCR analysis demonstrated that p68 knockdown 
decreases TPPP/p25 mRNA by almost 3-fold (Fig 3.1C). Next, the effect of p68 
knockdown in the regulation of TPPP/p25 expression at the protein level was further 
verified by immunoblot analysis. Knockdown of p68 decreases TPPP/p25 protein 
expression levels in the cells (Fig 3.1D). Overexpression of p68 in the cells after p68 
knockdown restored the downregulation of TPPP/p25 expression (Fig. 3.1E). These 
results together suggested that p68 played a role in TPPP/p25 gene transcription. 
 
3.3.2 P68 RNA helicase regulates the neurite outgrowth of PC12 neuronal cells. 
 The preceeding experiments demonstrated that p68 regulates TPPP/p25 
expression. Next, we explored the physiological relevance of this regulation. To address 
this issue, we used PC12 cells as our study system. PC12 cells (ATCC, Manassas, VA) 
are rat adrenal gland pheochromocytoma cells which can differentiate into cells 
resembling neurons with Nerve-Growth Factor (NGF) stimulation (Greene and Tischler 
1976). The expression levels of TPPP/p25 in PC12 cells were first examined using 
immunoblot analysis. The results showed that TPPP/p25 was expressed in these cells 
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(Fig 3.2A). TPPP/p25 expression was increased upon stimulation of the PC12 cells for 3 
days. This increase correlated with the neurite outgrowth of the PC12 cells under NGF 
stimulation (Fig 3.2B). To further evaluate whether TPPP/p25 expression plays a role in 
the differentiation, TPPP/p25 was knocked-down in the PC12 cells (Fig. 3.2C). The 
TPPP/p25 knockdown cells were induced for differentiation with 50 ng/ml NGF 
treatment. Data analysis showed that neurite outgrowth was reduced under NGF 
stimulation, while it was apparent in the cells treated with non-specific siRNA (Fig. 
3.2D). We questioned whether the regulation of TPPP/p25 expression by p68 RNA 
helicase has any functional significance in controlling the differentiation of PC12 cells to 
neurons. Thus, p68 was knocked-down in PC12 cells. As expected, TPPP/p25 levels in 
the p68 knockdown PC12 cells were reduced (Fig 3.2E & F). The p68 knockdown PC12 
cells were subsequently induced for differentiation by the NGF treatment. It was evident 
that the PC12 cells displayed a significantly reduced number of neurites upon NGF 
treatment with p68 knockdown (Fig 3.2G). These experiments indicated that p68 plays a 
role in PC12 differentiation via regulation of TPPP/p25 transcription. 
 
3.3.3 TPPP/p25 expression plays a role in the progression of gliomas. 
High levels of TPPP/p25 are observed in oligodendrocytes and neurons. Upon 
development and progression of oligodendrogliomas, TPPP/p25 expression is 
decreased until undetectable (Preusser, Lehotzky et al. 2007). The TPPP/p25 levels in 
10 different glioma tissue samples with same number of normal brain tissue sections 
were examined. Histology analyses revealed that TPPP/p25 levels were very high in 
both oligodendrocytes and neuronal cells in the normal brain tissues. However, in the 
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corresponding sites from glioma tissues, TPPPp25 levels were very low or undetectable 
(Fig 3.3A). Thus, histology analyses suggested that loss of TPPP/p25 expression 
correlates with the development and progression of the disease. To understand whether 
TPPP/p25 expression is involved in glioma development, the growth of several human 
glioma cell-lines specifically, T98G (ATCC, Manassas, VA), U87MG (ATCC, Manassas, 
VA), and LN229 (ATCC, Manassas, VA) were examined after overexpressing 
TPPP/p25. We first probed the expression levels of TPPP/p25 in these selected cell 
lines using RT-PCR and immunoblot analyses. The analyses showed that TPPP/p25 
was poorly expressed, if at all in these gliomas cells (Fig. 3.3B & C). We then analyzed 
its overexpression effects on the cell proliferation of these selected cells transfected 
with FLAG-TPPP/p25 expression plasmid. TPPP/p25 over-expression led to high levels 
of expression of TPPP/p25 protein relative to vector alone transfected cells (Fig 3.3D). 
Cell proliferation and viability of the TPPP/p25 expressing cells were analyzed by BrDU 
cell proliferation assay. Expression of TPPP/p25 dramatically decreased the cell 
proliferation rate of these glioma cells as shown by use of histology and BrDU assay 
(Fig 3.3E & F). We further analyzed whether the effects of expression of TPPP/p25 on 
the growth was mediated by cell apoptosis. To this end, we probed for activation of 
caspase-3 due to TPPP/p25 expression in T98G and U87MG cells. Data shown in 
figure 3.3G show that caspase-3 was not activated with or without TPPP/p25 
expression (Fig 3.3G). Since TPPP/p25 is a microtubule associated protein (Hlavanda, 
Kovacs et al. 2002), we measured the microtubule stability upon TPPP/p25 expression 
in T98G cells. Analysis of these experiments demonstrated that expression of 
TPPP/p25 in these glioma cells caused an increase in microtubule stability. The levels 
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of acetylated tubulin, a modified tubulin that has high tendency to polymerize and is a 
measure of microtubule stability (Piperno, LeDizet et al. 1987), increased (Fig 3.3H).  
 
3.4 DISCUSSION 
In this report, regulation of expression of TPPP/p25 gene is described. P68 is 
shown to mediate transcriptional regulation of TPPP/p25 gene by associating with 
TPPP/p25 gene promoter. The study suggests that p68 is functionally involved in 
neuronal differentiation, which echoes early observations showing that p68 plays a role 
in differentiation of adipocytes and skeletal muscle cells (Caretti, Schiltz et al. 2006) 
(Kitamura, Nishizuka et al. 2001).  
Molecular mechanism by which p68 regulates TPPP/p25 expression is still not 
known. Clearly, p68 is expressed in high levels in undifferentiated PC12 cells, while 
TPPP/p25 levels increase beyond this level during differentiation. There maybe two 
explanations for the observations: p68 is necessary, but not sufficient for upregulation of 
TPPP/p25 expression, and other factors are also required in concert to regulate 
TPPP/p25 expression and activate cell differentiation programs; p68 may be 
posttranslationally modified with growth factor stimulation and may be only a modified 
sub-population of p68 is active in regulating TPPP/p25 expression. It has been reported 
that p68 undergoes various posttranslational modifications upon exposure to different 
growth factors and cytokines stimulation of specific cells (Yang, Lin et al. 2005; Yang, 
Lin et al. 2006; Yang, Lin et al. 2007). These modified p68s function in a number of 
different cellular processes (Yang, Lin et al. 2005; Yang, Lin et al. 2006; Yang, Lin et al. 
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2007). It would be interesting to probe whether p68 is posttranslationally modified during 
induction of differentiation.  
Abnormal overexpression and accumulation of TPPP/p25, and its association 
with other neuronal-aggregating proteins, are major causes for a number of neuronal 
degenerative diseases (Kovacs, Laszlo et al. 2004; Lindersson, Lundvig et al. 2005; 
Kovacs, Gelpi et al. 2007). TPPP/p25 is believed to co-aggregate with tau and other 
cytoskeletal associated proteins and this leads to deposition of the peptides cleaved 
from these proteins especially under several stress conditions (Kovacs, Gelpi et al. 
2007). On the other hand, reduction of TPPP/p25 expression in oligodendrogliomas is 
clearly associated with the development of the disease by an unknown mechanism 
(Preusser, Lehotzky et al. 2007). Thus, regulation of the expression of TPPP/p25 needs 
to be finely balanced. Currently, molecular mechanisms that control TPPP/p25 
expression are largely unknown. This report represents the first study of exploring the 
regulatory mechanism for TPPP/p25 gene expression. 
TPPP/p25 is down-regulated in human brain tumors. Overexpression of 
TPPP/p25 in transfected glioma cell-lines reduced cancer cell proliferation. How 
expression of TPPP/p25 arrests glioma cell growth is another unanswered question. 
Our results demonstrate that expression of TPPP/p25 does not activate the caspase-3 
mediated cell apoptosis signaling. Furthermore, our results showed that the stability of 
microtubules is increased with the expression of TPPP/p25, suggesting a possibility of 
interrupting cell-cycle progression at mitosis, where both 
polymerization/deploymerization of microtubules is supposed to be active. This notion is 
consistent with one observation that TPPP/p25 expression affects the mitotic spindle 
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assembly. Alternatively, expression of TPPP/p25 may have a role in maintaining the 
differentiated state of neuronal cells, while loss of TPPP/p25 expression may be 
important for their de-differentiation.     
  
3.5 MATERIALS AND METHODS 
3.5.1 Reagents and Antibodies 
NGF was bought from Sigma (Sigma, St. Louis, MO). P68 antibodies were raised 
against C-terminal domain of p68. Polyclonal antibody was generated from Auburn 
University Hybridoma Facility while the monoclonal antibody was obtained from 
Invitrogen (Invitrogen, Grand Island, NY). The different commercial antibodies used 
were: TPPP/p25 antibody from Santa Cruz, Santa Cruz, CA and Abcam, Cambridge, 
MA, GAPDH antibody (Millipore, Billerica, MA), caspase-3 and cleaved caspase-3 
antibodies (Cell Signaling Technology, Beverly, MA), acetylated tubulin antibody (Cell 
Signaling Technology, Beverly, MA) and lamin A/C antibody (Cell Signaling Technology, 
Beverly, MA). 
 
3.5.2 Cell Culture, DNA constructs, Transfections, and siRNA Interference 
PC12 (Catalog # CRL-1721), HeLa (Catalog # CCL-2), T98G (Catalog # CRL-
1690) and U87MG (Catalog # HTB-14) cells were obtained from ATCC (ATCC, 
Manassas, VA). The cDNA of p68 ORF was subcloned into pHM6 (Roche, Indianapolis, 
IN) vector at HindIII site to get HA-tagged p68 expression vector. TPPP/p25 cDNA 
(Origene, Rockville, MD) was subcloned into p3XFLAG-myc-CMV™-24 Expression 
Vector (Sigma, St. Louis, MO). Fugene HD (Roche, Indianapolis, IN) and lipofectamine 
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2000 (Invitrogen, Grand Island, NY) were used to carry out transfections. SiRNA 
knockdown was done using lipofectamine RNAimax (Invitrogen, Grand Island, NY). P68 
siRNA was purchased from Dharmacon (Thermo Fisher Scientific Dharmacon, 
Lafayette, CO). SiRNA oligonucleotides with random sequence (non-targeting) was 
used as negative control. The siRNA sequence was as follows: siRNA oligonucleotides 
against p68 (sense: 5’-GCAAGUAGCUGCUGAAUAUUU-3’; antisense: 5’- 
AUAUUCAGCAGCUACUUGCUU-3’).  
 
3.5.3 Cellular Extract Preparation, Immunoblot Analysis and Immunofluorescence 
staining 
All cell lysates were prepared using 1X RIPA buffer and Bradford assay (Bio-
Rad, Hercules, CA) was used to determine protein concentration. Immunoblot analyses 
were performed by a previously developed procedure (Liu, Z. R., Sargueil, B. et al. 
1998). The immunocomplexes were visualized by chemiluminescence with Supersignal 
West Dura Extended Substrate (Pierce, Thermo Fisher Scientific Dharmacon, Lafayette, 
CO) and goat anti-mouse IgGs or anti-rabbit IgGs coupled to horseradish peroxidase 
were used as secondary antibodies (Thermo Fisher Scientific Dharmacon, Lafayette, 
CO). The immunofluorescence and confocal imaging procedures were very similar to 
previous studies (Yang, Lin et al. 2006). Immunohistochemical staining of normal and 
glioma tissue sections was done by Dr. Daniel Brat’s laboratory using tissue sections 
obtained from Emory’s tissue bank. 
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3.5.4 RT-PCR 
Total RNA extraction kit (Qiagen, Valencia, CA) was used to carry out RNA 
isolation and Improm II reverse transcription system (Promega, Madison, WI) was used 
for RT-PCR. The cDNA used in the reaction consisted of cDNA, forward and reverse 
primers and 1X master mix from Promega (Promega, Madison, WI).  The PCR cycle 
was as: 94°C for 15 sec, 55°C for 30 sec, and 72°C for 30 sec with an additional 
extension time of 10 mins. RT-PCR results were analysed by running the samples on 2 
to 3% agarose gels with ethidium bromide. Primers used were: TPPP/p25 (sense 5’- 
CAGGTGAAGAGCCTGGAGTC-3’; antisense 5’- GTTTCCTTGTCTGTGGGTGAA-3’); 
GAPDH (sense 5’- GAGTCAACGGATTTGGTCGT-3’; anti-sense 5’- 
TTGATTTTGGAGGGATCTCG-3’). GAPDH was used as PCR loading control.  
 
3.5.5 Chromatin Immunoprecipitation (ChIP) 
ChIP Kit from IMGENEX (IMGENEX, San Diego, CA) was used for chromatin 
immunoprecipitation assays. The TPPP/p25 promoter was immunoprecipitated using 
p68 (poly-p68) antibody. TPPP/p25 promoter immunoprecipitation was detected by 
PCR using primers: TPPP/p25 (sense 5’-CAGGTGAAGAGCCTGGAGTC-3’; antisense 
5’-GTTTCCTTGTCTGTGGGTGAA-3’); GAPDH (sense 5’- 
TACTAGCGGTTTTACGGGCG -3’) antisense 5’-TCGAACAGGAGGAGCAGAGAGCGA 
-3’). RNA Pol II (IMGENEX, San Diego, CA) and rabbit IgG (Santa Cruz, Santa Cruz, 
CA) antibodies were used for positive and negative controls respectively.  
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3.5.6 Cell Proliferation Assays 
Cell proliferation analysis was performed using BrdU cell proliferation kit from 
EMD Millipore (Millipore, Billerica, MA). Briefly, BrdU label was added for 18 hrs and the 
cells were subsequently incubated with anti-BrdU primary antibody (Millipore, Billerica, 
MA) and goat anti-mouse secondary IgG (Millipore, Billerica, MA, peroxidase 
conjugate). The nuclei incorporation of BrdU was measured using a spectrophotometer 
microplate reader (Victor 3TM; PerkinElmer Life Sciences) at a wavelength of 450nm. 
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Table 3.1 ChIP-on-ChIP analysis of cytokeletal genes regulated by p68. 
ChIP-on-ChIP study was performed using SW620 cells with pAbp68 and human 
promoter Tiling 1.0R array (Affymetrix). These genes showed up on all the three 
different ChIP-on-ChIP experiments for high affinity binding to the p68 promoter. 
Intermediate-filament 
associated
Plakophilin 3NM_007183
Intermediate-filament 
binding protein
Plectin 1, intermediate filament binding 
protein
NM_000445
Intermediate-filament 
associated
HornerinNM_001009931
Intermediate-filament 
associated
Keratin 72NM_001146225.1
Microtubule-
associated
Tubulin-β 8NM_177987.2
Intermediate-filament 
binding protein
Keratin associated protein 5-8NM_021046
Microtubule-
associated
Tubulin polymerization promoting proteinNM_007030
CytoskeletonGene NameID
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Figure 3.1A Chromatin immunoprecipitation (ChIP) of the TPPP/p25 promoter.  
HeLa cells grown at 37ºC were harvested for ChIP analyses with either p68-specific 
antibody (pAbp68) or IgG antibody as a control. PCR products from sheared chromatin 
served as inputs. Control reactions were set up using ChIP by RNA POL II and IgG 
antibodies.  
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Figure 3.1B & C Qualitative and quantitative RT-PCR demonstrating p68 
regulation of TPPP /p25 mRNA expression.  
Expression of TPPP/p25 was analyzed by qualitative RT-PCR (B) and real time RT-
PCR (C). Total RNA was isolated from the HeLa cells and used for RT-PCR. GAPDH 
RT-PCR was used as a PCR loading control. RT-PCR samples containing no template, 
no reverse transcriptase or positive control template were additional controls employed. 
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Figure 3.1D TPPP/p25 protein expression affected by p68 expression 
Expression of TPPP/p25 and p68 in HeLa cells were determined by immunoblot 
analysis of TPPP/p25 and p68 antibodies respectively. The lysate was prepared from 
cells with non-target (NT) or siRNA targeting p68 (p68). Immunoblot analysis of GAPDH 
using GAPDH antibody was used as a loading control for loading of total cellular 
proteins.  
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Figure 3.1E P68 upregulates TPPP/p25 expression 
Expression of TPPP/p25 and p68 in HeLa cells were determined by immunoblot 
analysis of TPPP/p25 and p68 antibodies respectively. The lysate was prepared from 
cells with non-target (NT) or siRNA targeting p68 (p68). HA vector and HA-p68 were 
exogenously expressed in the cells with p68 knockdown. Immunoblot analysis of 
GAPDH using GAPDH antibody was used as a loading control for loading of total 
cellular proteins.  
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Figure 3.2A Expression of TPPP/p25 in PC12 cells 
Immunoblot analysis of cellular extracts made from PC12 and HCT-116 cells was used 
to detect cellular level of TPPP/p25 by using TPPP/p25 antibody. HCT-116 cell lysate 
served as a positive control. Immunoblot analysis of GAPDH using GAPDH antibody 
was used as a loading control for loading of total cellular proteins. 
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Figure 3.2B NGF treatment upregulates TPPP/p25 expression 
Phase contrast microscopy of PC-12 cells (Upper panel) cultured on poly-lysine with 
NGF for 3 days (right column). The left column indicates PC12 cells grown in medium 
without NGF for 3 days. NGF concentration used was 50 ng/ml. Note the appearance of 
neurite outgrowth in NGF containing PC12 cell cultures. Expression of TPPP/p25 
protein level in PC12 cells was examined by immunoblot analysis of cell lysate with 
TPPP/p25 antibody. The cells were harvested for immunoblot analysis after treatment 
with NGF at 50ng/ml for 3 days. Immunoblot analysis with GAPDH antibody served as a 
control for equal loading. 
 
 151 
NT            TPPP/p25
TPPP/p25            
GAPDH           
P
r
im
e
r
s
  
  
  
  
  
  siRNA
C   
 
Figure 3.2C Knockdown of TPPP/p25 in PC12 cells 
Expression of TPPP/p25 after knockdown was detected by RT-PCR. GAPDH RT-PCR 
served as a PCR control for loading.   
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Figure 3.2D TPPP/p25 regulates the differentiation of PC12 neuronal cells. 
Immunofluorescent staining of PC12 cells after knockdown of TPPP/p25. TPPP/p25 
was knocked down in PC12 cells with TPPP/p25 siRNA and non-target siRNA was a 
control. PC12 cells were then stimulated with NGF. NGF was used at 50ng/ml 
concentration for 3 days. The left columns indicate PC12 cells cultured in medium 
without NGF for 3 days while the right columns denote PC12 cells with NGF treatment. 
The upper two panels represent non-targeting siRNA treated cells while the lower two 
panels represent TPPP/p25 knockdown cells. Tubulin antibody was used for detection 
of differentiation. Note the appearance of neurite outgrowth in NGF containing PC12 cell 
cultures.  
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Figure 3.2E P68 upregulates TPPP/p25 expression under NGF treatment of PC12 
neuronal cells at the RNA level. 
Expression of TPPP/p25 was examined by RT-PCR. P68 was knocked down in the 
PC12 cells and the cells were treated with and without NGF. NGF concentration used 
was 50 ng/ml. GAPDH RT-PCR served as a PCR control for loading. 
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Figure 3.2F P68 upregulates TPPP/p25 protein expression under NGF treatment of 
PC12 neuronal cells. 
Expression of TPPP/p25 protein in PC12 cells was determined by immunoblot analysis 
with TPPP/p25 antibody. The cells were harvested for immunoblot analysis after 
knockdown with p68 siRNA (p68) and non-target (NT) siRNA served as a control. The 
cells were grown in with and without NGF medium for 2 days. NGF concentration used 
was 50 ng/ml. Immunoblot analysis with GAPDH antibody was used as a loading 
control.  
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Figure 3.2G P68 RNA helicase regulates the differentiation of PC12 neuronal cells. 
Immunostaining of PC12 cells after knockdown of p68. PC12 cells with p68 siRNA and 
non-target siRNA were treated for 2 days with NGF. NGF was used at 50 ng/ml 
concentration. PC12 cells were stained with tubulin antibody for demonstration of 
microtubule rearrangement and differentiation and TPPP/p25 antibody to detect 
expression levels and distribution of TPPP/p25. Note the appearance of neurite 
outgrowth in NGF containing non-targeting PC12 cell cultures.  
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Figure 3.3A Immunohistochemical staining of TPPP/p25 in sections from normal 
brain and glioblastoma tissue sections. 
Left two panels represent TPPP/p25 staining of normal brain tissue sections while the 
right two panels denote TPPP/p25 staining of representative cases of glioblastoma 
tissue sections. In the left two panels, TPPP/p25 expression in paraffin-embedded 
normal brain tissue specimens was evaluated using anti-TPPP/p25 antibody. Intense 
brown staining of TPPP/p25 is observed in neuronal cell bodies with diffuse staining of 
neuropil and neuronal processes. TPPP/p25 immunoreactivity is also observed in 
oligodendrocytes of non-tumor brain tissue sections. Endothelial cells also stain positive 
for TPPP/p25. Right two panels represent glioblastoma tissue sections lacking 
TPPP/p25 expression in most tumor sections. Strong staining of vascular endothelial 
cells of native vascular structures and newly developing proliferating endothelial cells is 
also observed. Blue color indicates haematoxylin nuclear staining of the nuclei of all 
cells. 
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Figure 3.3B Expression of TPPP/25 in three different glioma cell-lines at the 
mRNA level. 
RT-PCR analysis of RNA extracted from glioma cells, specifically, T98G, U87MG and 
LN229 was performed using TPPP/p25 primers to detect endogenous TPPP/p25 RNA 
levels. HEK and HCT116 were used as positive controls of TPPP/p25 expression. 
GAPDH RT-PCR served as a PCR control for loading. 
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Figure 3.3C Expression of TPPP/25 in different glioma cell-lines at the protein 
level. 
Immunoblot analysis of cell lysate prepared from different glioma cells was performed to 
detect endogenous protein levels using TPPP/p25 antibody. Correspondingly, p68 
expression levels in these cells were also probed using p68 antibody. Mouse brain 
extract (MBE) was used as a positive control along with HEK and HCT-116 cell lysates. 
Immunoblot with GAPDH antibody served as a loading control while TPPP/p25 protein 
was seen as a doublet in these cells. 
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Figure 3.3D Analysis of TPPP/p25 expression in T98G and U87MG cells after 
transient overexpression of TPPP/p25.  
Immunoblot analysis of T98G and U87MG cell lysate after transfecting with FLAG or 
FLAG-TPPP/p25 (TPPP/p25) expression plasmid was done. Immunoblot analysis was 
performed with TPPP/p25 antibody and demonstrated abundant expression of 
TPPP/p25 protein. Immunoblot with GAPDH antibody served as a loading control. 
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Figure 3.3E TPPP expression effects on cellular proliferation and morphological 
features. 
Methylene blue staining of T98G and U87MG cells 48 hrs after transfection with FLAG 
(Vector) or FLAG-TPPP/p25 (TPPP/p25) was performed to detect morphological 
features. Two left panels represent T98G cell staining while two right panels denote 
U87MG cell staining. Top two panels are U87MG and T98G cells with TPPP/p25 
overexpression while bottom two panels represent U87MG and T98G cells without 
TPPP/p25 overexpression. Note dendritic processes in TPPP/p25 transfected cells. 
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Figure 3.3F TPPP/p25 expression decreases cell proliferation 
The role of TPPP/p25 overexpression on T98G and U87MG cells was established by 
BrdU proliferation assay. Cells were overexpressed with FLAG (Vector) or FLAG-
TPPP/p25 (TPPP/p25) expression plasmids. Growth rate was measured at 48 and 72 
hrs after transfection using mean absorbance reading at OD 405 nm. Error bars show 
standard deviations from three different experiments. 
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Figure 3.3G Detection of caspase-3 activation in apoptosis induction in T98G and 
U87MG cells upon expression of TPPP/p25. 
Immunoblot analysis was performed to show caspase-3 activation by detection of 
cleaved caspase-3 peptides using cleaved caspase-3 antibody. Cells were harvested 
48 hrs after tranfection with FLAG or FLAG-TPPP/p25 (TPPP/p25) expression 
plasmids. Immunoblot analysis with caspase-3 antibody was done to detect total 
caspase-3 levels in the cells. Immunoblot with lamin a/c antibody was the loading 
control. 
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Figure 3.3H Expression of TPPP/p25 increases stable microtubule levels. 
Immunoblot analysis of lysates from T98G cells was performed after transfecting with 
FLAG (Vincze, Olah et al.) or FLAG-TPPP/p25 (TPPP/p25) was performed. Immunoblot 
analysis with acetylated tubulin was done to measure the levels of stable microtubule. 
Immunoblot with tubulin antibody was used as a loading control while immunoblot with 
TPPP/p25 antibody was used to measure TPPP/p25 expression levels. 
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CHAPTER 4 
CONCLUSIONS AND DISCUSSIONS 
 
4.1 INTRODUCTION 
 P68 RNA helicase is implicated in different biological processes. It has been 
shown that p68 is an important splicing factor in pre-mRNA splicing (Liu 2002). 
Numerous studies have shown that p68 serves as a transcriptional co-activator for a 
number of different genes such as ERα, p53, Snail etc (Endoh, Maruyama et al. 1999) 
(Bates, Nicol et al. 2005; Carter, Lin et al. 2010). Previous reports have indicated the 
role of p68 in organ development and transformation (Stevenson, Hamilton et al. 1998). 
Tyrosine phosphorylation of p68 was studied by Yang et al. and they discovered an 
unanticipated function of c-abl in the EMT process. Tyrosine phosphorylated p68 
interacts with β-catenin and consequently, is involved in cell proliferation (Yang, Lin et 
al. 2006). Phosphorylated p68 also activates transcription of proliferative genes such as 
c-myc and cyclin D1 (Yang, Lin et al. 2007). The aim of this dissertation is to elucidate 
the role(s) of p68 in other processes, including characterizing the function of threonine 
phosphorylation of p68. This dissertation also aims to understand the transcriptional 
regulation of a cytoskeletal gene, TPPP by p68 and also study the role of p68 in cellular 
differentiation. 
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4.2 OXALIPLATIN TREATMENT OF CRC INDUCES P68 THREONINE 
PHOSPHORYLATION. 
 Colorectal cancer was relatively resistant to chemotherapy initially (Blijham 
1991). However, the clinical outcomes have improved in the past few years as a result 
of using a combination of two to three chemotherapeutic agents (Buyse, Zeleniuch-
Jacquotte et al. 1988). Platinum-based DNA damaging agents like oxaliplatin are 
among the commonly used drugs in colorectal cancer teatment. The apoptosis induced 
in tumor cells by oxaliplatin has been demonstrated as one of its mechanism of actions 
in chemotherapy (Zunino, Perego et al. 1997). However, characterization of molecular 
pathways that mediate the cellular response to oxaliplatin and complete understanding 
of its mode of action are essential for further improving the therapeutic efficacy of the 
drug. 
 In our study, we found that p68 is one of the cellular targets of oxaliplatin that 
mediates the downstream effects of oxaliplatin in apoptosis. P68 is implicated in p53-
mediated apoptosis induced by DNA damaging agent etoposide (Bates, Nicol et al. 
2005). Thus, p68 may be a common element in the DNA damaging pathways. Our 
results show that oxaliplatin treatment dramatically increases p68 threonine 
phosphorylation. The threonine phosphorylation reaches a peak and then p68 gets 
dephosphorylated suggesting that oxaliplatin treatment activates a phosphatase that 
dephosphorylates p68. Phosphorylation and dephosphorylation of proteins represent a 
common mechanism for regulating enzymatic activity and cellular functions of proteins 
including numerous transcription factors (Holmberg, Tran et al. 2002). P68 is known to 
be subjected to modification by phosphorylation and has been demonstrated to be 
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phosphorylated at multiple residues (Yang and Liu 2004). Phosphorylation at multiple 
sites suggests that p68 regulation is complex. Tyrosine phosphorylation of p68 is 
observed in several different cancer cells. PDGF-stimulation of HT-29 cells leads to 
tyrosine phosphorylation of p68 at Y593 by c-abl (Yang, Lin et al. 2005; Yang, Lin et al. 
2006) TNF-α treatment phosphorylates p68 at threonine and dephosphorylates p68 at 
tyrosine residues indicating that TNF-α treatment reciprocally regulates the threonine 
and tyrosine phosphorylations of p68 (Yang, Lin et al. 2005). Like TNF-α treatment, 
oxaliplatin also causes threonine phosphorylation of p68 and may also dephosphorylate 
p68 at tyrosine to affect cell survival. Threonine phosphorylation and tyrosine 
dephosphorylation may represent a cellular apoptotic response to oxaliplatin treatment. 
This may imply that p68 is a multifunctional protein that has different biological roles in 
multiple cellular pathways and specifically, phosphorylation of p68 regulates the 
enzymatic activity and cellular functions of p68 in different pathways in response to 
different external stimuli. 
 
4.3 P68 IS PHOSPHORYLATED BY P38 MAP-KINASE AT T564 AND/OR T446 
UPON OXALIPLATIN TREATMENT. 
 P38 MAP-kinase is known to be activated following treatments with DNA 
damaging compounds, UV light, ionizing radiation, etoposide. It is involved in mediating 
cancer cell apoptosis triggered by these agents (Tanos, Marinissen et al. 2005; Wang 
and Lippard 2005; Wood, Nail et al. 2006; Lu, Rau et al. 2011). Although different 
activators and substrates of p38 in different DNA damaging pathways are somewhat 
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known, the exact signaling pathway is still unclear and the different molecular factors 
involved vary and depend on different DNA-damaging agents. 
In our studies, we found that oxaliplatin treatment of colon cancer induces p38 
activation and phosphorylation in a time dependent manner. P38 
activation/phosphorylation follows a similar time course with p68 phosphorylation at 
threonine suggesting a parallel response. In vitro phosphorylation and co-
immunoprecipitation assays demonstrate that p38 interacts with and phosphorylates 
p68. This data is in consistence with the earlier reports of p68 being a new substrate for 
p38. P68 is phosphorylated by p38 in response to TNF-α stimulation and this represents 
a new cellular mechanism by which p38 executes TNF-α signal downstream (Yang, Lin 
et al. 2005). To further confirm that p38 phosphorylates p68 in vivo, p38 constitutively 
activated mutant is used. Expression of the p38 constitutively activated mutant 
increases p68 phosphorylation at threonine. Phosphorylation assays demonstrate T564 
and/or T446A as the phosphorylation sites of p38 and it is well established that p38 
MAP-kinase often phosphorylates multiple sites in its targets (Yang, Xiong et al. 2002; 
De Chiara, Marcocci et al. 2006). 
 
4.4 PHOSPHORYLATION OF P68 AT THREONINE MEDIATES THE EFFECTS OF 
OXALIPLATIN IN THE INDUCTION OF APOPTOSIS 
Our studies show that p68 phosphorylation at T564/446 by p38, at least partially, 
mediates the effects of oxaliplatin on apoptosis induction. Phosphorylation causes 
conformational change in critical domains which may enhance the binding to 
downstream target proteins functioning in distinct signaling pathways. How the 
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phosphorylation of p68 at T564 and T446 mediates cell apoptosis is an open question. 
One plausible explanation is that the phosphorylated p68 may change p68 interacting 
partners in the cells, which causes p68 to target a particular apoptosis mediating protein 
or complex. The consequence for the p68 targeting is activation of apoptotic function of 
the targeted protein or complex. A number of DEAD-box RNA helicases associate with 
apoptosis induction protein or complex. For example, DDX42 modulates the apoptotic 
function of ASPP2 by direct interaction with it (Uhlmann-Schiffler, Kiermayer et al. 
2009). Interaction between GABA receptor associated protein (GABARAP) and DDX47 
is required for induction of neuronal cell apoptosis (Lee, Rho et al. 2005). However, the 
mechanism by which this DEAD-box RNA helicase regulates the apoptotic process is 
not known. Thus, it will be very interesting to find whether p68 phosphorylation at T564 
and/or T446 mediates the association of the protein with a particular apoptosis inducing 
complex to activate the complex. Another explanation of p68 phophorylation mediating 
the effects of oxaliplatin on apoptosis induction may be that p38 MAP-kinase 
phosphorylates specific transcription factors or other proteins to regulate cell apoptosis, 
proliferation or inflammatory processes. Also, the involvement of p68 in transcriptional 
regulation is well studied. Thus, it seems plausible that p38-mediated p68 
phosphorylation may promote or activate the transcription activation function of p68 and 
may represent a new mechanism in regulating gene expression during apoptosis 
induction in response to oxaliplatin. It is also of interest to note that p68 interacts with 
p53 tumor suppressor in response to etoposide treatment to stimulate transcription of 
p53-dependent genes, including p21 and Bax and regulates p53-mediated apoptosis 
(Bates, Nicol et al. 2005). It is highly probable that phospho-p68 may be involved in this 
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process, as phosphorylation may be activating the transcription co-activator function of 
p68 to bind specific promoter DNA sequences. Thus, phospho-p68 may be needed by 
different stressors to regulate cellular apoptosis in different pathways.  It is known that 
phosphorylation of p53 at key regulatory residue like serine 15 stimulates p53-
transcriptional activity (Siliciano, Canman et al. 1997; Banin, Moyal et al. 1998).  DDX3 
RNA helicase exhibits tumor suppressor function including growth inhibition by 
transcriptional modulation of p21 gene expression. It activates p21 promoter in an 
ATPase-dependent but helicase-independent mechanism through its multiple Sp1 sites 
(Chao, Chen et al. 2006). Thus, this study may represent a new and/or alternate 
pathway for oxaliplatin mediated apoptosis where in response to oxaliplatin, p38-
mediated p68 phosphorylation could activate gene expression by interacting with other 
transcriptional factors to promote apoptosis. 
 
4.5 P68 RNA HELICASE REGULATES TRANSCRIPTION OF THE TPPP/25 GENE. 
 In this study, we report that p68 plays a role in TPPP/p25 gene transcription. 
TPPP/p25 is a microtubule-associated protein belonging to the cytoskeletal gene family. 
Oncomine meta-analysis study of p68 showed that p68 is co-expressed with several 
other cytoskeletal genes and p68 probably regulates these genes via transcription or 
splicing (Wilson and Giguere 2007). This study was confirmed by Chip-on-chip analysis 
in our lab using p68 antibody. The study indicated that p68 interacts with the promoters 
of a number of cytoskeleton-regulating genes. Further studies were done to narrow 
down p68 regulation to a particular cytoskeletal gene, TPPP/p25. Chip experiment 
demonstrated that p68 is associated with the TPPP/p25 promoter. TPPP/p25 RNA and 
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protein levels in p68 knockdown cells showed that when p68 is knocked down, 
TPPP/p25 levels decrease whereas when p68 is not knocked down, TPPP/p25 
expression is maintained at normal levels. All these results indicate that p68 positively 
regulates TPPP/p25 expression. 
Interestingly, TPPP/p25 is not the only gene that is regulated by p68. P68 is 
known to transcriptionally coactivate a number of genes such as ERα, p53, Snail etc 
(Endoh, Maruyama et al. 1999) (Bates, Nicol et al. 2005; Carter, Lin et al. 2010). 
Moreover, how p68 functions in transcription co-activation is not very well defined. It is 
quite possible that p68 regulates the formation of a competent transcription complex. It 
may either act as an adaptor protein for recruiting or facilitating the assembly of 
transcription factors or stabilizing their interactions with chromatin via chromatin 
remodeling by acting as an ATPase motor. P68 has been shown to participate in active 
recruitment of TBP, RNA Pol II and chromatin remodeling SWI/SNF complex to the 
muscle transcriptome and facilitates chromatin remodeling (Caretti, Schiltz et al. 2006). 
It also directly interacts with the transcriptional co-activators p300 and CBP to facilitate 
gene transcription by RNA Pol II. ATPase and unwinding activity of p68 are essential in 
this case (Rossow and Janknecht 2003). Alternatively, p68 could influence transcription 
by interacting with transcriptional repressor HDAC1. P68 can also function as a 
transcriptional corepressor depending on the transcriptional complex and promoter on 
which it is recruited. It is known to repress transcription by associating with HDAC1 
(Wilson, Bates et al. 2004). Phospho-p68 interacts with HDAC1 and MBD3:Mi-2/NuRD 
in the nuclear remodeling and deacetylation complex promoting release of HDAC1 from 
the complex thereby activating Snail1 gene transcription. Thus, this Snail1 
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transcriptional regulation, in turn, suppresses E-cadherin expression (Carter, Lin et al. 
2010). Interestingly, phosphorylated form of p68 has also been involved in 
transcriptional regulation. Phosphorylation of p68 at Y593 is found to activate cyclin D1 
and c-myc transcription thereby promoting cell proliferation induced by PDGF. Phospho-
p68 is recruited to cyclin D1 and c-myc promoters by its interaction with β-
catenin.TCF/LEF complex (Yang, Lin et al. 2007). Thus, transcriptional regulation by 
phospho-p68 adds another dimension to the function of p68 in the transcriptional 
regulation process. 
 
4.6 P68 RNA HELICASE REGULATES PC12 NEURITE OUTGROWTH VIA 
REGULATION OF TPPP/p25 EXPRESSION.  
Functional study of TPPP/p25 regulation showed that p68 coactivates TPPP/p25 
transcription and is necessary for neuronal cells to differentiate. Reduction of p68 levels 
in PC12 cells leads to dramatic reduction of TPPP/p25 levels and failure of neurite 
formation of PC12 cells indicating that p68, in part, is crucial for the differentiation 
process. In another study, p68 has been found to be involved in PC12 differentiation by 
functioning as an adaptor protein in mediating the association of v-src with PtdIns-3 
kinase. This interaction is critical in cytoskeletal rearrangement responsible for the 
outgrowth of neurites in PC12 cells (Haefner and Frame 1997). Likewise, knockdown of 
TPPP/p25 in PC12 cells partially blocked the neurite formation process. Overall, our 
results indicate that p68 and TPPP/p25 are necessary for PC12 neurite formation and 
that p68 plays a role in PC12 differentiation via regulation of TPPP/p25 expression.  
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P68 has been showed to be involved not only in PC12 cell differentiation but also 
in adipocyte differentiation. Knockdown of p68 in mouse 3T3-L1 cells blocked 
differentiation of these cells into adipocytes (Kitamura, Nishizuka et al. 2001). DDX17 
(p72) found in the cells in a heterodimeric form with DDX5 (p68) has been implicated in 
cellular differentiation process where DDX17 transcripts are in very high levels in rat 
brain during embryogenesis but found in the adult stage. This suggests that DDX17 
plays a role in neuronal differentiation during CNS development (IP, Chung et al. 2000) 
Similarly, transcripts of chick and mouse homologs of p68 has been found to be in high 
abundance in different embryonic tissues while p68 is implicated in the differentiation of 
the monocytic leukemia cells U937 to macrophages (Stevenson, Hamilton et al. 1998; 
Jost, Schwarz et al. 1999; Gingras and Margolin 2000; Seufert, Kos et al. 2000). 
Furthermore, p68 is also found to be essential for skeletal myogenesis and plays a 
critical role in co-regulating MyoD transcription and skeletal muscle differentiation 
(Caretti, Schiltz et al. 2006). DDX3 is essential for spermatogenesis and DDX4 is 
required for oogenesis (Lasko and Ashburner 1988; Lasko and Ashburner 1990; 
Tomancak, Guichet et al. 1998; Foresta, Ferlin et al. 2000). DDX41 is involved in visual 
and CNS system development while DDX25 is critical for spermatogenesis (Schmucker, 
Vorbruggen et al. 2000; Tsai-Morris, Sheng et al. 2004). Tight regulation of gene 
expression is important during differentiation and since these RNA helicases participate 
in various stages of RNA metabolism like transcription etc, it indicates the importance of 
RNA helicases as regulators of differentiation. Nonetheless, the precise role of p68 in 
differentiation is still unknown. This poses several questions where future research 
could be targeted: What is the role of p68 in differentiation? Could p68 engage in 
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transcriptional programs that control differentiation? What are the downstream targets of 
p68 in its function as differentiation regulator? 
 
4.7 TPPP/p25 EXPRESSION IS IMPORTANT IN GLIOMA PROGRESSION 
 Glioblastomas are the most common and the most aggressive malignant tumors 
in humans, involving glial cells with a median survival of 10 to 12 months (Westermark 
and Nister 1995; Schechter 1999). It is reported that TPPP/p25 is highly expressed in 
oligodendrocytes suggesting their role in the normal functioning of the central nervous 
system (Takahashi, Tomizawa et al. 1991; Takahashi, Tomizawa et al. 1993; Vincze, 
Tokesi et al. 2006). However, study on the functional role of TPPP/p25 expression in 
glioblastomas is not established. In our study, we found through immunohistological 
analysis of tissue samples from glioblastoma patients that TPPP/p25 levels are very low 
or absent. This is also confirmed by undetectable levels in several glioblastoma cell 
lines. This indicates that loss of TPPP/p25 expression correlates with the development 
and progression of glioblastoma as reduced expression of this protein may be involved 
in the providing growth advantage to tumor cells. We also report in this study that 
TPPP/p25 inhibits tumorigenicity of glioma cells in vitro. Overexpression of TPPP/p25 in 
glioma cells results in significant decrease in cell proliferation suggesting that TPPP/p25 
is a negative regulator of growth in glioblastomas and deregulation of expression of 
TPPP/p25 may be linked with their transformed phenotype. TPPP/p25 overexpression 
did not activate caspase-3 implying that TPPP/p25 suppresses glioma cell growth by its 
inhibitory effect on the cell proliferation rate.  
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 The reason for downregulation of TPPP/p25 in brain tumors at the RNA and 
protein levels is not known. It may be possible that TPPP/25 gene may be silenced by 
promoter hypermethylation in glioblastomas indicating that the role of TPPP/p25 is in 
either maintaining the differentiated phenotype or triggering anti-proliferative effect. 
Also, since TPPP/p25 is a microtubule-associated protein that stabilizes microtubules in 
T98G glioblastoma cells, induction of this microtubule stabilizing protein in glioblastoma 
may have implications for not only tumor progression but also to sensitize tumors to MT 
agents. MT agents like vinca alkaloids and taxols are used for the treatment for several 
cancers, however, drug resistance is the major setback for treatment (Dumontet and 
Sikic 1999). Cancer cells activate mechanisms to counteract these drugs by 
overexpressing MT-destabilizing proteins or covalently modifying tubulins to render 
themselves resistant to the effects of MT stabilizing drugs such as taxol resulting in drug 
resistance (Alli, Bash-Babula et al. 2002; Martello, Verdier-Pinard et al. 2003). Thus, re-
expression of TPPP/p25 by gene therapy may overcome such resistance and may have 
beneficial effects on glioblastoma aggressive tumors. 
 
4.8 REFERENCES 
Alli, E., J. Bash-Babula, et al. (2002). "Effect of stathmin on the sensitivity to 
antimicrotubule drugs in human breast cancer." Cancer research 62(23): 6864-
6869. 
Banin, S., L. Moyal, et al. (1998). "Enhanced phosphorylation of p53 by ATM in 
response to DNA damage." Science 281(5383): 1674-1677. 
 175 
Bates, G. J., S. M. Nicol, et al. (2005). "The DEAD box protein p68: a novel 
transcriptional coactivator of the p53 tumour suppressor." The EMBO journal 
24(3): 543-553. 
Blijham, G. H. (1991). "Chemotherapy of colorectal cancer." Anti-cancer drugs 2(3): 
233-245. 
Buyse, M., A. Zeleniuch-Jacquotte, et al. (1988). "Adjuvant therapy of colorectal cancer. 
Why we still don't know." JAMA : the journal of the American Medical Association 
259(24): 3571-3578. 
Caretti, G., R. L. Schiltz, et al. (2006). "The RNA helicases p68/p72 and the noncoding 
RNA SRA are coregulators of MyoD and skeletal muscle differentiation." 
Developmental cell 11(4): 547-560. 
Carter, C. L., C. Lin, et al. (2010). "Phosphorylated p68 RNA helicase activates Snail1 
transcription by promoting HDAC1 dissociation from the Snail1 promoter." 
Oncogene 29(39): 5427-5436. 
Chao, C. H., C. M. Chen, et al. (2006). "DDX3, a DEAD box RNA helicase with tumor 
growth-suppressive property and transcriptional regulation activity of the 
p21waf1/cip1 promoter, is a candidate tumor suppressor." Cancer research 
66(13): 6579-6588. 
De Chiara, G., M. E. Marcocci, et al. (2006). "Bcl-2 Phosphorylation by p38 MAPK: 
identification of target sites and biologic consequences." The Journal of biological 
chemistry 281(30): 21353-21361. 
Dumontet, C. and B. I. Sikic (1999). "Mechanisms of action of and resistance to 
antitubulin agents: microtubule dynamics, drug transport, and cell death." Journal 
 176 
of clinical oncology : official journal of the American Society of Clinical Oncology 
17(3): 1061-1070. 
Endoh, H., K. Maruyama, et al. (1999). "Purification and identification of p68 RNA 
helicase acting as a transcriptional coactivator specific for the activation function 
1 of human estrogen receptor alpha." Molecular and cellular biology 19(8): 5363-
5372. 
Foresta, C., A. Ferlin, et al. (2000). "Deletion and expression analysis of AZFa genes on 
the human Y chromosome revealed a major role for DBY in male infertility." 
Human molecular genetics 9(8): 1161-1169. 
Gingras, M. C. and J. F. Margolin (2000). "Differential expression of multiple unexpected 
genes during U937 cell and macrophage differentiation detected by suppressive 
subtractive hybridization." Experimental hematology 28(1): 65-76. 
Haefner, B. and M. C. Frame (1997). "Distinctive regulation of v-Src-associated 
phosphatidylinositol 3-kinase during PC12 cell differentiation." The Biochemical 
journal 328 ( Pt 2): 649-655. 
Holmberg, C. I., S. E. Tran, et al. (2002). "Multisite phosphorylation provides 
sophisticated regulation of transcription factors." Trends in biochemical sciences 
27(12): 619-627. 
Ip, F. C., S. S. Chung, et al. (2000). "Developmental and tissue-specific expression of 
DEAD box protein p72." Neuroreport 11(3): 457-462. 
Jost, J. P., S. Schwarz, et al. (1999). "A chicken embryo protein related to the 
mammalian DEAD box protein p68 is tightly associated with the highly purified 
 177 
protein-RNA complex of 5-MeC-DNA glycosylase." Nucleic acids research 
27(16): 3245-3252. 
Kitamura, A., M. Nishizuka, et al. (2001). "Expression of p68 RNA helicase is closely 
related to the early stage of adipocyte differentiation of mouse 3T3-L1 cells." 
Biochemical and biophysical research communications 287(2): 435-439. 
Lasko, P. F. and M. Ashburner (1988). "The product of the Drosophila gene vasa is very 
similar to eukaryotic initiation factor-4A." Nature 335(6191): 611-617. 
Lasko, P. F. and M. Ashburner (1990). "Posterior localization of vasa protein correlates 
with, but is not sufficient for, pole cell development." Genes & development 4(6): 
905-921. 
Lee, J. H., S. B. Rho, et al. (2005). "GABAA receptor-associated protein (GABARAP) 
induces apoptosis by interacting with DEAD (Asp-Glu-Ala-Asp/His) box 
polypeptide 47 (DDX 47)." Biotechnology letters 27(9): 623-628. 
Liu, Z. R. (2002). "p68 RNA helicase is an essential human splicing factor that acts at 
the U1 snRNA-5' splice site duplex." Molecular and cellular biology 22(15): 5443-
5450. 
Lu, Q., T. F. Rau, et al. (2011). "Increased p38 mitogen-activated protein kinase 
signaling is involved in the oxidative stress associated with oxygen and glucose 
deprivation in neonatal hippocampal slice cultures." The European journal of 
neuroscience 34(7): 1093-1101. 
Martello, L. A., P. Verdier-Pinard, et al. (2003). "Elevated levels of microtubule 
destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-
tubulin mutation." Cancer research 63(6): 1207-1213. 
 178 
Rossow, K. L. and R. Janknecht (2003). "Synergism between p68 RNA helicase and the 
transcriptional coactivators CBP and p300." Oncogene 22(1): 151-156. 
Schechter, C. B. (1999). "Re: Brain and other central nervous system cancers: recent 
trends in incidence and mortality." Journal of the National Cancer Institute 91(23): 
2050-2051. 
Schmucker, D., G. Vorbruggen, et al. (2000). "The Drosophila gene abstrakt, required 
for visual system development, encodes a putative RNA helicase of the DEAD 
box protein family." Mechanisms of development 91(1-2): 189-196. 
Seufert, D. W., R. Kos, et al. (2000). "p68, a DEAD-box RNA helicase, is expressed in 
chordate embryo neural and mesodermal tissues." The Journal of experimental 
zoology 288(3): 193-204. 
Siliciano, J. D., C. E. Canman, et al. (1997). "DNA damage induces phosphorylation of 
the amino terminus of p53." Genes & development 11(24): 3471-3481. 
Stevenson, R. J., S. J. Hamilton, et al. (1998). "Expression of the 'dead box' RNA 
helicase p68 is developmentally and growth regulated and correlates with organ 
differentiation/maturation in the fetus." The Journal of pathology 184(4): 351-359. 
Tanos, T., M. J. Marinissen, et al. (2005). "Phosphorylation of c-Fos by members of the 
p38 MAPK family. Role in the AP-1 response to UV light." The Journal of 
biological chemistry 280(19): 18842-18852. 
Tomancak, P., A. Guichet, et al. (1998). "Oocyte polarity depends on regulation of 
gurken by Vasa." Development 125(9): 1723-1732. 
Tsai-Morris, C. H., Y. Sheng, et al. (2004). "Gonadotropin-regulated testicular RNA 
helicase (GRTH/Ddx25) is essential for spermatid development and completion 
 179 
of spermatogenesis." Proceedings of the National Academy of Sciences of the 
United States of America 101(17): 6373-6378. 
Uhlmann-Schiffler, H., S. Kiermayer, et al. (2009). "The DEAD box protein Ddx42p 
modulates the function of ASPP2, a stimulator of apoptosis." Oncogene 28(20): 
2065-2073. 
Wang, D. and S. J. Lippard (2005). "Cellular processing of platinum anticancer drugs." 
Nature reviews. Drug discovery 4(4): 307-320. 
Westermark, B. and M. Nister (1995). "Molecular genetics of human glioma." Current 
opinion in oncology 7(3): 220-225. 
Wilson, B. J., G. J. Bates, et al. (2004). "The p68 and p72 DEAD box RNA helicases 
interact with HDAC1 and repress transcription in a promoter-specific manner." 
BMC molecular biology 5: 11. 
Wilson, B. J. and V. Giguere (2007). "Identification of novel pathway partners of p68 and 
p72 RNA helicases through Oncomine meta-analysis." BMC genomics 8: 419. 
Wood, L. J., L. M. Nail, et al. (2006). "The cancer chemotherapy drug etoposide (VP-16) 
induces proinflammatory cytokine production and sickness behavior-like 
symptoms in a mouse model of cancer chemotherapy-related symptoms." 
Biological research for nursing 8(2): 157-169. 
Yang, L., C. Lin, et al. (2005). "Signaling to the DEAD box--regulation of DEAD-box p68 
RNA helicase by protein phosphorylations." Cellular signalling 17(12): 1495-
1504. 
 180 
Yang, L., C. Lin, et al. (2006). "P68 RNA helicase mediates PDGF-induced epithelial 
mesenchymal transition by displacing Axin from beta-catenin." Cell 127(1): 139-
155. 
Yang, L., C. Lin, et al. (2007). "Phosphorylation of p68 RNA helicase plays a role in 
platelet-derived growth factor-induced cell proliferation by up-regulating cyclin D1 
and c-Myc expression." The Journal of biological chemistry 282(23): 16811-
16819. 
Yang, L. and Z. R. Liu (2004). "Bacterially expressed recombinant p68 RNA helicase is 
phosphorylated on serine, threonine, and tyrosine residues." Protein expression 
and purification 35(2): 327-333. 
Yang, T. T., Q. Xiong, et al. (2002). "Phosphorylation of NFATc4 by p38 mitogen-
activated protein kinases." Molecular and cellular biology 22(11): 3892-3904. 
Zunino, F., P. Perego, et al. (1997). "Role of apoptotic response in cellular resistance to 
cytotoxic agents." Pharmacology & therapeutics 76(1-3): 177-185. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 181 
CHAPTER 5 
 
MATERIALS AND METHODS 
 
5.1 MAMMALIAN CELL CULTURE TECHNIQUES 
5.1.1 Mammalian Cell Culture 
The cell lines used were HCT116 (Catalog # CCL-247), HeLa CCL2 (Catalog  # 
CCL-2), PC12 (Catalog # CRL-1721) and T98G (Catalog # CRL-1690) obtained from 
ATCC (American Type Culture Collection, Manassas, VA) and were grown in McCoy’s 
5A medium, MEM, DMEM and MEM respectively. Media contained Fetal Bovine Serum 
(FBS) (Hyclone, Logan, UT) as a supplement. The cells were routinely passaged until 
they were subconfluent (70 to 80%), which was approximately every two to three days, 
and were incubated at 37°C incubator. Trypsin (Cellgro, Manassas, VA) was used to 
detach the cells from the T175 cm2 flasks. After detachment, the cells were centrifuged 
for 5 mins at 1200 rpm to eliminate trypsin, and then cultured in the respective fresh 
medium as described above. 
 
5.1.2 Mammalian Cell Storage and Thawing 
The cells were stored for long-term by freezing and storing them in liquid 
nitrogen. Before placing the cells in the liquid nitrogen, they were detached from the 
flasks by trypsination, centrifuged at 1200 rpm and resuspended in their normal medium 
containing 20% FBS and 10% DMSO (Sigma, St. Louis, MO). The cells were added to 
special cryotubes for storing cells at -80°C, slowly frozen in an isopropanol bath 
overnight and left in liquid nitrogen. 
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The frozen cells were thawed by placing in a water bath, centrifuged and 
resuspended in required culture medium containing 10% FBS. 
 
5.1.3 Transfection 
5.1.3.1 Plasmid Transfection 
Fugene HD or X-tremeGENE 9 DNA transfection reagents (Roche, Indianapolis, 
IN) were used for most of the transfection experiments. The cells were trypsinized 24 
hours before transfection and 3-5 x 105 cells were seeded in medium containing 10% 
FBS without antibiotics in 6-well plate so that the cell density would be approximately 60 
to 70% confluent the next day. Transfection reagent, diluent and the DNA that was to be 
transfected were allowed to equilibrate to room temperature (22°C) and mixed well 
before proceeding. The DNA (2 µg) was diluted in 100 µl Optimem-reduced serum 
medium (Invitrogen, Grand Island, NY) placed in polystyrene tube and gently mixed. 
The transfection reagent (3 µl) was then added to the mixture in a 3:2 ratio. The 
complex was allowed to form by incubating the mix for 15 mins and added into the 
wells. After incubation of the cells at 37°C incubator for 24-48 hrs, they were either 
treated or harvested. 
 
5.1.3.2 siRNA Transfection 
 RNA oligonucleotides used to knockdown p68 gene expression were siGENOME 
duplex siRNA from Dharmacon (Thermo Fisher Scientific Dharmacon, Lafayette, CO). 
The sequences of the duplex siRNA against p68 were as follows: siRNA 
oligonucleotides against p68 (sense: 5’-GCAAGUAGCUGCUGAAUAUUU-3’; antisense: 
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5’- AUAUUCAGCAGCUACUUGCUU-3’). The siRNA knockdown was done using 
Lipofectamine RNAimax (Invitrogen, Grand Island, NY) reagent. A day before siRNA 
knockdown, 2-4 x105 cells were seeded. The siRNA duplex was dissolved in 1X siRNA 
buffer (Thermo Fisher Scientific Dharmacon, Lafayette, CO) at a concentration of 40 
pmol/µl and RNase-free water by rotating in a rocking platform for 30 mins. About 3µl 
(120 pmol) of siRNA was added to 250 µl of Optimem-reduced serum medium 
(Invitrogen, Grand Island, NY) in a polystyrene tube and mixed gently. Lipofectamine 
RNAimax (5μl) was added to 250 µl of Optimem medium in another tube and also 
mixed well. An irrelevant siRNA or non-targeting siRNA (Thermo Fisher Scientific 
Dharmacon, Lafayette, CO) served as a negative control. The siRNA-lipofectamine 
complex was then allowed to form by adding the siRNA mixture slowly to the 
lipofectamine mixture and incubating for 25 mins at room temperature. After incubation, 
the complex (500 µl) was added dropwise to the cells that have been washed two times 
with Optimem medium, incubated for 4 hrs and feedbacked with complete medium. 
After 24 hrs, fresh medium with 10% FBS (Hyclone, Logan, UT) was added. After 48 
hrs, they were then harvested or the p68 wild-type or mutants were transfected the 
same day using fugene HD transfection reagent and harvested after an additional 48 
hrs. The transiently expressed p68 wild-type and the mutants were blocked from 
knockdown by mutating four nucleotides in the siRNA targeting sequence such that the 
amino-acid sequence was not altered.  
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5.2 BACTERIAL CULTURE TECHNIQUES 
5.2.1 Culture of Bacterial Cells and their Storage 
Plasmid DNA that was used for transfection, cloning, and other techniques was 
amplified using bacterial E.coli strains JM109 (Promega, Madison, WI), DH5α 
(Promega, Madison, WI) and XL-1 blue (Stratagene, Cedar reek, TX), while BL21-
codon Plus (Stratagene, Cedar reek, TX) was used for the expression of recombinant 
protein. The bacteria were inoculated in sterile Luria-Bertani (LB) medium in a 37ºC 
shaker set to 220 rpm. The composition of LB medium was as: 1% tryptone, 1% NaCl, 
0.5% yeast extract, and 50 µg/ml of Ampillicin or kanamycin for antibiotic-resistant strain 
selection. The antibiotics were added to autoclaved medium approximately around 40 to 
50°C. The LB agar plates contained 1.5% agar in addition to the above mentioned 
composition of LB medium. The bacteria were either inoculated into sterile LB medium 
using a sterile inoculation loop or spread onto the agar plates using a sterile plastic 
spreader, and incubated in an incubator at 37°C for 16-18 hrs. 
 
5.2.2 Competent Cell Preparation 
Competent cells are bacterial cells whose cell walls are rendered porous to allow 
the plasmid DNA to enter the cells. E.coli strains JM109 and DH5α were made 
competent using the following steps. An isolated bacterial colony was seeded into 
sterile 10 ml LB broth, and grown overnight in a 37°C shaker. Next day, culture (1 ml) 
was inoculated into sterile LB medium (50 ml) and grown till OD600 of 0.375. The culture 
was then aliquoted into 50 ml of sterile, pre-chilled, polypropylene tubes (or 50 ml 
centrifuge tubes). After placing the cells for 10 mins on ice, the pelleted cells were 
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resuspended in CaCl2 solution (10 ml) and centrifuged again. After resuspension in 
CaCl2 solution (10 ml), the cells were left on ice for 30 mins. After this final incubation 
step, the pelleted competent cells were resuspended in ice-cold CaCl2 solution (1 ml) 
and dispensed into prechilled, sterile micro-centrifuge tubes (100 µl each). Prechilled 
pipette tips were used for dispensing. The tubes were then immediately transferred and 
transferred at -80°C until further use. 
 
5.2.3 Transformation 
E.coli competent cells (JM109 or DH5α) were used for transformation of plasmid 
DNA. Competent cells (100 µl) were placed in a sterile micro-centrifuge tube and 10-
500 ng of plasmid DNA was then added to the tube. The DNA/competent cells were 
placed for 30 mins in an ice bucket and then heat-shocked at 42°C waterbath for 90 
seconds. After heat-shock, the mix was immediately placed on ice for 2 to 3 mins. 
Thereafter, 200 µl of prewarmed sterile LB medium without any antibiotics was added to 
and further incubated in a shaker maintained at 37°C with a speed of 220 rpm for 1 
hour. The cells were then spread onto sterile LB agar plates with either ampicillin or 
kanamycin and incubated overnight at 37°C. 
 
5.3 DNA RELATED TECHNIQUES 
5.3.1 Isolation of Plasmid DNA 
5.3.1.1 Isolation of Plasmid DNA in a Mini-Scale (Mini-prep) 
Plasmid DNA isolation and purification were performed using Qiaprep Spin Mini 
Kit (Qiagen, Valencia, CA). An isolated bacterial colony, inoculated into 2 ml of sterile 
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LB medium, was incubated for 16 to 18 hrs in a 37°C shaker set to 220 rpm. The 
pelleted cells were resuspended in the resuspension buffer P1. Around 250 µl of lysis 
buffer P2 was added to the tube which was inverted 4-6 times. This step lysed the 
bacteria. After the lysis, neutralization buffer N3 (300 µl) was immediately added to 
neutralize the alkaline conditions generated by the lysis buffer and the contents of the 
tube were again mixed by inverting 4-6 times. The mixture was then subjected to 
centrifugation and the supernatant containing the DNA solution was applied to the spin 
column. It was again centrifuged to enable the DNA to bind to the silica column. The 
column was rinsed with buffer PB (500 µl) to eliminate the endonuclease present in 
endA+ bacteria such as JM109 and subsequently washed again with buffer PE (750 µl) 
containing ethanol and centrifuged. Elution was done with elution buffer TE (10 M Tris-
HCl, pH 8.5) or water and confirmed by either agarose gel electrophoresis or DNA 
sequencing. 
 
5.3.1.2 Isolation of Plasmid DNA in a large-scale (Midi-prep) 
Large scale DNA purification was done using Wizard Plus DNA Purification 
System (Promega, Madison, WI). Plasmid DNA containing bacteria were seeded into 
sterile LB medium with required antibiotic and grown in 37°C shaker for 18 hrs. After 
centrifugation, the pellet was dissolved in resuspension buffer (3 ml). Lysis buffer (3 ml) 
was added and then the solution was inverted 4 to 6 times to mix. The lysate was then 
neutralized by adding 3ml of neutralization buffer and centrifuged at 13000 rpm for 20 
mins. Pellet was mixed with DNA purification resin. This mixture was then added to a 
midiprep column and vacuum was used to remove the solution. The DNA-resin mix in 
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the column was rinsed two times with column wash buffer with ethanol (15 ml) and the 
supernatant was removed each time with the application of vacuum. After the wash 
solution was removed from the column, the vacuum was allowed to further run for 
additional 30 seconds for the complete removal of wash solution. However, the resin in 
the column was always prevented from being dried for too long as the DNA yield would 
decrease. The column was then centrifuged to eliminate any trace wash buffer. The 
DNA was then eluted with pre-warmed (60 to 70°C) 300 µl of nuclease free water. After 
adding water to the column, it was incubated for 1 min and then centrifuged to elute the 
DNA. DNA solution was then further centrifuged for 5 mins to remove any white resin 
that might be left in the solution. The supernatant containing the DNA was then 
concentrated and stored at -20°C. 
 
5.3.2 Concentration of DNA 
DNA was purified by ethanol precipitation to remove any salt or protein contamination. 
In this method, 3M sodium acetate (1/10th volume) and 100% ethanol (2 volumes) were 
added to the DNA sample. After thorough mixing, the sample was kept at -20°C for 18 
hrs. The tube was centrifuged for 15 mins to pellet DNA which was rinsed with 80% 
ethanol and centrifuged. The pellet was then dried and dissolved in sterile D/W. The 
DNA concentration was then measured using a spectrophotometer (UV-1700 
Spectrophotometer, Shimadzu Corporation) at OD260. 
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5.3.3 Measurement of DNA Quality and Concentration   
DNA concentration was measured photometrically using a spectrophotometer. The 
absorbance was measured at OD260 and applied to the following formula which gives 
the DNA concentration: DNA concentration (µg/ml) = OD260 X Dilution factor X (50 µg 
DNA/ml)/ (1 OD260 unit). DNA quality was determined by measuring the ratio of 
absorbance at OD260 and at OD280. A ratio between 1.65 and 1.85 was acceptable. 
 
5.3.4 Agarose Gel Electrophoresis 
Agarose gel electrophoresis is the technique for purification and visualization of 
nucleic acids on agarose gel using a double stranded DNA binding dye such as 
Ethidium Bromide. Larger molecular weight DNAs ranging from 0.5 to 2 kbp like 
plasmids and genomic DNA were separated on 1% agarose gels (w/v) while smaller 
molecular DNAs (less than 0.5 kbp) were separated on 2-3% gel. 2% agarose gel was 
prepared by adding 2 gm of agarose (EMD, San Diego, CA) in 100 ml of 1X TAE buffer 
(Tris-Base, Glacial acetic acid, EDTA, pH 8.0). The mix was heated in a microwave till 
the agarose was completely melted and ethidium bromide was added. Ethidium 
bromide is a DNA binding dye that intercalates between DNA and allows for 
visualization of DNA using UV light.  This agarose solution was then poured onto gel 
casting apparatus with a comb containing well inserts to make suitable wells and 
allowed to set for 30 mins. After solidification of the gel, 1X TAE buffer was used as the 
running buffer and poured into the gel running unit after removing the comb. Next, the 
DNA sample was mixed with 6X DNA loading buffer (Fermentas, Glen Burnie, MA) to a 
final concentration of 1X and loaded into the wells. DNA marker was also loaded to 
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determine the DNA size. The gel was run at a voltage at 120 V and 200 mA for 1 hour 
and visualized using a UV transilluminator.   
 
5.3.5 Gel Extraction of DNA 
After agarose gel electrophoresis, DNA purified by QIAquick Gel Extraction Kit 
(Qiagen, Valencia, CA) can be used for restriction enzyme digestion, ligation and 
purification of PCR products. The DNA is excised from the gel after electrophoresis 
using a scalpel and weighed after placing in a microcentrifuge tube. Buffer QG provided 
with the kit was then added to the DNA sample which solubilizes the agarose gel 
fragment enabling the DNA to bind to the silica membrane and determine the optimum 
pH for DNA binding. Three times the volume of Buffer QG was added per gram of the 
weight of the gel (100 mg of agarose slice = 300 µl of Buffer QG). The DNA was placed 
in a 50°C waterbath to enable the gel to dissolve. After 10 mins, if the color of the 
solution was orange or purple, it meant that the pH of the solution was not appropriate 
for the proper binding of the DNA to the column. In this case, 3M sodium acetate, pH 
5.0 (10 μl) was added so that the pH of the solution would turn to <7.5. Next, one gel 
volume of isopropanol was added to increase the yield of DNA. The solution was then 
loaded onto a QIAquick column and centrifuged. The column was then rinsed with 
buffer QG again and centrifuged. Finally, ethanol containing buffer PE was added to the 
column to remove the residual salts, agarose and dyes. The column was let to sit for 1 
min and centrifuged until completely dried. DNA eluted using water or buffer EB (10 mM 
Tris-HCl, pH 8.5) was used for subsequent applications. 
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5.3.6 Polymerase Chain Reaction 
Polymerase chain reaction (PCR) is used in applications such as mutagenesis 
(to mutate specific sequence), RT-PCR (amplify cDNA from mRNA), cloning (cloning 
specific sequences of genes in plasmid vector) etc. A typical PCR reaction consisted of 
the following: 1 unit of DNA polymerase- Hotstart pfuTurbo (Stratagene, Cedar reek, 
TX), 10X cloned pfu buffer at a final concentration of 1X, 100 ng of template DNA, 1 mM 
dNTP and 100 ng of forward and reverse primers specific for the DNA to be amplified 
and nuclease free water to make up the volume to 50 µl. The primers were designed 
using the Primer3 software. The PCR mix containing the template was first denatured at 
95°C for 2 mins to unwind the double helix. Next, 28-33 cycles of the following steps 
were performed: 95°C for 30 seconds, 55°C for 30 seconds and 72°C for 30 seconds. 
Elongation at 72°C for 10 mins was done to make sure that all the PCR products were 
double stranded and then ectrophoresed. 
 
5.3.7 Restriction Enzyme Digestion 
Restriction enzyme digestion is an important tool in recombinant DNA technology 
and molecular biology. The process employs a restriction enzyme which recognizes 
specific DNA sequences and cleaves them at those sites. These DNA sequences can 
then be ligated into another plasmid which also has been cleaved at the same site. The 
standard components for restriction enzyme digestion were as: water, appropriate 
buffer, DNA upto 1 μg and restriction enzyme upto 1μl. The mixture was incubated at a 
temperature that was optimal for the enzyme which was mostly around 37°C. The 
digestion products were extracted after electrophoresis. A double restriction enzyme 
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digestion was also performed using the above procedure with the exception of using 
two enzymes instead of one. Also, the buffer and other conditions were compatible for 
both the enzymes. If two enzymes were not compatible for single reaction, then 
sequential restriction digestion was performed.  
 
5.3.8 DNA ligation 
Ligation is the process of joining the linearized cut segments of DNA that has 
been either digested by restriction enzyme or phosphorylated at 5’ phosphate end of the 
insert DNA and dephosphorylated at the 3’ hydroxyl end of the vector. Ligation is 
performed by an enzyme called DNA ligase that joins the 5’ phosphate and 3’ hydroxyl 
groups of DNA segments that have either overhangs generated by restriction enzyme 
digestion or cohesive ends generated by PCR products. T4 DNA ligase (Fermentas, 
Glen Burnie, MA) was used for the ligation. A typical ligation reaction consisted of the 
following:  5X ligation buffer used at a final concentration of 1X, insert DNA, vector DNA 
and T4 DNA ligase. After vortexing and centrifuging, the reactions were left for 4 hours 
at room temperature and for 18 hrs at 4°C and finally transformed into competent 
bacterial cells for amplification or stored at -20°C.  
 
5.3.9 Insert DNA Phosphorylation and Vector DNA Dephosphorylation 
For some applications that required single restriction enzyme digestion instead of 
using two restriction enzymes, the following procedure was followed to prevent the 
single restriction site digested vector DNA from self recircularization and ligation. 
Alkaline phosphatases catalyze the removal of phosphate group from 5’ end of DNA 
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thereby preventing the DNA from self recircularization. Shrimp alkaline phosphatase 
(Fermentas, Glen Burnie, MA) was used for this purpose. 1 unit of the phosphatase, 1 
µg of cut vector DNA were mixed in 1X SAP buffer and incubated for 30 mins at 37°C.  
Phosphorylation of the insert DNA was the next step for ligating the 
dephosphorylated vector. Phosphorylation was generally performed using T4 
Polynucleotide Kinase (T4 PNK) (Fermentas, Glen Burnie, MA) which catalyses γ-
phosphate transfer from ATP to the 5’ terminal of polynucleotides or 3’ phosphate 
bearing mononucleotides. A typical reaction consists of: 10X reaction buffer, water, 
PCR product and T4 PNK. The DNA then was subsequently used for the ligation 
reaction. 
 
5.3.10 DNA Sequencing 
Sequencing of the plasmid DNA after ligation or mutagenesis was done at the 
Georgia State University Core Facility. Sequencing primers such as T7 or SP6 were 
provided by the facility while some application specific primers were designed using 
Primer3 software. The primers were suspended in nuclease free water and used. 
 
5.3.11 Cloning of TPPP/P25/p68/p68 mutants/p38 mutants 
The cDNA of p68 ORF was subcloned into mammalian expression vector pHM6 
(Roche, Indianapolis, IN) at HindIII site to get HA-tagged p68 expression vector. The 
expressed protein has HA tag at the N-terminus. Quick-Change site-directed 
mutagenesis kit (Stratagene, Cedar reek, TX) was used to prepare various p68 single 
and double threonine mutants (threonine replaced by alanine) and the mutations were 
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confirmed by DNA sequencing. P38α cDNA (Origene, Rockville, MD) was subcloned 
into p3XFLAG-myc-CMV™-24 Expression Vector (Sigma, St. Louis, MO). Mutations to 
get the constitutively active form of p38 were done using the reference (Diskin, Askari et 
al. 2004). TPPP/p25 cDNA was subcloned into p3XFLAG-myc-CMV™-24 Expression 
Vector (Sigma, St. Louis, MO). P38 and TPPP/p25 expressed proteins have FLAG tag 
at the N-terminus. 
 
5.4 RNA RELATED TECHNIQUES 
5.4.1 RNA Isolation 
RNeasy Plus kit (Qiagen, Valencia, CA) was employed for RNA extraction. To 
isolate RNA, the cells were grown on 6-well plates until they reached 80-90% 
confluence and then rinsed twice with cold 1X PBS. The cell lysis was done with 350 µl 
buffer RLT supplemented with β-mercaptoethanol (Sigma, St. Louis, MO). The cells 
were lifted from the plates with cell lifters (Corning Costar, Corning, NY), added to 
Qiashredder column (Qiagen, Valencia, CA) for homogenization and centrifuged. 
Homogenized lysate was then loaded onto gDNA eliminator column for removal of the 
genomic DNA and centrifuged for 1 min. Ice-cold 70% ethanol was then mixed with 
equal volume of supernatent and applied to RNeasy column and centrifuged for 30 
seconds. Buffer RW1 was used to wash the column and subsequently rinsed twice with 
buffer RPE (500 µl). After centrifugation, the RNA was eluted twice with 30–50 µl DEPC 
treated water. The RNA concentration was measured using a spectrophotometer and 
stored at -20°C. 
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5.4.2 Measurement of RNA Concentration 
The RNA concentration was measured photometrically using a spectrophotometer (UV-
1700 Spectrophotometer, Shimadzu Corporation). The absorbance was measured at 
OD260 and applied to the following formula which gives the RNA concentration: RNA 
concentration (µg/ml) = OD260 X Dilution factor X (50 µg RNA/ml)/ (1 OD260 unit).  
 
5.4.3 Reverse Transcription – Polymerase Chain Reaction (RT-PCR) 
RT-PCR couples reverse transcription and PCR methods to generate double 
stranded cDNA from mRNA to examine gene expression. Two step RT-PCR was 
performed using the kit, ImProm II Reverse Transcription System (Promega, Madison, 
WI). The first step of RT-PCR is reverse transcription. RNA isolated from the 
mammalian cells was converted to cDNA and PCR was performed in the second step. 1 
µg of RNA was added in the RNase-free PCR tube along with 1 µl of Oligo dt and water. 
A positive control containing 1.2 kb kanamycin RNA and a negative control without any 
RNA were also set up according to the same procedure mentioned above. The samples 
were incubated at 70°C and then placed in ice water for atleast 5 mins. The following 
concoction consists of: 5X reaction buffer (4 µl), 5 mM MgCl2 (4 µl), water (4 µl), 100 
mM dNTP (1 µl), RNase inhibitor (1 µl) and Reverse transcriptase (1 µl). The reactions 
were then subjected to the following cycle: 25°C for 5 mins, 45°C for 1 hour and 70°C 
for 15 mins in the PCR machine. Once the RNA was transcribed to cDNA, the 
amplification of the cDNAs was performed using PCR. PCR reactions were set up using 
roughly 2 µl (100ng) of cDNA, 50-100 ng of appropriate forward and reverse primers 
and 1X master mix from Promega, Madison, WI (containing DNA polymerase, dNTPs 
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and MgCl2). The PCR cycle was as: initial denaturation (94°C for 2 minutes), followed 
by 30 cycles of 94°C for 15 sec, 55°C for 30 sec, and 72°C for 30 sec with an additional 
extension time of 10 mins. Primers used were: TPPP/p25 (sense 5’- 
CAGGTGAAGAGCCTGGAGTC-3’; antisense 5’- GTTTCCTTGTCTGTGGGTGAA-3’); 
GAPDH (sense 5’- GAGTCAACGGATTTGGTCGT-3’; anti-sense 5’- 
TTGATTTTGGAGGGATCTCG-3’).    RT-PCR results were analyzed by running the 
samples on 2 to 3% agarose gels with ethidium bromide. 
 
5.4.4 Real time RT-PCR 
 
Quantitative RT-PCR allows simultaneous visualization and quantification of the 
PCR product. The reverse transcription was performed to generate the cDNA before its 
amplification. For the real time PCR, the following concoction was prepared: 100 ng of 
cDNA, 1X Fast SYBR Green master mix (Applied Biosystems, Foster City, CA), 
primers, water to 25 μl. The mixture was loaded to a specific 96 well PCR plate (Applied 
Biosystems, Foster City, CA). Applied Biosystems 7500 Fast Real Time machine was 
used for PCR: 95ºC for 15 seconds, then 40 cycles of 95ºC for 3 seconds and 60ºC for 
30 seconds. Plate analysis was performed using Applied Biosystems SDS v1.4 
program. A dissociation curve was generated to examine the purity of the PCR product 
and the results were analyzed using relative analysis. From the Ct values and the 
formula 2-(dCt), dCt and ddCt values were calculated and the results were shown as fold 
change.  
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5.5 PROTEIN RELATED TECHNIQUES 
5.5.1 Cell Lysate Preparation 
5.5.1.1 Whole Cell Lysate Preparation 
Mammalian cells subjected to various treatments such as transfection or drug 
treatment have to be lysed in order to release different cellular proteins that need to be 
investigated. The cells were initially rinsed twice with 1X PBS. The PBS was removed 
and required volume of cold 1X PBS containing Protease inhibitor cocktail (Sigma, St. 
Louis, MO), Phosphatase inhibitor cocktail 2 (Tyrosine phosphatase inhibitor (Sigma, St. 
Louis, MO) and Phosphatase inhibitor cocktail 3 (Threonine phosphatase inhibitor 
(Sigma, St. Louis, MO) were added. Cell lifter (Corning Costar, Corning, NY) was used 
to harvest the cells and the cells were pelleted. Cell lysis was done using 1X RIPA 
(Radioimmunoprecipitation) buffer (Millipore, Billerica, MA) (0.5M Tris-HCl, pH 7.4, 2.6% 
deoxycholic acid, 1.5M NaCl, 10mM EDTA, 10% NP-40) containing 1mM PMSF 
(phenylmethylsulphonyl fluoride), 1mM NaF, 1:100 dilution Protease inhibitor cocktail, 
Phosphatase inhibitor cocktail 2, and Phosphatase inhibitor cocktail 3 and rotated. After 
one hour, the tubes were centrifuged for 10 mins at 13,200 rpm to remove the cellular 
debris. The supernatant which contained the desired protein was placed in another 
centrifuge tube and stored at -80°C. 
 
5.5.1.2 Nuclear and Cytoplasmic Extract Preparation 
 Some proteins are expressed in the nucleus and it is often necessary to separate 
them from the cytoplasm for downstream applications. Nuclear extract kit (Active motif, 
Carlsbad, CA) was used for preparation of nuclear fraction of the cells. Cells treated 
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according to the application, were first rinsed with 1X PBS and subsequently harvested 
in cold 1X PBS supplemented with Phosphatase inhibitor cocktail to limit protein 
modifications. The pellet was dissolved in 1X Hypotonic Buffer (500 µl) and placed for 
15 mins on ice to make the cell membrane fragile. Detergent (25 µl) was added into the 
tubes and vortexed. The tubes were then centrifuged at 13000 rpm for 30 seconds to 
pellet the nuclear fraction and collect the cytoplasmic extract in the supernatant in 
another tube. The nuclear pellet was then rinsed with 1X PBS buffer to prevent 
cytoplasmic extract contamination into the nuclear pellet. The nuclei were then lysed in 
AMI lysis buffer with PIC and DTT and rotated on a rotating platform. After vortexing for 
30 seconds, the tubes were centrifuged to pellet the nuclear debris. The supernatant 
representing the nuclear extract was collected.  
 
5.5.2 Recombinant Protein Expression and Purification  
The procedure used to express and purify p68 is similar to the procedure 
reported previously. P68 ORF and various mutants were cloned into pET-30a+ 
expression vector and transformed into E.coli BL21-CodonPlus bacteria (Stratagene, 
Cedar reek, TX) were used to express protein. The bacteria were subcultured in fresh 
st. LB broth till OD600 reached around 0.6. Induction of the cells was done with IPTG for 
18 hr and washed with 1X PBS buffer after harvesting, pelleted and stored at - 80°C. 
They were then disrupted by freeze-thaw cycle at -80°C, resuspended in lysis buffer (50 
mM Tris-HCl pH 8.0, 1 mM DTT, 10 mM PMSF, 300 mM NaCl ad 10% glycerol). They 
were then subjected to lysozyme (0.5 mg/ml) digestion. DTT and PMSF were also 
added at 1 mM final concentration. The cells were further subjected to ultrasonication 
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and pelleted. After centrifugation, the expressed protein was found in the precipitate 
which was dissolved in denaturing buffer containing 8 M urea, 50 mM Tris-HCl pH 8.0, 
0.2% Triton-100 and 250 mM NaCl. The lysate was passed through Ni-NTA column for 
purification of recombinant protein by affinity separation. After column wash using the 
denaturing wash buffer (8 M urea, 50 mM Tris-HCl pH 8.0, 250 mM NaCl, 20 mM 
imidazole pH 8.0, and 0.2% Triton-100), the protein was eluted using elution buffer with 
8 M urea, 250 mM Imidazole, 50 mM Tris-HCl pH 8.0, 250 mM NaCl, 0.5 mM DTT and 
10% glycerol, and 0.2% Triton-100. Refolding of the eluted protein was done by 
stepwise dialysis procedure (8 M→6 M→4 M→2 M→0 M) to remove urea using 
refolding buffer (200 mM arginine, 50 mM Tris-HCl pH 8.0, 250 mM NaCl, 0.5 mM DTT, 
10% glycerol, and 0.2% Triton-100) and preserved in further 15 to 20% glycerol. 
 
5.5.3 Determination of Protein Concentration by Biorad Method 
The proteins obtained from either whole cell lysate or nuclear/cytoplasmic extract 
or pure recombinant protein preparation was accurately quantified by modified Bradford 
Assay using Coomassie Brilliant Blue (Bio-Rad, Hercules, CA). 200 µl of 5X Biorad dye 
solution was added in a cuvette to which appropriate amount of either standard protein 
or 1 µl of sample whose concentration has to be determined was added. A volume of 
800 µl was made up for each dilution with sterile distilled water so that the total volume 
of each reaction was 1 ml. The absorbance was determined at an OD595 using a 
spectrophometer (Shimadzu) after incubation at room temperature for 5 mins. Those 
absorbance values were applied to the slope-intercept formula generated by the 
standard curve using Excel to give the protein concentration. 
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5.5.4 In Vitro Kinase Assay 
In this assay, about 1μg of purified proteins were added to the reaction consisting 
of 200-250ng of p38α/SAPK2a enzyme (Upstate cell signaling), 10 μCi/μl of [γ-
32P]ATP, Magnesium/ATP cocktail (75 mM MgCl2 and 25 mM β-glycerol phosphate, 
500 μM ATP in 20 mM MOPS, pH 7.2, 1 mM sodium orthovanadate, 5 mM EGTA, and 
1mM dithiothreitol) and 5X reaction buffer (125 mM Tris-HCl, pH 7.5, 0.1 mM EGTA) in 
a volume of 25μl. After incubation for 30 mins at 30°C, 5X loading buffer (Fermentas, 
Glen Burnie, MA) were added. The samples run on two SDS-PAGE gels were subjected 
to either autoradiography or Coomassie blue staining. 
 
5.5.5 SDS-PolyAcrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE (Sodium dodecyl sulphate polyacrylamide gel electrophoresis) 
separates proteins according to their electrophoretic mobilities. SDS is an anionic 
detergent whose binding to proteins gives uniform distribution of charge per unit mass 
on the proteins so that during electrophoresis, they can be fractionated based on their 
size. The electrophoretic apparatus used to separate proteins was bought from BioRad 
and assembled. Polyacrylamide gels consisted of acrylamide, bisacrylamide, SDS, a 
buffer of designated pH and stabilizer to initiate polymerization. Normally, by varying the 
acrylamide concentrations in the gel, 5 to 25% acrylamide gels can be prepared with 
higher percentage gels used to separate smaller proteins and lower percentage gels 
used to separate proteins with higher molecular weight. Normally, 10 to 14% gels were 
used to study p68 and TPPP/P25 expression. The separating gel consisting of 
polyacrylamide 29:1, 40%, 1.5 mM Tris-HCl, pH 8.8, 10% ammonium persulphate, 10% 
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SDS, TEMED, and water was poured into the casting system formed from two glass 
plates and allowed to polymerize for atleast 40 mins. A layer of isopropanol was added 
during the polymerization procedure to remove any bubbles. After polymerization of the 
separating gel, the isopropanol was poured off and the region above the gel was 
washed with distilled water. 4% stacking gel was prepared which consisted of the same 
components as mentioned for the separating gel except 0.5 mM Tris-HCl, pH 6.8 was 
used instead of 1.5 mM Tris-HCl, pH 8.8. Stacking gel was allowed to polymerize for 10 
mins after which they were ready for electrophoresis. 
 The protein samples (roughly 50 µg) to be separated were denatured by mixing 
with 2X SDS loading buffer containing either DTT or β-mercaptoethanol and placed for 
10 mins at 100°C. The1X SDS-PAGE running buffer was added to the gel running unit 
consisting of the prepared gels. The samples loaded were first run at 60 V and then run 
for 120 V till the dye ran out of the gel. Appropriate molecular weight maker was also 
simultaneously run with the gel and any unused wells were filled with 2X SDS loading 
buffer. Gel was subsequently either stained with Coomassie Blue dye to visualize the 
protein bands or subjected to transfer to nitrocellulose membrane if immunoblotting was 
to be performed. 
 
5.5.6 Coomassie Blue Staining 
The proteins on a polyacrylamide gel can be observed by staining with 
coomassie blue stain (0.1% Coomassie Brilliant Blue, 10% acetic acid, 20% methanol, 
and water). After staining with coomassie blue stain on a rotator, the gel was placed in 
destaining buffer (40% methanol, 10% acetic acid, water) overnight. They were washed 
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with water and visualized using UVP Bioimaging and Analysis System (White light only) 
attached to CCD camera. 
 
5.5.7 Generation of anti-p68 antibody 
 Anti-p68 antibody was generated from the C-terminal region of human p68 (a.a 
437-614). Polyclonal (from rabbit) antibody was generated at Auburn Hybridoma 
Facility) while monoclonal (from mouse) antibody against p68 was obtained from 
Invitrogen. 
 
5.5.8 Immunoblotting 
Immunoblotting is a technique used for detection of expression and regulation of 
proteins from either pure protein preparation or whole cell lysate or extract. The proteins 
separated on a gel by electrophoresis are examined for the expression of the protein 
using an antibody against the protein. In a typical western blot experiment, the protein 
sample in the extract was denatured by heating at 100°C and loaded onto a gel of 
appropriate concentration. It was run at appropriate voltage and the proteins from the 
gel were transferred. The gel was placed on a sheet of 3 MM Whatman filter paper 
prewetted with the transfer buffer and a presoaked nitrocellulose membrane was then 
placed on top of the gel. The air bubbles trapped in between the layers were removed 
using a roller apparatus and another filter paper was placed. The cassette was then 
placed in a tank submerged with transfer buffer and the transfer was allowed to take 
place either at 50 mA for overnight at 4°C or 120 mA at RT for 2 hrs. It is generally 
preferred to transfer the proteins overnight for larger molecular weight proteins. After the 
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transfer was complete, the membrane was rinsed with water and then stained with 
Ponceau S stain (VWR International, West Chester, PA) for 2 mins to visualize the 
complete transfer of proteins and equal loading of the samples. The membrane was 
then again rinsed with water and then with 1X TBS containing 0.1% Tween-20 until the 
Ponceau S stain was completely removed. The membrane was subsequently incubated 
on a rocking platform with a blocking buffer containing 5% BSA in 1X TBST for 1 hour to 
mask non-specific binding sites. Next, the membrane was exposed to primary antibody 
diluted in 1X TBST buffer containing 5% BSA at an appropriate dilution ranging from 
1:500 to 1:2000 and incubated overnight. It was rinsed with 1X TBST for five minutes 
three times each and then incubated with secondary antibody (Pierce, Thermo Fisher 
Scientific Dharmacon, Lafayette, CO) (1: 4000 dilution in 1X TBST containing 5% BSA) 
for 1 hr. After another wash, SuperSignal West Dura Extended Duration Substrate 
(Pierce, Thermo Fisher Scientific Dharmacon, Lafayette, CO) was developed. Blot was 
incubated with the substrate for 2 mins and the signal was detected with the x-ray 
machine. 
The blotted membrane could be re-used and re-blotted two to three times with 
another antibody by stripping the previous primary antibody. Restore Plus Stripping 
Buffer (Pierce, Thermo Fisher Scientific Dharmacon, Lafayette, CO) was used to strip 
the primary antibody from the membranes. The membrane was washed and incubated 
with the stripping buffer (4 to 5 ml per blot) for 45 mins. After washing, the membrane 
was blocked with 5% BSA in 1X TBST for 1 hr. A different antibody at an appropriate 
dilution was added for another round of blotting. 
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5.5.9 Immunoprecipitation (IP) 
 Immunoprecipitation is a method used to pull down proteins using protein G 
beads followed by SDS-PAGE and immunoblotting. Usually, 200 to 300 μg of nuclear 
extract or upto 1 mg of whole-cell extract diluted in either RIPA buffer or NETS buffer 
were used. 1-3 μg of primary antibody was added and incubated at 4°C for overnight. 
After adding Protein G beads and washing with 1X RIPA buffer, the proteins captured 
by the antibody-bead complex were eluted by denaturing with 2X sample buffer 
containing β-mercaptoethanol for 10 mins at 95°C. The immunoprecipitated protein was 
then detected by SDS-PAGE followed by immunoblotting. 
 
5.5.10 Chromatin Immunoprecipitation (ChIP) Assay 
Chromatin Immunoprecipitation is a technique used to identify DNA-protein 
association. QuickChIPTM kit from Imgenex (Imgenex Corp, San Diego, CA) was used to 
carry out the ChIP assay. Cells were grown till they were around 70 to 80% confluent. 
The next day, the cells were fixed and crosslinked with formaldehyde. The crosslinking 
process was stopped by adding glycine directly to the formaldehyde/media solution for 5 
mins at RT with frequent swirling. The fixed cells after washing with 1X PBS 
supplemented with 1X PMSF and 1X PIC were harvested in 1X PBS. Lysis of the 
harvested cells was done with SDS lysis buffer. Sonication of the lysate was done on 
the ice using a sonicator and centrifuged. To check if the shearing process generated 
on an average 500 bp DNA fragments, 25 μl of the sheared chromatin was reverse 
crosslinked and agarose gel electrophoresis was carried out. Next, 100 μl of salmon 
sperm DNA/protein G beads was used to pre-clear the sheared chromatin for 1 hr. The 
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precleared chromatin was then used for immunoprecipitation with the appropriate ChIP 
grade antibody. Next day, protein G beads (60 μl) added to the complex were incubated 
for 2 hrs. After washing the complex extensively with different wash buffers with 
increasing salt concentrations to prevent non-specific binding, the immunocomplex was 
eluted from the beads, reverse crosslinked and the released chromatin was purified. 
The purified DNA was amplified by PCR and analyzed. 
 
5.5.11 Immunostaining 
 For immunostaining, the cells were seeded on culture plates with coverslips or 
chambered slides and either transfected or treated with the respective drug. Fixing of 
the cells was done with 4% paraformaldehyde in PBS for 15 mins. Permeabilization was 
done with 0.25% Triton X-100 in PBS after washing with 1X PBS. After blocking the 
cells with 3% BSA in PBST, the cells were incubated with appropriate primary antibody 
for 1 hr. Secondary antibody, either anti-Alexa Fluor 555 (orange, anti-rabbit) or anti-
FITC (green, anti-mouse) IgG antibodies in 3% BSA in PBST (0.1%) was added to the 
cells and incubated at RT for 1 hr in the dark. After washing with PBS for three times 
five mins each, Prolong Gold antifade reagent containing DAPI (Molecular Probes) was 
used to mount the slides. The slides were cured overnight at RT and viewed using Zeiss 
LSM Confocal Microscope or fluorescent microscope.  
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5.5.12 Cell Proliferation Assay 
5.5.12.1 MTT Assay 
Cell viability was measured using MTT assay (Sigma, St. Louis, MO). 4000 cells 
were seeded 24 hrs before knockdown and transfection of cells with vectors containing 
p68 and the mutants. Subsequently, 24 hrs after transfection and different drug 
treatment, reconstituted MTT-reagent (5 mg/ml MTT in RPMI-1640 without phenol red) 
was added to the cells and left at 37°C for 2-4 hours. Formazan crystals were dissolved 
with the MTT Solubilization solution (0.1 N HCl in isopropanol). Cell proliferation was 
measured using a spectrophotometric plate reader (Victor 3TM; PerkinElmer Life 
Sciences) by reading the absorbance at A570.  
 
5.5.12.2 BrdU Cell Proliferation Assay 
BrdU cell proliferation assay (Millipore, Billerica, MA) was used for measuring cell 
proliferation. Briefly, 4000 cells were seeded, treated and incubated with the BrdU label 
diluted in fresh cell culture medium at 37°C incubator. Cells were treated with 
Fixative/Denaturing solution and subsequently, incubated with anti-BrdU primary 
antibody (Millipore, Billerica, MA). After washing the unbound primary antibodies, 
secondary goat anti-mouse secondary IgG (Millipore, Billerica, MA, peroxidase 
conjugate) was used at RT for 30 mins. After incubation with the substrate and stop 
solutions, the nuclei incorporation of BrdU was measured using a spectrophotometer 
microplate reader (Victor 3TM; PerkinElmer Life Sciences) at a wavelength of 450nm. 
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5.5.12.3 Caspase-3/CPP32 Colorimetric Assay 
Cells plated on 6-well plates were treated with 10 μM oxaliplatin after p68 
knockdown and transfection and caspase-3/CPP32 colorimetric assay (Biovision 
Research Products, Milpitas, CA) was used to measure the activity of caspase-3. 
Briefly, after apoptosis induction, the cells were lysed in Cell Lysis Buffer. Cell lysate in 
Cell Lysis Buffer, 2X buffer and 4 mM DEVD-pNA substrate were incubated at 37°C. 
They were read at A405 using a microtiter plate reader (Victor 3TM; PerkinElmer Life 
Sciences). 
 
5.6 Materials 
Table 5.1 Cell-lines      
Cell-line 
  
ATCC Number Origin Culture Medium 
HeLa  CCL-2 Human epithelial 
cervical adenocarcinoma 
MEM + 10% FBS + 1mM 
Sodium Pyruvate + 1mM 
Non-essential amino-acids 
HEK 293 CRL-1573   Human kidney epithelial 
cells immortalized by 
adenovirus  
DMEM + 10% FBS 
HCT 116 CRL-247 Human colorectal 
carcinoma 
McCoy’s 5A + 10% FBS 
LN229 CRL-2611 Human glioblastoma  DMEM + 10% FBS 
PC12 CRL-1721 Rat adrenal gland  DMEM + 10% FBS + 5% 
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pheochromocytoma horse serum 
SW620 
  
CCL-227 Human colorectal 
adenocarcinoma from 
lymph node (metastatic 
site) 
L-15 Medium + 10% FBS 
T98G CRL-1690 Human glioblastoma 
multiforme 
MEM + 10% FBS + 1mM 
Sodium Pyruvate + 1mM 
Non-essential amino-acids 
U-87MG HTB-14 Human glioblastoma, 
astrocytoma 
MEM + 10% FBS + 1mM 
Sodium Pyruvate + 1mM 
Non-essential amino-acids 
 
 
Table 5.2 Bacterial Strains 
Bacterial Strains Company 
BL21-CodonPlus (DE3)-RIL Stratagene, Cedar reek, TX 
JM109 Promega, Madison, WI 
XL-1 Blue Supercompetent Cells Stratagene, Cedar reek, TX 
 
Table 5.3 Antibodies 
Antibody Animal of origin Company 
Acetylated tubulin Rabbit polyclonal Cell Signaling Technology, 
Beverly, MA 
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α-tubulin Mouse monoclonal Sigma Aldrich, St. Louis. MO 
Caspase-3 Rabbit polyclonal Cell Signaling Technology, 
Beverly, MA 
Cleaved-caspase-3 Rabbit polyclonal Cell Signaling Technology, 
Beverly, MA 
FLAG Mouse monoclonal Sigma  Aldrich, St. Louis, MO 
GAPDH Mouse monoclonal Millipore, Billerica, MA 
HA Rabbit polyclonal Georgia State University, Animal 
center facility 
HA, chip grade Rabbit polyclonal Abcam, Cambridge, MA 
Lamin A/C Rabbit polyclonal Cell Signaling Technology, 
Beverly, MA 
P38 Rabbit polyclonal Cell Signaling Technology, 
Beverly, MA 
P-p38 Rabbit polyclonal Cell Signaling Technology, 
Beverly, MA 
P68 Rabbit polyclonal Georgia State University, Animal 
center facility 
P68-rgg Mouse monoclonal Auburn University Hybridoma 
Facility 
P-threonine (14B3) Mouse monoclonal Calbiochem, Billerica, MA 
TPPP Rabbit polyclonal Santa Cruz Biotechnology, 
Santa Cruz, CA 
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TPPP Rabbit monoclonal Abcam, Cambridge, MA 
   
 
 
Table 5.4 Chemicals/Reagents 
Chemical Name Company 
γ-32P] ATP PerkinElmer, Waltham, MA 
Acetic acid VWR International, West Chester, PA 
 
Acetone VWR International, West Chester, PA 
Acrylamide/bisacrylamide Fisher BioReagent, Fairlawn, NJ 
Adenosine triphosphate Fermentas, Glen Burnie, MA 
Agar Sigma Aldrich, St. Louis, MO 
 
Agarose MP Biomedicals, Aurora, OH 
Alcohol VWR International, West Chester, PA 
Ammonium persulfate Sigma Aldrich, St. Louis, MO 
Ampicillin Sigma Aldrich, St. Louis, MO 
Bacto Yeast Extract BD Bioscience, Spark, MD 
Bacto Tryptone BD Bioscience, Spark, MD 
β-Mercaptoethanol Sigma Aldrich, St.Louis, MO 
Bovine serum albumin Promega, Madison, WI 
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Bromophenol Blue EMD Biosciences, San Diego, CA 
Cell culture media Mediatech, Herndon, VA 
Coomassie blue Sigma Aldrich, St. Louis, MO 
Dithiothreitol Shelton Scientific, Shelton, CT 
Ethanol AAPER Alcohol & Chemical, 
Shelbyville, KY 
Ethidium bromide Sigma, St. Louis, MO 
Ethylenedinitro-tetraacetic acid (EDTA) Sigma Aldrich, St. Louis, MO 
Ethylene glycol bis(2-aminoethyl 
ether)- 
  
 
N,N,N'N'-tetraacetic acid (EGTA) Sigma Aldrich, St. Louis, MO 
Fetal calf serum Hyclone, Logan, UT 
Formaldehyde Calbiochem, San Diego, CA 
FuGENE HD Transfection Reagent Roche Applied Science, Indianapolis, 
IN 
Glycine MP Biomedicals, Aurora, OH 
Hydrochloric acid VWR International, West Chester, PA 
Imidazole Sigma Aldrich, St. Louis, MO 
Isopropyl-ß-D-thiogalactopyranosid Sigma Aldrich, St. Louis, MO 
Isopropanol VWR International, West Chester, PA 
Kanamycin Sigma Aldrich, St. Louis, MO 
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Lipofectamine 2000 Invitrogen, Grand Island, NY 
Lipofectamine RNAimax Invitrogen, Grand Island, NY 
Lysozyme Sigma Aldrich, St. Louis, MO 
Magnesium/ATP Cocktail Upstate, Charlottesville, VA 
Magnesium Chloride Fisher Biotech, Fairlawn, NJ 
Methanol VWR International, West Chester, PA 
Methylene blue Sigma Aldrich, St. Louis, MO 
Molecular weight marker (DNA) Fermentas, Glen Burnie, MA 
Molecular weight marker (protein) Fermentas, Glen Burnie, MA 
N- (2-hydroxyethyl) piperazine-N`-(2- 
ethanesulfonic acid) (HEPES) 
Sigma Aldrich, St. Louis, MO 
Nickel-nitrilotriacetic acid (Ni-NTA) 
agarose 
Qiagen, Valencia, CA 
Nonidet P40 Roche Applied Science, Indianapolis, 
IN 
Oligonucleotides Sigma-Genosys, Woodlands, TX 
Penicillin-Streptomycin solutions Mediatech, Herndon, VA 
Phenol/Chloroform Promega, Madison, WI 
Phenylmethylsulfonyl fluoride Fluka, Switzerland 
Phosphatase inhibitor cocktail Sigma Aldrich, St. Louis, MO 
Phorbol 12-Myristate 13-acetate (PMA) Promega, Madison, WI 
Poly-L-lysine solution Sigma Aldrich, St. Louis, MO 
Ponceau S Sigma Aldrich, St. Louis, MO 
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2-Propanol VWR International, West Chester, PA 
Protease inhibitor cocktail Sigma Aldrich, St. Louis, MO 
Protein G agarose Upstate, Charlottesville, VA 
RNasin Promega, Madison, WI 
Sodium acetate Promega, Madison, WI 
Sodium azide Fluka, Switzerland 
Sodium bicarbonate Sigma Aldrich, St. Louis, MO 
Sodium chloride Fisher BioReagent, Fairlawn, NJ 
Sodium dodecyl sulfate Fisher BioReagent, Fairlawn, NJ 
Sodium fluoride Fluka, Switzerland 
Sodium hydroxide Fisher BioReagent, Fairlawn, NJ 
Sodium orthovanadate EMD Biosciences, San Diego, CA 
Sodium pyruvate Cellgro, Herndon, VA 
SYBR Green RT-PCR Master Mix Applied Biosystems, Foster City, CA 
Taxol USB, Cleveland, OH 
Tris base Fisher Biotech, Fairlawn, NJ 
Triton X-100 Sigma Aldrich, St. Louis, MO 
Trypan Blue Sigma Aldrich, St. Louis, MO 
0.25% Trypsin-EDTA Cellgro, Herndon, VA 
Tween-20 Sigma Aldrich, St. Louis, MO 
Urea Fisher Biotech, Fairlawn, NJ 
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Table 5.5 Experimental Kits 
Name of the kit Company 
Bio-Rad Protein Assay Bio-Rad, Hercules, CA 
BrDU Cell Proliferation assay Calbiochem, Billerica, MA 
 
ChIP-IT™ Chromatin Immunoprecipitation Kit Active Motif, Carlsbad, CA 
 
Improm-II Reverse Transcription System Promega, Madison, WI 
 
Nuclear Extraction Kit Active Motif, Carlsbad, CA 
 
RNeasy® Mini Kit Qiagen, Valencia, CA 
 
QIAprep Spin Miniprep Kit Qiagen, Valencia, CA 
QIAquick Gel Extraction Kit Qiagen, Valencia, CA 
 
QuikChange® II Site-Directed Mutagenesis 
Kit    
Stratagene, Cedar reek, TX 
 
Quick-ChIP Kit  Imgenex, San Diego, CA 
Wizard® plus DNA purification System Promega, Madison, WI 
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Table 5.6 Laboratory Equipments 
Name of the Euipment Company 
AllegraTM 6R Centrifuge Beckman Coulter, Fullerton, CA 
C25 Incubator shaker NewBrunswick Scientific, Edison, NJ 
EpiChemi3™ Darkroom Bioimaging System UVP, Inc., Upland, CA 
 
Eppendorf Centrifuge 5415D Eppendorf AG, Hamburg, Germany 
 
Eppendorf Mastercycler Eppendorf AG, Hamburg, Germany 
 
Mini-PROTEAN® II Electrophoresis Cell Biorad Laboratories, Hercules, CA 
 
NuAire™ CO2 Water-Jacketed Incubator NuAire, Plymouth, MN 
 
Purifier Class II Biosafety Cabinet Labconco, Kansas City, MO 
 
Centrifuge Thermo Electron Corporation, 
Asheville, NC 
 
Sonic Dismembrator 500 Fisherscientific, Fairlawn, NJ 
 
UV-1700 UV-Visible Spectrophotometer Shimadzu Corporation, Kyoto, Japan 
Victor3V 1420 Multilabel Counter PerkinElmer PerkinElmer, Waltham, MA 
 
